Negative regulation of interferon lambda induced JAK-STAT signaling and development of patient-derived xenograft models from fresh human hepatocellular carcinoma biopsies by Blumer, Tanja


























	  Originaldokument	  gespeichert	  auf	  dem	  Dokumentenserver	  der	  Universität	  Basel	  edoc.unibas.ch	  
	  	  















































I	  dedicate	  my	  PhD	  thesis	  to	  my	  grandmothers	  Myrtha	  and	  Ronny,	  two	  strong	  women	  who	  



































	  Acknowledgments	  	  I	  would	  like	  to	  express	  my	  gratitude	  to…	  	  …	  Prof.	  Dr.	  med.	  Markus	  Heim	  for	  giving	  me	  the	  opportunity	  to	  complete	  my	  PhD	  thesis	  in	  his	  lab,	  for	  the	  valuable	  discussions	  about	  my	  projects	  and	  for	  teaching	  me	  how	  fascinating	  translational	  research	  is.	  	  …	  my	   committee	  members	   Prof.	   Dr.	   Gerhard	   Christofori	   and	   Prof.	   Dr.	   Petr	   Broz	   for	   their	   time,	   helpful	  inputs	  and	  discussions	  during	  the	  committee	  meetings.	  	  	  …	  Dr.	  Stefan	  Wieland	  for	  his	  support	  during	  my	  PhD,	  for	  the	  critical	  reading	  of	  my	  manuscripts	  and	  thesis,	  and	  for	  explaining	  to	  me	  the	  intricacies	  of	  the	  English	  language.	  I	  really	  appreciated	  it.	  	  	  	  …	   Dr.	   François	   Duong	   for	   being	   my	   supervisor	   during	   the	   first	   years	   of	   my	   PhD.	   For	   his	   creative	  experimental	  ideas,	  endless	  discussions	  and	  for	  the	  daily	  coffee	  break.	  I	  really	  enjoyed	  working	  with	  you.	  	  	  …	  all	  the	  great	  people	  from	  the	  Hepatology	  group	  for	  an	  enjoyable	  working	  atmosphere,	  endless	  support,	  countless	   laughs	   and	   lively	   discussions	   during	   the	   lunch	   breaks.	   Special	   thanks	   to	   Dr.	   Mairene	   Coto-­‐Llerena,	  Marie-­‐Anne	  Meier	  and	  Sandro	  Nuciforo	  for	  their	  support,	  and	  countless	  discussions	  which	  were	  not	  only	  about	  science	  during	  our	  daily	  coffee	  break.	  	  …	   all	   the	   helpful	   people	   from	   the	   Institute	   of	   Pathology	   for	   their	   support	   during	   the	   last	   years.	   Special	  thanks	  to	  Dr.	  med.	  Matthias	  Matter,	  Prof.	  Dr.	  med.	  Luigi	  Tornillo	  and	  Prof.	  Dr.	  med.	  Luigi	  Terracciano	  for	  the	  help,	  and	  for	  the	  endless	  patience	  in	  explaining	  to	  me	  the	  mysteries	  of	   liver	  tumor	  histology.	  Special	  thanks	   to	  Dr.	  Charlotte	  Ng	   for	   a	  wonderful	   and	  very	   fruitful	   collaboration.	   I	   really	   appreciated	  working	  with	  you.	  	  …	  	  all	  the	  people	  for	  their	  helpful	  inputs	  and	  critical	  reading	  of	  my	  PhD	  thesis,	  and	  manuscripts.	  	  …	  my	  friends	  for	  supporting	  me	  during	  the	  last	  years,	  for	  cheering	  me	  up	  after	  failed	  experiments	  and	  for	  all	  the	  great	  events	  outside	  the	  lab.	  You	  are	  amazing.	  	  …	  my	   family,	   especially	   my	   two	   sisters,	   my	  mother	   and	  my	   father	   for	   their	   endless	   support,	   love	   and	  motivation.	  I	  know	  that	  I	  can	  always	  count	  on	  you.	  	  …	  Fabian	  for	  always	  supporting	  and	  believing	  in	  me	  and	  for	  the	  amazing	  time	  we	  spent	  together.	  You	  are	  my	  inspiration.	  	  	  
	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	  Summary	  
	  Type	   I	   and	   type	   III	   interferons	   (IFNs)	   act	   as	   the	   first	   line	   of	   defense	   against	   invading	  pathogens	  by	  inducing	  a	  fast	  and	  strong	  host	  response	  characterized	  by	  the	  expression	  of	   hundreds	   of	   interferon	   stimulated	   genes	   (ISGs).	   However,	   the	   magnitude	   and	  duration	   of	   cellular	   responses	   to	   viral	   and	   bacterial	   infections	   needs	   to	   be	   controlled	  properly	   to	   maintain	   tissue	   homeostasis.	   Ubiquitin	   specific	   peptidase	   18	   (USP18),	  suppressor	   of	   cytokine	   signaling	  1	   (SOCS1)	   and	   SOCS3	   are	   the	   three	   known	   inducible	  negative	  regulators	  of	  the	  IFN-­‐α	  induced	  signaling	  cascade.	  However,	  the	  role	  of	  USP18	  on	  IFN-­‐λ	  signaling	  is	  a	  matter	  of	  controversy.	  Furthermore,	  the	  physiological	  relevance	  of	  the	  relative	  contribution	  of	  SOCS1	  and	  SOCS3	  on	  in	  vitro	  IFN-­‐λ	  signaling	  needs	  to	  be	  validated	  in	  vivo.	  Thus,	  we	  aimed	  to	  investigate	  the	  role	  of	  USP18,	  SOCS1	  and	  SOCS3	  on	  the	  IFN-­‐λ induced	  signaling	  cascade	  both	  in	  vitro	  and	  in	  vivo.	  	  Based	  on	  experiments	  with	  USP18,	  SOCS1	  and	  SOCS3	  knockout	  cells,	  we	  demonstrated	  that	   USP18	   is	   the	   major	   negative	   regulator	   of	   IFN-­‐α	   induced	   JAK-­‐STAT	   signaling	  whereas	  IFN-­‐λ	  is	  negatively	  regulated	  by	  SOCS1.	  Furthermore,	  using	  USP18	  and	  SOCS1	  knockout	   mice,	   we	   confirmed	   USP18	   and	   SOCS1	   as	   physiological	   relevant	   negative	  regulators	  of	  IFN-­‐α	  and	  IFN-­‐λ,	  respectively.	  Importantly,	  we	  demonstrated	  that	  negative	  regulation	   of	   IFN-­‐α	   was	   strong	   and	   immediate	   while	   that	   for	   IFN-­‐λ	   was	  more	   subtle	  both	   in	   kinetics	   as	   well	   as	   magnitude.	   Taken	   together,	   our	   results	   suggest	   that	   the	  differences	   in	   negative	   regulations	   are	   the	   basis	   for	   the	   distinct	   kinetic	   properties	   of	  IFN-­‐α	  and	  IFN-­‐λ	  signaling	  reflecting	  their	  specific	  functions.	  IFN-­‐α	  signaling	  provides	  a	  powerful	   and	   immediate	   defense	   system	   against	   systemic	   infections	   but	   has	   to	   be	  controlled	  tightly	  to	  maintain	  tissue	  homeostasis.	  Therefore	  a	  strong	  negative	  regulator	  like	   USP18	   that	   completely	   shuts	   down	   the	   system	   is	   needed.	   By	   contrast,	   IFN-­‐λ	  provides	   a	   continuous	   first	   line	  defense	   in	  mucosal	   epithelial	   cells	   that	   are	   constantly	  exposed	   to	   pathogens.	   Thus,	   SOCS1	   facilitates	   a	   maintained	   but	   controlled	   IFN-­‐λ	  signaling	  that	  allows	  fighting	  invading	  pathogens	  without	  loosing	  tissue	  homeostasis.	  	  	  Hepatocellular	   carcinoma	   (HCC)	   is	   the	   second	  deadliest	   cancer	  worldwide	  with	  yearly	  increasing	  incidence	  and	  unsatisfying	  treatment	  options.	  Thus,	  there	  is	  a	  clear	  need	  for	  new	   and	   more	   efficient	   drugs	   for	   the	   treatment	   of	   HCC.	   A	   major	   obstacle	   for	   the	  
	  	  
understanding	  of	   the	  pathogenesis	  of	  HCC	   is	   the	   lack	  of	  an	  efficient	   in	  vivo	  model	   that	  accurately	  reflects	  the	  broad	  spectrum	  of	  human	  HCC.	  Patient-­‐derived	  xenograft	  (PDX)	  models	   gained	   a	   lot	   of	   interest	   in	   pre-­‐clinical	   studies	   of	   anti-­‐cancer	   drugs.	   Indeed,	  several	   HCC	   PDX	   models	   have	   been	   established	   in	   recent	   years.	   However,	   all	   these	  models	   are	   derived	   from	   resected	  HCC	   specimen	   and	   therefore	   limited	   to	   early	   stage	  disease.	   Patients	   with	   advanced	   stage	   HCC	   are	   not	   represented,	   although	   they	  would	  benefit	  most	   from	  new	   treatment	   options.	   Therefore,	  we	   aimed	   to	   generate	  HCC	   PDX	  models	   from	   fresh	   human	   HCC	   biopsies	   that	   cover	   all	   disease	   stages,	   with	   special	  interest	  in	  advanced	  stage	  HCC.	  We	  successfully	  established	  and	  passaged	  eleven	  HCC	  PDX	  mouse	  models	  from	  patients	  presenting	   with	   all	   major	   underlying	   liver	   diseases.	   The	   biopsies	   that	   successfully	  engrafted	  were	  representative	  of	  the	  spectrum	  of	  poorly	  differentiated	  HCCs,	  including	  both	   early	   and	   late-­‐stage	   disease.	   Importantly,	   the	   PDX	   models	   recapitulated	   tumor	  morphology,	   differentiation	   grade	   and	   the	   expression	  pattern	  of	   known	  HCC	  markers.	  Finally,	   RNA	   sequencing	   analyses	   demonstrated	   that	   our	   PDX	  models	  maintained	   the	  transcriptomic	  profiles	  and	  expression	  of	  somatic	  mutations	  of	  their	  originating	  tumors	  over	  at	  least	  four	  generations.	  Taken	  together,	  these	  novel	  HCC	  PDX	  models	  do	  not	  only	  allow	  investigation	  of	  the	  biology	  of	  all	  stages	  of	  HCC	  but	  also	  the	  study	  of	  drug-­‐induced	  resistance	  mechanisms	  and	  the	  development	  of	  new	  HCC	  therapies.	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1	  The	  Interferon	  System	  
1.1	  Interferons	  Interferons	   (IFNs)	   are	   cytokines,	   which	   are	   crucial	   for	   the	   induction	   of	   an	   efficient	  immune	   response	   against	   foreign	  material.	   Already	   early	   chordates	   500	  million	   years	  ago	   have	   developed	   IFNs	   as	   early	   elements	   of	   their	   innate	   and	   adaptive	   immune	  system1.	   In	  1957,	   IFNs	  were	   first	  described	  by	   Isaacs	  and	  Lindenmann	  as	  a	   substance	  that	  protects	  cells	  from	  viral	  infection2.	  IFNs	  belong	  to	  the	  Class	  II	  cytokines	  known	  to	  be	  involved	  in	  minimizing	  the	  damage	  induced	  by	  external	  noninfectious	  agents,	  viruses	  or	  other	   microorganisms1.	   They	   have	   a	   broad	   range	   of	   biological	   activities,	   including	  inhibition	   of	   cell	   proliferation,	   immunomodulatory	   effects	   and	   induction	   of	   antiviral	  responses3,4.	  10	  mammalian	  IFN	  species	  (IFN-­‐α,	  IFN-­‐β,	  IFN-­‐ε,	  IFN-­‐κ,	  IFN-­‐ω,	  IFN-­‐δ,	  IFN-­‐τ,	  IFN-­‐ζ/limitin,	   IFN-­‐γ	  and	   IFN-­‐λ)	  have	  been	  discovered	   from	  which	  seven	  (IFN-­‐α,	   IFN-­‐β,	  IFN-­‐ε,	   IFN-­‐κ,	   IFN-­‐ω,	   IFN-­‐γ	  and	  IFN-­‐λ)	  are	  found	  in	  humans5,6.	  Based	  on	  their	  structural	  features,	   receptor	   usage	   and	   biological	   activities,	   they	   are	   divided	   into	   three	   groups:	  type	   I,	   type	   II	   and	   type	   III	   IFNs6-­‐8.	  The	  different	   IFN	  classes	  will	  be	  described	   in	  more	  detail	  in	  the	  following	  chapters.	  	  
1.1.1	  Type	  I	  interferons	  In	  humans,	  the	  group	  of	  type	  I	  IFNs	  comprises	  12	  functional	  IFN-­‐α	  species	  and	  a	  single	  member	   each	   of	   IFN-­‐β,	   IFN-­‐ε,	   IFN-­‐κ	   and	   IFN-­‐ω5.	   All	   genes	   encoding	   type	   I	   IFNs	   are	  clustered	   on	   chromosome	   9	   and	   are	   devoid	   of	   introns4,9.	   While	   type	   I	   IFNs	   can	   be	  produced	  by	  all	  nucleated	  cells	  in	  response	  to	  invading	  pathogens10,11,	  macrophages	  and	  plasmacytoid	   dendritic	   cells	   (pDCs)	   additionally	   produce	   type	   I	   IFNs	   in	   response	   to	   a	  variety	   of	   foreign	  material	   that	   they	   sample	   from	   the	   outside,	   without	   being	   infected	  themselves.	   Indeed,	   pDCs	   are	   considered	   as	   professional	   type	   I	   IFN	   producers12-­‐14.	  Within	  the	  first	  24	  hours	  upon	  viral	  infection,	  pDCs	  produce	  100-­‐1000	  times	  more	  type	  I	  IFN	  compared	  to	  other	  blood	  cell	  types11,12.	  	  Type	   I	   IFNs	  signal	   through	  a	  single	  cell	   surface	  receptor	   that	   is	   found	  on	  all	  nucleated	  cells10.	  The	  IFN-­‐α/β	  receptor	  (IFNAR)	  is	  composed	  of	  the	  IFNAR1	  and	  IFNAR2	  subunits,	  the	   latter	  one	  harboring	  the	  major	   ligand	  binding	  domain6.	  The	  essential	  role	  of	   type	  I	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IFNs	  in	  the	  antiviral	  defense	  has	  been	  demonstrated	  in	  mice	  deficient	  for	  components	  of	  the	  type	  I	  IFN	  system.	  These	  mice	  are	  highly	  susceptible	  to	  and	  unable	  to	  cope	  with	  viral	  infections15.	  Similarly,	  two	  infants	  with	  genetic	  defects	  in	  the	  IFN	  system	  died	  from	  viral	  infection	  despite	  best	  medical	  care16.	  	  	  
1.1.2	  Type	  II	  interferon	  The	   only	   member	   of	   the	   type	   II	   IFN	   family	   is	   IFN-­‐γ,	   which	   is	   encoded	   by	   a	   gene	  containing	  three	  introns	  located	  on	  human	  chromosome	  124,9.	  IFN-­‐γ	  is	  secreted	  by	  cells	  of	  the	  innate	  and	  adaptive	  immune	  system	  such	  as	  natural	  killer	  (NK)	  and	  natural	  killer	  T	   cells	   and	   activated	   T	   cells,	   respectively13,17.	   In	   contrast	   to	   type	   I	   and	   III	   IFNs,	   IFN-­‐
γ forms	  homodimers	  and	  signals	  through	  a	  heterotetrameric	  receptor	  comprised	  of	  two	  IFN-­‐γ	  receptor	  1	  (IFNGR1)	  and	  two	  IFNGR2	  chains18,19.	  	  IFN-­‐γ	   is	  involved	  in	  the	  innate	  and	  adaptive	  immune	  response	  against	  viruses,	  bacteria	  and	   parasites8,20.	   Beside	   its	   direct	   antiviral	   effect,	   IFN-­‐γ	   has	   immunostimulatory	   and	  immunomodulatory	   roles.	   For	   example,	   it	   activates	   macrophages,	   mediators	   of	  nonspecific,	   cell-­‐mediated	   host	   defense	   and	   stimulates	   their	   antigen	   presentation	  through	   major	   histocompatibility	   complex	   class	   I	   and	   II	   molecules.	   Furthermore,	   it	  induces	   the	   transcription	   of	   interferon	   stimulated	   genes	   (ISGs),	   many	   of	   which	   have	  antiviral	   activities21-­‐23.	   Mice	   deficient	   for	   IFN-­‐γ	   signaling	   have	   shown	   an	   impaired	  capacity	  to	  cope	  with	  viruses,	  bacteria	  and	  parasites,	  demonstrating	  the	   importance	  of	  IFN-­‐γ−mediated	  immune	  responses17,22,24.	  Taken	   together,	   type	   I	   and	   type	   II	   IFNs	   work	   synergistically	   to	   induce	   innate	   and	  adaptive	  immune	  responses	  that	  contribute	  to	  the	  clearance	  of	  viral	  infections.	  	  	  
1.1.3	  Type	  III	  interferons	  Type	  III	  IFNs	  functionally	  resemble	  type	  I	  IFNs,	  inducing	  antiviral	  protection	  in	  vitro9,25	  and	  in	  vivo26.	  In	  humans,	  the	  type	  III	  IFN	  family	  consists	  of	  four	  members;	  IFN-­‐λ1	  (IL29),	  IFN-­‐λ2	   (IL28A),	   IFN-­‐λ3	   (IL28B)	   and	   the	   newly	   discovered	   IFN-­‐λ427.	   The	   distinct	   but	  closely	  related	  IFN-­‐λ1,	  -­‐λ2	  and	  -­‐λ3	  have	  been	  discovered	  by	  two	  independent	  groups	  in	  20039,25	   whereas	   the	   IFN-­‐λ4	   has	   been	   identified	   only	   in	   2013	   in	   the	   polyI:C-­‐induced	  gene	  expression	  profile	  of	  primary	  human	  hepatocytes27.	  The	  genes	  encoding	  IFN-­‐λ1,	  -­‐
λ2	  and	   -­‐λ3	  are	  clustered	  on	  human	  chromosome	  19	  and	  each	  of	   them	   is	   composed	  of	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five	   exons9.	   The	   newly	   discovered	   IFNL4	   gene	   is	   also	   located	   within	   the	   IFNL	   locus,	  upstream	  of	  the	  IFNL3	  gene	  and,	  at	   the	  protein	   level,	   is	  only	  expressed	  in	  a	   fraction	  of	  the	   human	   population	   as	   a	   consequence	   of	   a	   genetic	   polymorphism	   that	   induces	   a	  deletion	   frameshift	   in	   the	  ss469415590	  allele27	   (Figure	  1).	  Paradoxically,	   the	  potential	  to	   produce	   the	   fully	   active	   IFN-­‐λ4	   is	   strongly	   associated	   with	   impaired	   clearance	   of	  hepatitis	  C	  virus	  (HCV)	  and	  a	  poorer	  response	  to	  pegylated	  (peg)	  IFN-­‐α/ribavirin	  (RBV)	  combination	  treatment	  of	  chronic	  HCV	  patients27,28.	  However,	  the	  exact	  role	  of	  IFN-­‐λ4	  in	  HCV	  clearance	  remains	  to	  be	  elucidated.	  	  Type	   I	   and	   type	   III	   IFNs	   are	   induced	   by	   similar	   signaling	   pathways29,30	   and	   pDCs	   are	  currently	  thought	  to	  be	  the	  main	  producers	  of	  IFN-­‐λ31,32.	  Besides	  pDCs,	  other	  cells	  such	  as	   respiratory	   epithelial	   cells,	   keratinocytes,	   hepatocytes	   and	   primary	   neuronal	   cells	  have	   also	   been	   reported	   to	   produce	   IFN-­‐λ33.	   Type	   III	   IFNs	   signal	   through	   a	  heterodimeric	   IFN-­‐λ	   receptor	   (IFNLR)	   complex	   consisting	   of	   the	   IFN-­‐λ	   specific	  IFNLR1 chain	   and	   the	   ubiquitously	   expressed	   accessory	   chain	   IL-­‐10R2,	   used	   by	   IL-­‐10	  and	  related	  cytokines9,20,25,34,35.	  In	  contrast	  to	  the	  ubiquitous	  expression	  of	  the	  type	  I	  IFN	  receptor,	   the	   expression	   of	   the	   IFNLR1	   chain	   is	   mostly	   restricted	   to	   epithelial	   cells,	  especially	  in	  the	  respiratory	  and	  the	  gastrointestinal	  tract33,36-­‐38.	  Given	  the	  epithelial	  cell	  restricted	   IFNLR1	   expression,	   the	   type	   III	   IFN	   system	   is	   believed	   to	   primarily	   protect	  mucosal	  epithelial	  cells	  from	  infection38,39	  and	  thus	  to	  serve	  as	  a	  defense	  system	  at	  the	  border,	  where	  virus	  infection	  is	  a	  frequent	  challenge36,39.	  Nevertheless,	  type	  III	  IFNs	  are	  also	  involved	  in	  the	  defense	  of	  hepatotropic	  viruses,	  shown	  for	  hepatitis	  B	  virus	  (HBV)	  and	  HCV40,41.	  	  
	  
1.1.3.1	  Human	  versus	  mouse	  IFN-­‐λ  One	  major	  difference	  between	   the	  human	  and	   the	  mouse	   type	   III	   interferon	  system	   is	  the	  number	  of	  functional	  IFN-­‐λs.	  As	  described	  above	  in	  chapter	  1.1.3,	  the	  human	  type	  III	  IFN	   family	   encompasses	   four	   members;	   IFN-­‐λ1-­‐4.	   In	   contrast,	   the	   mouse	   genome	  encodes	   only	   for	   functional	   IFN-­‐λ2	   and	   IFN-­‐λ3	   proteins	   whereas	   Ifnl1	   is	   a	  pseudogene20,39.	   Furthermore,	   it	   has	   been	   demonstrated	   that	  while	   IFN-­‐λ4	   sequences	  exist	   in	   most	   mammalian	   species	   they	   are	   absent	   in	   rodents42.	   At	   the	   protein	   level,	  human	  and	  mouse	  type	  III	  IFNs	  differ	  in	  their	  glycosylation.	  In	  mice,	  IFN-­‐λ2	  and	  IFN-­‐λ3	  are	  N-­‐glycosylated	  whereas	  in	  humans,	  only	  IFN-­‐λ4	  is	  glycosylated20,34,43.	  Interestingly,	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the	   IFNLR1	   is	   weakly	   expressed	   on	   hepatocytes	   in	   the	   human41	   but	   not	   the	   mouse	  liver38,44.	  Accordingly,	  the	  mouse	  liver	  is	  not	  responsive	  to	  IFN-­‐λ.	  The	  weak	  response	  to	  IFN-­‐λ	  stimulation	  observed	  in	  mouse	  liver	  is	  derived	  from	  cholangiocytes,	  the	  epithelial	  cells	   forming	   the	   bile	   duct44.	   Despite	   these	   differences,	   mouse	   IFN-­‐λs	   have	   strong	  antiviral	   and	   immunomodulatory	   capacities,	   similar	   to	   their	   human	   orthologues20,25.	  Viral	  infection	  studies	  in	  Ifnlr1	  knock	  out	  mice	  identified	  IFN-­‐λ	  as	  a	  potent	  contributor	  in	  controlling	   respiratory	   and	   gastrointestinal	   viruses36.	   Furthermore,	   and	   unlike	   type	   I	  and	  II	  IFNs45,	  mouse	  and	  human	  IFN-­‐λs	  are	  not	  species	  specific	  and	  are	  able	  to	  bind	  the	  receptors	  of	  both	  species.	  Mouse	  IFN-­‐λ2	  and	  IFN-­‐λ3	  were	  capable	  of	  inducing	  antiviral	  protection	  and	  MHC	  class	  I	  antigen	  expression	  in	  several	  human	  cell	  lines.	  The	  same	  was	  true	  for	  human	  IFN-­‐λ1	  in	  mouse	  B16	  cells20. 
 
Figure	   1.	   Schematic	   representation	   of	   the	   genomic	   organization	   of	   the	   IFN-­‐λ 	   genes	   on	   human	  
chromosome	   19	   and	   mouse	   chromosome	   7.	   In	   humans,	   the	   type	   III	   IFN	   family	   consists	   of	   four	  members;	  IFN-­‐λ1-­‐λ4,	  with	  their	  genes	  located	  on	  chromosome	  19.	  An	  intact	  IFN-­‐λ4	  open	  reading	  frame	  is	  only	  present	  in	  the	  human	  sub-­‐population	  bearing	  the	  ΔG	  genotype.	  The	  mouse	  genome	  encodes	  for	  only	  two	  functional	  IFN-­‐λ	  proteins;	  IFN-­‐λ2	  and	  IFN-­‐λ3.	  IFN-­‐λ1	  is	  a	  pseudogene	  because	  of	  a	  stop	  codon	  in	  exon	  1	  and	  lack	  of	  exon	  2.	  Ψ,	  pseudogene46.	  	  	  
1.1.4	  Clinical	  relevance	  of	  interferons	  After	   the	   discovery	   of	   IFNs	   in	   1957,	   it	   was	   expected	   that	   they	   would	   be	   rapidly	  developed	   for	   the	   treatment	   of	   a	   variety	   of	   viral	   infections.	   However,	   their	   species	  specificity47	   and	   difficult	   purification6	   slowed	   down	   their	   therapeutic	   development48.	  Recombinant	  IFN-­‐α-­‐2b	  was	  first	  described	  by	  Hoofnagle	  et	  al.	  as	  potential	  treatment	  of	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non-­‐A,	   non-­‐B	   hepatitis,	   even	   before	   HCV	   was	   first	   described49.	   Finally,	   IFN-­‐α-­‐2b	   was	  approved	   for	   the	   treatment	   of	   HCV	   in	   199150.	   The	   combination	   of	   IFN-­‐α-­‐2b	  with	   the	  nucleoside	   analogue	   RBV	   further	   improved	   the	   rate	   of	   sustained	   virological	   response	  (SVR:	   undetectable	   HCV-­‐RNA	   6	   month	   after	   end	   of	   treatment)	   in	   HCV	   infected	  patients51,52.	   Later	  on,	   IFN-­‐α-­‐2b	  was	   replaced	  by	   IFN-­‐α-­‐2b	   conjugated	   to	  polyethylene	  glycol	   (peginterferon),	   extending	   its	   half-­‐life	   and	   improving	   the	   treatment	   outcome	   in	  HCV	   infected	   patients48,53.	   However,	   the	   development	   of	   new	   direct-­‐acting	   antivirals	  (DAAs)	  has revolutionized	  the	  field	  of	  hepatitis	  C	  treatment	  with	  SVRs	  higher	  than	  90%	  for	  all	  genotypes28,54.	  Apart	  from	  its	  use	  in	  hepatitis	  C,	  IFN-­‐α	  has	  been	  developed	  for	  the	  treatment	   of	   hairy	   cell	   leukemia6,55,	   malignant	  melanoma56	   and	   chronic	   hepatitis	   B57.	  IFN-­‐β	  underwent	  clinical	  development	   for	  multiple	  sclerosis	  and	   is	  currently	  still	  used	  for	   this	   treatment	   indication6,48,58.	   IFN-­‐γ	   is	   approved	   for	   the	   treatment	   of	   chronic	  granulomatous	  disease59,60.	  	  Although	   type	   I	   IFNs	  are	  approved	   for	   the	   treatment	  of	  HCV,	   their	   severe	   side-­‐effects,	  probably	   a	   function	   of	   the	   ubiquitously	   expressed	   IFNAR,	   often	   require	   dosing	  reductions	  or	  treatment	  discontinuations	  and	  thus,	  make	  it	  difficult	  to	  achieve	  a	  SVR61.	  Therefore	   IFN-­‐λs	   might	   be	   an	   alternative	   to	   the	   current	   IFN-­‐α	   therapy	   as	   it	   induces	  fewer	  side	  effects	  with	  restricted	  inflammatory	  costs	  for	  the	  host39	  due	  to	  the	  cell	  type	  specific	   IFNLR	   expression	   and	   a	   more	   restricted	   cell	   response	   pattern60.	   Indeed,	   the	  milder	   side	   effects	   of	   IFN-­‐λ	   compared	   to	   IFN-­‐α were	   confirmed	   in	   phase	   I62	   and	   II40	  clinical	  trials	  with	  pegIFN-­‐λ1	  on	  chronic	  HCV	  patients.	  However,	  the	  phase	  III	  study	  with	  chronic	   HCV	   patients	   could	   not	   demonstrate	   a	   beneficial	   role	   of	   pegIFN-­‐
λ/RBV/telaprevir	  (TVR)	  combination	  compared	  to	  pegIFN-­‐α/RBV/TVR63.	  Although	  IFN-­‐
λ	   will	   most	   probably	   not	   become	   the	   standard	   of	   care	   for	   HCV	   patients,	   it	   has	   the	  potential	   to	  be	  used	   in	   the	   treatment	  of	  other	  diseases.	   Indeed,	   in	  vivo	   studies	  using	  a	  B16	   murine	   melanoma	   model	   revealed	   antitumor	   activities	   for	   IFN-­‐λ20,	   suggesting	   a	  therapeutic	  potential	  in	  cancer	  treatment.	  	  
	  
1.2	  The	  JAK-­‐STAT	  signal	  transduction	  pathway	  The	   binding	   of	   IFNs	   as	   well	   as	   other	   cytokines	   to	   their	   cognate	   receptors	   initiates	   a	  signaling	   cascade	   involving	   Janus	   kinases	   (JAKs),	   the	   IFN	   receptor	   itself	   and	  transcription	   factors	   termed	   signal	   transducers	   and	   activators	   of	   transcription	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(STATs)21,64.	   This	   signal	   cascade	   is	   tailored	   to	   transmit	   the	   IFN	   signal	   from	   the	   cell	  surface	  to	  the	  nucleus,	  resulting	  in	  transcriptional	  induction	  of	  hundreds	  of	  IFN	  induced	  effector	   genes	   termed	   interferon	   stimulated	   genes	   (ISGs)21,65	   (Figure	  2).	   The	   so-­‐called	  canonical	   JAK-­‐STAT	   pathway	   is	   evolutionary	   conserved	   in	   eukaryotic	   organisms	   from	  slime	  molds	  to	  humans	  and	  is	  well	  characterized	  (reviewed	  in23,64,66-­‐69).	  	  
Figure	  2.	  Canonical	  JAK-­‐STAT	  pathway.	  The	  binding	  of	  the	  ligand	  to	  its	  corresponding	  receptor	  induces	  a	  cascade	  of	   tyrosine	  phosphorylation	  events	   that	   finally	   induce	   the	  expression	  of	   interferon	  stimulated	  genes	   (ISGs).	   Cytokine-­‐receptor	   interaction	   triggers	   dimerization	   of	   the	   receptor,	   followed	   by	  transphosphorylation	   and	   activation	   of	   the	   receptor-­‐associated	   Janus	   kinases	   (JAKs).	   This	   leads	   to	   the	  phosphorylation	  of	  the	  cytoplasmic	  receptor	  tails	  and	  recruitment	  of	  the	  signal	  transducers	  and	  activators	  of	   transcription	   (STATs)	   proteins.	   STATs	   become	   activated	   by	   phosphorylation,	   form	   dimers	   and	  translocate	  to	  the	  nucleus	  where	  they	  induce	  the	  expression	  of	  ISGs.	  Modified	  from66.	  	  
1.2.1	  Janus	  kinases	  JAKs	   are	   evolutionary	   conserved	   tyrosine	   kinases	   that	   associate	   with	   cytokine	  receptors67.	  In	  mammals,	  the	  family	  of	  JAKs	  comprises	  four	  members;	  JAK1,	  JAK2,	  JAK3	  and	   tyrosine	   kinase	   2	   (TYK2)70-­‐76.	   While	   JAK1,	   JAK2	   and	   TYK2	   are	   ubiquitously	  expressed,	  JAK3	  expression	  is	  mostly	  restricted	  to	  NK	  and	  T	  cells74.	  	  As	  shown	  in	  Figure	  3,	  different	  cytokine	  receptor	  chains	  are	  associated	  with	  particular	  JAKs.	  Specifically,	  JAK1	  and	  TYK2	  associate	  with	  the	  type	  I	  IFN	  receptor	  chains	  IFNAR2	  
ISGs
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and	   IFNAR168,77,78	   and	   also	   with	   the	   type	   III	   IFN	   receptor	   chains	   IFNLR128,79	   and	   IL-­‐10R235,80,	  respectively.	  The	  type	  II	  IFN	  receptor	  chains	  IFNGR1	  and	  IFNGR2	  on	  the	  other	  hand	   are	   complexed	   with	   JAK1	   and	   JAK2,	   respectively81,82.	   Cytokine	   binding	   leads	   to	  receptor	  dimerization	  that	   in	   turn	   facilitates	   transactivation	  of	   the	  receptor-­‐associated	  JAKs	  through	  mutual	  tyrosine	  phosphorylation.	  Next,	  the	  activated	  JAKs	  phosphorylate	  tyrosine	   residues	   on	   the	   intracellular	   receptor	   chains	   creating	   docking	   sites	   for	  STATs7,67,68	  (Figure	  2).	  	  	  
1.2.2	  Signal	  transducers	  and	  activators	  of	  transcription	  STATs	   comprise	   a	   family	   of	   latent,	   cytoplasmic	   transcription	   factors	   that	   are	   rapidly	  activated	   upon	   receptor-­‐ligand	   coupling.	   They	   act	   as	   both,	   signaling	   molecules	   and	  transcription	  factors,	  shuttling	  between	  cytoplasm	  and	  nucleus21,69.	  In	  mammals,	  seven	  STAT	  genes	  have	  been	  identified67,83,	  STAT1	  and	  STAT284,	  STAT385,	  STAT486,87,	  STAT5A88,	  




Figure	   3.	   IFN	   signaling	   through	   the	   JAK-­‐STAT	   pathway.	   All	   IFN	   receptors	   connect	   to	   the	   JAK-­‐STAT	  pathway	  to	  transmit	  signals	  from	  the	  cell	  surface	  to	  the	  nucleus.	  Type	  I	  and	  type	  III	   IFNs	  signal	  through	  distinct	  receptors	  but	  activate	  the	  same	  downstream	  signaling	  cascade.	  They	  mainly	  induce	  the	  formation	  of	   the	   heterotrimeric	   transcription	   factor	   IFN-­‐stimulated	   gene	   factor	   3	   (ISGF3)	   complexes	   and	   STAT1	  homodimers	  that	  bind	  to	  IFN-­‐stimulated	  response	  elements	  (ISRE)	  and	  gamma	  activated	  sequence	  (GAS)	  elements	  in	  the	  nucleus,	  respectively.	  This	  leads	  to	  the	  expression	  of	  a	  highly	  overlapping	  set	  of	  interferon	  stimulated	  gens	  (ISGs).	  By	  contrast,	  IFN-­‐γ	  (the	  only	  type	  II	  IFN),	  induces	  STAT1	  homodimers	  but	  does	  not	  activate	  the	  ISGF3	  complex	  thus,	  inducing	  a	  partially	  overlapping	  but	  distinct	  set	  of	  ISGs	  compared	  to	  type	  I	  and	  III	  IFNs.	  Modified	  from13.	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(PIAS)),	  while	  others	  are	  ISGs	  themselves	  that	  are	  transcriptionally	  induced	  by	  IFNs.	  The	  latter	   group	   is	   represented	   by	   suppressor	   of	   cytokine	   signaling	   (SOCS)	   and	  ubiquitin-­‐specific	   peptidase	   18	   (USP18)	   that	   act	   in	   a	   negative-­‐feedback	   loop	   on	   the	   JAK-­‐STAT	  cascade.	  	  	  
1.3.1	  Constitutively	  expressed	  negative	  regulators	  of	  the	  JAK-­‐STAT	  pathway	  The	  first	  group	  of	  molecules	  identified	  as	  negative	  regulators	  of	  cytokine	  signaling	  were	  protein	  tyrosine	  phosphatases	  (PTPs)113.	  They	  encompass	  a	  large	  and	  diverse	  family	  of	  more	  than	  100	  enzymes	  with	  high	  substrate	  specificity114,115.	  SH2	   domain-­‐containing	   phosphatase	   1	   (SHP1)	   and	   SHP2	   are	   two	   constitutively	  expressed	  cytoplasmic	  PTPs.	  SHP1	  is	  mainly	  expressed	  in	  hematopoietic	  cells	  and	  has	  an	  important	   regulatory	   function	   in	   immune	   cells116,117.	   In	   contrast,	   SHP2	   is	   ubiquitously	  expressed	   and	   appears	   to	   be	   involved	   in	   many	   signaling	   pathways	   downstream	   of	  growth	  factors	  and	  cytokines118,119.	  SHP2	  serves	  primarily	  as	  a	  positive	  regulator	  during	  cell	  growth	  and	  development119.	  However,	  SHP2	  has	  dual	   functions	  as	   it	  also	  regulates	  the	   JAK-­‐STAT	   pathway	   upon	   IFN-­‐γ	   and	   to	   lesser	   extent	   IFN-­‐α	   induction	   in	   mouse	  fibroblast	   cells118.	   Both	   SHP1	   and	   SHP2	   attenuate	   the	   cytokine-­‐mediated	   signal	  transduction	   by	   dephosphorylating	   the	   cytokine	   receptors,	   JAKs	   and/or	  STATs107,110,111,116	  (Figure	  4).	  	  Protein	  tyrosine	  phosphatase	  1B	  (PTP1B)	  and	  T	  cell	  protein	  tyrosine	  phosphatase	  (TC-­‐PTP)	   are	   two	   closely	   related	   PTPs	   involved	   in	   regulation	   of	   several	   signaling	  pathways120.	  Although	  closely	  related,	  knockout	  studies	  in	  mice	  suggest	  distinct	  function	  of	  the	  two	  proteins120.	  PTP1B	  knockout	  studies	  demonstrated	  that	  this	  PTP	  plays	  a	  role	  in	   the	   leptin	   and	   insulin	   metabolism114,120,	   suggesting	   to	   be	   the	   key	   link	   between	  metabolic	   diseases	   and	   inflammation115.	   On	   the	   other	   hand,	   TC-­‐PTP	   is	   strongly	  expressed	   in	   the	   hematopoietic	   system	   and	   has	   a	   critical	   role	   in	   the	   regulation	   of	  immune	   homeostasis121,	   as	   shown	   in	   knockout	   mice	   that	   die	   from	   systemic	  inflammation	   and	  defects	   in	   hematopoiesis122.	   Furthermore,	   it	  was	   demonstrated	   that	  PTP1B	  and	  TC-­‐PTP	  negatively	  regulate	  cytokine	  signaling	  at	  the	  level	  of	  the	  receptors	  by	  dephosphorylation	   of	   JAK2	   and	   TYK2114	   and	   JAK1	   and	   JAK3121,	   respectively.	   Of	   note,	  TC45	  (also	  named	  TC-­‐PTPa),	  the	  nuclear	  isoform	  of	  TC-­‐PTP	  is	  able	  to	  dephosphorylate	  STAT1	   and	   STAT3	   induced	   by	   IFN-­‐α,	   IFN-­‐γ	   and	   IL-­‐6	  within	   the	   nucleus	   of	  MEFs	   and	  primary	  thymocytes123	  (Figure	  4).	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CD45	  is	  a	  another	  negative	  regulator	  of	  cytokine	  signaling	  that	  specifically	  bind	  to	  and	  dephosphorylates	   JAKs	   within	   hematopoietic	   cells124.	   Its	   role	   on	   hematopoiesis	   is	  underscored	  by	  the	  finding	  that	  10%	  of	  lymphoblastic	  leukemia	  patients	  show	  a	  loss	  of	  CD45125.	  	  The	  mammalian	  PIAS	   family	   includes	   PIAS1,	   PIAS3,	   PIASx	   and	  PIASy126,127.	   PIAS1	   and	  PIAS3	   specifically	   bind	   to	   dimers	   of	   tyrosine	   phosphorylated	   STAT1126	   and	   STAT3127,	  respectively,	   and	   block	   their	   DNA	   binding	   capacity,	   thereby	   inhibiting	   transcriptional	  activation107,126.	  PIAS	  proteins	  may	  act	  like	  a	  buffer	  titrating	  the	  concentration	  of	  active	  STAT	  dimers	  that	  are	  available	  within	  a	  cell	  upon	  cytokine	  stimulation112	  (Figure	  4).	  	  	  Taken	  together,	  these	  constitutively	  expressed	  molecules	  have	  a	  different	  physiological	  function	   compared	   to	   the	   inducible	  negative	   regulators	   that	   act	   in	   a	   classical	  negative	  feedback	  loop	  on	  cytokine	  stimulation	  (described	  in	  section	  1.3.2).	  	  
	  
	  
Figure	  4.	  Negative	  regulation	  of	  the	  JAK-­‐STAT	  pathway.	  The	  Janus	  kinase	  (JAK)-­‐signal	  transducer	  and	  activator	  of	   transcription	   (STAT)	  pathway	   is	   regulated	  at	   the	   level	  of	   the	  receptors,	   signaling	  molecules	  and	   transcription	   factors.	  Protein	   tyrosine	  phosphatases	   (PTPs)	  and	  protein	   inhibitor	  of	  activated	  STAT	  (PIAS)	   represent	   the	   constitutively	   expressed	   negative	   regulators.	   In	   contrast,	   suppressor	   of	   cytokine	  signaling	   (SOCS)	   and	  ubiquitin-­‐specific	  peptidase	  18	   (USP18)	  belong	   to	   the	  group	  of	   cytokine-­‐inducible	  regulators	  that	  inhibit	  the	  JAK-­‐STAT	  pathway.	  Modified	  from111.	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1.3.2	  Cytokine-­‐inducible	  negative	  regulators	  of	  the	  JAK-­‐STAT	  pathway	  As	   mentioned	   above,	   besides	   constitutively	   expressed	   regulators,	   there	   are	   also	  inducible	  negative	   regulators	   of	   the	   JAK-­‐STAT	   signaling	   cascade,	   namely	   several	   SOCS	  proteins	  and	  USP18.	  	  	  	  




Figure	   5.	   Structural	   organization	   and	   mode	   of	   action	   of	   SOCS	   proteins.	   (A)	   The	   suppressor	   of	  cytokine	  signaling	  (SOCS)	  family	  consists	  of	  8	  members,	  including	  the	  cytokine-­‐inducible	  SH2-­‐containing	  protein	   (CIS)	   and	   SOCS1-­‐7.	   All	   of	   these	   proteins	   share	   a	   similar	   structure	   with	   a	   variable	   N-­‐terminal	  domain,	  an	  extended	  SH2	  domain	  (ESS),	  a	  SH2	  domain	  and	  a	  C-­‐terminal	  SOCS	  box.	  SOCS1	  and	  SOCS3	  are	  the	   only	   members	   that	   have	   an	   additional	   kinase	   inhibitory	   region	   (KIR)	   domain.	   (B)	   Left	   side:	   Upon	  binding	  of	  cytokines	  to	  the	  corresponding	  receptor,	  the	  JAK-­‐STAT	  cascade	  becomes	  activated	  and	  induces	  the	  transcription	  of	  several	  IFN-­‐stimulated	  genes	  (ISGs),	   including	  SOCS	  genes.	  Right	  side:	  SOCS	  proteins	  inhibit	  JAK-­‐STAT	  signaling	  by	  multiple	  mechanisms	  including	  (1.)	  the	  KIR-­‐dependent	  JAK	  inhibition,	  (2.)	  the	   SH2-­‐dependent	   competition	   for	   receptor	   motifs	   and	   (3.)	   the	   SOCS	   box-­‐dependent	   proteasomal	  targeting.	  The	  colors	  used	  for	  the	  different	  parts	  of	  the	  SOCS	  proteins	  correspond	  to	  those	  in	  Figure	  5A135.	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One	   important	   mechanism	   is	   the	   KIR-­‐dependent	   JAK	   inhibition	   (shown	   under	   1.	   in	  Figure	   5B,	   right	   side).	   The	   KIR	   domain	   of	   SOCS1	   and	   SOCS3	   directly	   inhibits	   the	   JAK	  catalytic	   activity133,134.	   It	   was	   demonstrated	   that	   SOCS1	   directly	   binds	   to	   the	   tyrosine	  residue	   in	  the	  activation	   loop	  of	   JAKs129-­‐131	  whereas	  SOCS3	  inhibits	   JAKs	  by	  binding	  to	  the	   tyrosine	   residues	   of	   the	   cytokine	   receptor	   in	   close	   proximity	   of	   the	   kinase136,137.	  Furthermore,	  SOCS1	  is	  able	  to	   inhibit	  all	   four	  known	  mammalian	  JAKs	  whereas	  SOCS3	  affects	  only	  three	  of	  them;	  JAK1,	  JAK2	  and	  Tyk2	  but	  not	  JAK3138,139.	  	  An	  additional	  mode	  of	  action	  of	  the	  SOCS	  proteins	  is	  the	  SH2-­‐dependent	  competition	  for	  receptor	   motifs	   (shown	   under	   2.	   in	   Figure	   5B,	   right	   side).	   For	   example,	   CIS	   prevents	  STAT5	   recruitment	   by	   binding	   with	   its	   SH2	   domain	   to	   the	   phosphorylated	   cytokine	  receptor140-­‐142.	  	  Finally,	  SOCS	  box-­‐dependent	  proteasomal	  targeting	  represents	  the	  third	  mode	  of	  action	  of	  SOCS	  proteins	  (shown	  under	  3.	  in	  Figure	  5B,	  right	  side).	  The	  SH2	  and	  the	  ESS	  domain	  bind	  phosphorylated	  tyrosine	  motifs133	  while	  the	  SOCS	  box	  forms	  an	  E3	  ubiquitin	  ligase	  complex	  that	  leads	  to	  the	  ubiquitination	  of	  the	  target	  proteins135,143.	  Thus,	  marking	  SOCS	  target	  proteins	  for	  proteasomal	  degradation135,144.	  	  	  
1.3.2.1.1	  Suppressor	  of	  cytokine	  signaling	  1	  and	  3	  SOCS	  family	  proteins	  are	  induced	  by	  cytokines	  and	  growth	  factors	  including	  IFN-­‐α,	  IFN-­‐
β,	   IFN-­‐γ	   and	   IFN-­‐λ	   in	   vitro	   and	   in	   vivo145-­‐150	   with	   the	   magnitude	   of	   induction	   being	  dependent	  on	  the	  cell-­‐type	  and	  stimuli129,151.	  	  SOCS1	  and	  SOCS3	  are	  considered	  as	   the	   two	  most	  potent	  members	  of	   the	  SOCS	   family	  probably	  because	   their	  primary	  mode	  of	  action	   is	  mediated	  by	   the	  KIR	  domain	   that	   is	  absent	   from	   all	   other	   SOCS	   proteins133,134.	   The	   KIR	   domain	   enables	   direct	   SOCS-­‐JAK	  interaction	  and	  thus	  inhibition	  of	  the	  JAKs	  enzymatic	  activity152.	  Of	  note,	  SOCS2,	  a	  SOCS	  member	   devoid	   of	   the	   KIR	   domain,	   has	   no	   inhibitory	   effect	   on	   the	   type	   I	   and	   II	   IFN-­‐induced	  signaling	  cascade153.	  Interestingly	  however,	  the	  C-­‐terminal	  SOCS-­‐box,	  although	  conserved	  in	  all	  SOCS,	  seems	  to	  be	  dispensable	  for	  the	  inhibition	  of	  cytokine	  signaling154.	  Initially	  SOCS1	  and	  SOCS3	  were	  identified	  as	  inhibitors	  of	  the	  type	  I	  and	  II	  IFN-­‐induced	  JAK-­‐STAT	  signaling	   in	   in	  vitro	   studies	   including	  SOCS	  overexpression153,155	  with	  SOCS1	  showing	  more	   potent	   inhibition	   than	   SOCS3153.	   The	   effect	   of	   SOCS1	   on	   IFN-­‐γ-­‐induced	  signaling	   was	   further	   confirmed	   using	   SOCS1	   knockout	   cells156.	   More	   recent	  overexpression	  studies	  established	  that	  SOCS1	  and	  SOCS3	  also	  act	  as	  negative	  regulators	  
I	  Introduction	  
	  14	  
on	  IFN-­‐λ	  signaling	  and	  expression	  of	  antiviral	  genes157-­‐159.	  Taken	  together,	  according	  to	  the	  in	  vitro	  data,	  the	  negative	  regulatory	  activity	  of	  SOCS1	  and	  SOCS3	  extends	  to	  type	  I,	  II	  and	  III	  IFN	  signaling.	  
In	  vivo	  studies	  with	  Socs1	  –	  Ifng	  double	  knockout	  mice	  confirmed	  the	  effect	  of	  SOCS1	  on	  type	  I	  and	  II	  IFN	  signaling	  observed	  in	  vitro145,149,156,160.	  Of	  note,	  the	  premature	  death	  of	  
Socs1	   single	   knockout	   mice	   caused	   primarily	   by	   hypersensitivity	   to	   IFN-­‐γ161,162	   is	  prevented	  by	  Socs1	  –	  Ifng	  double	  knockout163,	  demonstrating	  SOCS1	  as	  a	  key	  modulator	  of	  IFN-­‐γ	  signaling.	  	  SOCS3	  deficient	  mice	  exhibit	  embryonic	  lethality164,165.	  However,	  studies	  of	  mice	  with	  a	  conditional	  SOCS3	  deletion	  in	  the	  liver	  or	  in	  macrophages	  demonstrated	  normal	  STAT1	  activation	   by	   IFN-­‐γ156,	   contradicting	   the	   in	   vitro	   results	   obtained	   with	   SOCS3	  overexpression.	   Although	   SOCS	   overexpression	   studies	   showed	   that	   they	   have	  inhibitory	   effects	   on	   a	   wide	   range	   of	   cytokines,	   in	   vitro	   and	   in	   vivo	   knock	   out	  experiments	  revealed	  a	  much	  more	  specific	  activity	  for	  only	  a	  few	  cytokines139.	  	  Taken	  together,	  it	  seems	  clear	  that	  SOCS1	  is	  a	  potent	  negative	  regulator	  of	  type	  I	  and	  II	  IFN	  signaling	  in	  vitro	  and	  in	  vivo,	  whereas	  its	  role	  on	  IFN-­‐λ	  signaling	  needs	  to	  be	  further	  investigated	   in	   a	   more	   physiological	   experimental	   setting.	   Similarly,	   while	   SOCS3	  overexpression	   in	   vitro	   inhibits	   IFN-­‐λ	   signaling,	   its	   role	   in	   vivo	   needs	   to	   be	   further	  clarified.	  	  	  
1.3.2.2	  Ubiquitin-­‐specific	  peptidase	  18	  Besides	   the	   SOCS	   proteins	   discussed	   in	   the	   previous	   section,	   USP18	   is	   an	   additional	  cytokine-­‐inducible	  negative	  regulator	  of	  the	  JAK-­‐STAT	  pathway.	  USP18	  is	  known	  to	  play	  a	  dual	  role;	  as	  an	  ISG15	  isopeptidase	  as	  well	  as	  a	  negative	  regulator	  of	  the	  IFN	  system166.	  USP18	   (initially	   named	   UBP43	   because	   of	   its	   molecular	   weight	   of	   43kDa)	   was	   first	  described	   in	   1999	   as	   a	   murine	   protein	   with	   deubiquitinating	   enzyme	   activity167.	   The	  human	   orthologue	   showing	   70%	   homology	   with	   the	   murine	   USP18	   protein	   was	  identified	  one	  year	  later168.	  Human	  USP18	  exists	  as	  two	  isoforms;	  the	  full	  length	  and	  the	  N-­‐terminal	  truncated	  form.	  The	  translation	  of	  the	  full-­‐length	  USP18	  protein	  is	   initiated	  by	   a	   rare	   start	   codon	   CUG,	   characterized	   by	   a	   low	   translation	   initiation	   efficiency	  followed	  by	  a	  frequent	  skip	  by	  the	  scanning	  ribosome	  that	  promotes	  the	  expression	  of	  the	  truncated	  USP18169.	  USP18	  belongs	  to	  a	  large	  family	  of	  ubiquitin-­‐specific	  proteases,	  enzymes	   that	   cleave	   ubiquitin	   from	   ubiquitinated	   protein	   substrates167,168.	   Although	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USP18	  shows	  significant	  homology	  to	  well-­‐characterized	  ubiquitin-­‐specific	  peptidases,	  it	  only	   efficiently	   cleaves	   the	   ubiquitin-­‐like	   protein	   ISG15	   from	   ISGylated	   proteins170,171.	  Therefore,	   its	   enzymatic	   activity	   seems	   to	   be	   crucial	   for	   proper	   cellular	   balance	   of	  ISG15-­‐conjugated	  proteins	  in	  healthy	  and	  stressed	  organisms170,171.	  	  The	   expression	   of	   USP18	   is	   strongly	   induced	   by	   viral	   infection,	   IFNs	   and	  lipopolysaccharides	   (LPSs)	   assuming	   a	   role	   in	   processes	   including	   cell	   proliferation,	  inflammation,	  stress	  and	  immune	  responses170,172.	  However,	  the	  magnitude	  of	  induction	  is	  cell-­‐type-­‐specific	  and	  varies	  a	  lot	  in	  response	  to	  different	  stimuli166.	  Amongst	  others,	  the	  expression	  of	  USP18	  is	  induced	  by	  type	  I	  and	  type	  III	  IFNs	  in	  vitro	  and	  in	  vivo147,148,173	  and	  is	  not	  induced	  by	  IFN-­‐γ147,173.	  Importantly,	  USP18	  is	  not	  only	  an	  isopeptidase	  but	  has	  also	  a	  role	  as	  a	  potent	  inhibitor	  of	  IFN	  signaling,	  independently	  of	  its	  enzymatic	  function	  towards	   ISG15109,174.	   USP18	   was	   initially	   described	   as	   a	   potent	   negative	   regulator	   of	  type	   I	   IFN	   signaling	   in	  vitro174.	   For	   example,	  murine	   and	  human	  USP18	  deficient	   cells	  were	   hypersensitive	   to	   IFN-­‐α	   and	   IFN-­‐β	   stimulation	   evident	   as	   prolonged	   STAT1	  phosphorylation	  and	  increased	  ISG	  induction	  and	  eventual	  apoptosis109,174-­‐176.	  Of	  note,	  it	  has	   been	   demonstrated	   that	   both	   human	   isoforms,	   the	   full	   length	   and	   the	  N-­‐terminal	  truncated	  USP18,	  do	  not	  differ	  in	  the	  negative	  regulation	  of	  the	  IFN-­‐α-­‐induced	  signaling	  cascade169.	  Direct	  binding	  of	   the	  C-­‐terminus	  of	  USP18	   to	   the	   IFNAR2	  subunit	  prevents	  the	  interaction	  of	   JAK1	  with	  the	  receptor,	   in	  turn	  blocking	  downstream	  signaling109.	   In	  contrast	  to	  type	  I	  IFNs,	  USP18	  does	  not	  modulate	  the	  IFNγ-­‐induced	  JAK-­‐STAT	  signaling	  pathway174,177	   and	   does	   not	   interact	   with	   the	   IFNGR109.	   Overexpression	   studies	  demonstrated	   that	  USP18	  has	  a	  marginal	   inhibitory	  effect	  on	   IFN-­‐λ induced	   JAK-­‐STAT	  pathway	   in	   vitro173.	   Furthermore,	   co-­‐immunoprecipitation	   experiments	   suggest	   that	  USP18	  does	  not	  directly	  bind	  the	  IFNLR1178.	  Taken	  together,	  the	  in	  vitro	  data	  showed	  a	  negative	  regulatory	  role	  of	  USP18	  on	  the	  type	  I	  IFN	  system,	  no	  effect	  on	  the	  type	  II	  IFN	  system and	  a	  minor	  effect	  on	  the	  type	  III	  IFN	  system.	  Importantly,	  the	  strong	  inhibitory	  effect	  of	  USP18	  on	  IFN-­‐α	  induced	  JAK-­‐STAT	  signaling	  observed	  in	  vitro,	  was	  confirmed	  in	  USP18	  deficient	  mice148	  and	  is	  underscored	  by	  a	  rare	  human	   type	   I	   interferonopathie,	   the	   pseudo-­‐TORCH	   syndrome.	   This	   disease	   is	  characterized	  by	  a	  USP18	  deficiency	   leading	  to	  an	  uncontrolled	  type	   I	   IFN	  system	  that	  results	  in	  severe	  brain	  damage179.	  Furthermore,	  it	  was	  demonstrated	  that	  USP18	  is	  responsible	  for	  the	  establishment	  of	  a	  long	   lasting	   desensitized	   state	   upon	   type	   I	   and	   III	   IFNs,	   leading	   to	   IFN-­‐α	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unresponsiveness	   for	  up	   to	  72h.	  This	   long	   lasting	   refractoriness	  was	  not	  observed	   for	  IFN-­‐β,	  IFN-­‐γ	  or	  IFN-­‐λ147,148,173.	  This	  suggests	  that	  the	  inhibitory	  effect	  of	  USP18	  is	  specific	  to	   IFN-­‐α	   induced	   signaling.	   In	   contrast,	   a	   different	   study	   postulates	   USP18	   as	   an	  inhibitor	  of	  IFN-­‐λ-­‐induced	  signaling178.	  	  Taken	   together,	   USP18	   is	   a	   potent	   negative	   inhibitor	   of	   the	   IFN-­‐α induced	   JAK-­‐STAT	  pathway	   in	   vitro	   and	   in	   vivo	   but	   has	   no	   effect	   on	   type	   II	   IFN-­‐induced	   signaling.	  Importantly,	   its	   inhibitory	   role	   on	   IFN-­‐λ-­‐induced	   signaling	   is	   still	   a	   matter	   of	  controversy	  and	  needs	  further	  clarification.	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2	  Liver	  Cancer	  Liver	  cancer	   is	   the	  sixth	  most	  common	  cancer	  worldwide	  with	  approximately	  850’000	  new	  cases	  annually	  with	  increasing	  incidence	  rates180,181.	  Around	  800’000	  people	  die	  of	  liver	  cancer	  each	  year	  which	  ranks	   this	  disease	  as	   the	  second	   leading	  cause	  of	  cancer-­‐related	   deaths	   worldwide181,182.	   The	   ratio	   of	   mortality	   to	   incidence	   is	   close	   to	   one,	  showing	  a	  very	  poor	  prognosis	  for	  patients	  suffering	  from	  liver	  cancer181.	  The	  majority	  (80-­‐90%)	  of	  primary	  liver	  cancers	  are	  hepatocellular	  carcinoma	  (HCC)	  originating	  from	  hepatocytes,	   the	   epithelial	   liver	   cells183-­‐185.	   The	   second	   most	   frequent	   primary	   liver	  cancers	   accounting	   for	   10-­‐12%	   of	   all	   cases	   are	   intrahepatic	   cholangiocarcinomas	  originating	   from	   cholangiocytes,	   the	   epithelial	   cells	   that	   line	   the	   bile	   ducts181,183.	  Furthermore,	   hepatic	   angiosarcoma186	   and	   the	   pediatric	   neoplasm,	   hepatoblastoma187	  are	  two	  very	  rare	  forms	  of	  liver	  cancer.	  In	  the	  following	  chapters	  we	  will	  focus	  on	  HCC.	  	  	  
2.1	  Etiologies	  of	  hepatocellular	  carcinoma	  	  The	  burden	  of	  liver	  cancer	  is	  not	  evenly	  distributed	  throughout	  the	  world.	  Incidence	  and	  mortality	  rates	  vary	  between	  countries,	  reflecting	  the	  uneven	  distribution	  of	  major	  risk	  factors	   responsible	   for	   HCC	   development183,185,188	   as	   shown	   in	   Table	   1	   and	   Figure	   6.	  Various	   etiologies	   have	   been	   linked	   to	   HCC	   development,	   including	   HBV	   and	   HCV	  infection,	   aflatoxin	   B1	   intake,	   chronic	   alcohol	   consumption	   and	   obesity,	   typically	  conditions	  that	  induce	  cirrhosis180,189.	  The	  different	  risk	  factors	  and	  their	  mechanism	  of	  hepatocarcinogenesis	  are	  summarized	  in	  Figure	  7	  and	  will	  be	  described	  in	  more	  detail	  below.	   The	   highest	   prevalence	   of	   HCC	   is	   observed	   in	   sub-­‐Saharan	   Africa	   and	   east	  Asia181,183,	   where	   viral	   hepatitis	   is	   endemic190,	   with	   China	   alone	   accounting	   for	   more	  than	   50%	   of	   the	   total	   number	   of	   HCC	   cases	   and	   deaths	   worldwide181,191	   (Figure	   6).	  Whereas	   in	   the	  majority	   of	   these	   high-­‐rate	   HCC	   countries	   chronic	   HBV	   infection	   and	  aflatoxin	   B1	   exposure	   are	   the	   leading	   risk	   factors,	   HCV	   infection,	   alcohol	   abuse	   and	  obesity	   have	   become	   important	   risk	   factors	   in	   Western	   Europe	   and	   Northern	  America183,191	  (Table	  1).	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Table	   1:	   Geographical	   distribution	   of	   main	   risk	   factors	   for	   HCC	   worldwide	   NASH:	   non-­‐alcoholic	  steatohepatitis.	  Modified	  from185.	  	  
	  
	  
Figure	  6.	  Regional	  variation	  in	  the	  age-­‐standardized	  incidence	  (blue)	  and	  death	  (red)	  rates	  of	  liver	  
cancer.	  Number	  of	  cases	  per	  100’000	  persons	  (Source:	  GLOBOCAN	  2012	  (IARC)).	  	  
Chronic	  HBV	  infection.	  Chronic	  HBV	  infection	  is	  one	  of	  the	  major	  risk	  factors	  that	  can	  lead	  to	  liver	  damage,	  resulting	  in	  fibrosis	  and	  cirrhosis	  and	  finally	  HCC183-­‐185,192.	  Chronic	  HBV	  infection	  accounts	  for	  approximately	  50%	  of	  all	  HCC	  cases	  around	  the	  world	  (Table	  1),	  with	  the	  majority	  (70-­‐80%)	  of	  patients	  with	  HBV-­‐related	  HCC	  having	  cirrhosis193.	  At	  least	   three	  mechanisms	  by	  which	  HBV	   infection	  could	  contribute	   to	  HCC	  development	  have	   been	   suggested.	   First,	   viral	   proteins	   (especially	   the	   hepatitis	   B	   protein	   X	   (HBx))	  
HCV$[%] HBV$[%] Alcohol$[%] Others$[%]
Europe 60870 10815 20 10
North$America 50860 20 20 10$(NASH)
Asia$and$Africa 20 70 10 10$(Aflatoxin$B1)
Japan 70 10820 10 10
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have	  been	   reported	   to	  modulate	   cell	   proliferation	   and	   viability194.	   For	   example,	   it	   has	  been	   shown	   that	   84%	   of	   transgenic	   mice	   with	   elevated	   levels	   of	   the	   HBx	   protein	  developed	   HCC	   by	   the	   age	   of	   13-­‐24	   months195.	   However,	   the	   direct	   evidence	   from	  human	  tissues	   is	  still	  missing.	  Second,	  the	  HBV	  life	  cycle	   involves	  the	  presence	  of	  viral	  DNA	  in	  the	  nucleus	  that	  is	  prone	  to	  integration	  into	  the	  human	  genome.	  Such	  integration	  in	   cellular	   DNA	   of	   human	   HCCs	   was	   first	   reported	   in	   the	   1980s196-­‐198.	   The	   HBV	   DNA	  integration	   often	   leads	   to	   rearrangement	   of	   the	   targeted	   and	   flanking	   regions,	  potentially	   activating	   oncogenes	   and	   inducing	   chromosomal	   instability199,200.	   Of	   note,	  most	  of	   the	  observed	   integrations	  were	  not	  recurrent	  and	  appeared	  only	   in	  one	  of	   the	  analyzed	   samples.	   However,	   a	   few	   genes	   with	   recurrent	   integration	   sites	   were	  identified,	  among	  them	  the	  promoter	  region	  of	  telomerase	  reverse-­‐transcriptase	  (TERT),	  which	  can	  activate	  telomerase	  and	  other	  oncogenes194,201.	  Third,	  chronic	  HBV	  infection	  induces	   hepatocyte	   injury	   and	   inflammation,	   which	   triggers	   necrosis	   and	   HCC	  development200,202	  (Figure	  7).	  	  
Aflatoxin	  B1.	  Epidemiological	   studies	  have	  proven	   that	   there	   is	  a	  correlation	  between	  consumption	   of	   aflatoxin	   B1	   contaminated	   food	   and	   HCC	   development184,185,203.	  Aflatoxins	  are	  fungal	  metabolites	  that	  contaminate	  food,	  especially	  in	  regions	  of	  Asia	  and	  sub-­‐Saharan	  Africa	  where	  poor	   food	  storage	  condition	   is	  a	  problem183,185.	  Aflatoxin	  B1	  intake	  was	  correlated	  with	  mutations	  in	  the	  tumor	  suppressor	  gene	  TP53	  and	  increased	  incidence	   of	   HCC,	   especially	   in	   HBV-­‐infected	   individuals204,205.	   However,	   two	   case	  control	  studies	  suggest	  aflatoxin	  B1	  as	  a	  direct	  risk	   factor	   for	  HCC	  development	   in	   the	  absence	  of	  chronic	  HBV	  infection206,207.	  	  
Chronic	  HCV	  infection.	  HCV,	  a	  RNA	  virus,	  has	  been	  declared	  as	  a	  human	  carcinogen	  by	  the	   International	  Agency	   for	  Research	   on	  Cancer	   (IARC)	   in	   1994.	  Different	   from	  HBV,	  HCV	  infection	  is	  more	  prevalent	   in	  Europe,	  the	  United	  States	  and	  Japan	  where	  it	   is	  the	  major	  risk	  factor	  for	  HCC	  development183,208	  (Table	  1).	  About	  15-­‐35%	  of	  chronically	  HCV	  infected	   individuals	   develop	   HCC	   by	   the	   age	   of	   75183,192.	   In	   most	   of	   the	   HCV-­‐related	  HCCs,	  cancer	  development	  is	  preceded	  by	  advanced	  hepatic	  fibrosis	  or	  cirrhosis209.	  Since	  HCV,	   in	   contrast	   to	  HBV,	  does	  not	   integrate	   in	   the	  human	  genome,	   its	  HCC	  promoting	  activity	   most	   likely	   involves	   induction	   of	   hepatic	   inflammation	   and	   fibrosis	   and	  promoting	   malignant	   transformation	   of	   infected	   cells208,210,211	   (Figure	   7).	   Of	   note,	   a	  meta-­‐analysis	   of	   21	   published	   studies	   suggests	   that	   patients	   infected	   with	   HCV	   of	  genotype	   1b	   have	   an	   increased	   risk	   of	   developing	  HCC	   compared	   to	   patients	   infected	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with	   any	   other	   genotype	   of	   HCV212.	   However,	   it	   is	   still	   unclear	   if	   HCV	   is	   a	   direct	  carcinogen	  or	  whether	  other	  pathological	   conditions	   (e.g.	   steatosis,	  oxidative	  stress	  or	  inflammation)	   that	   are	   linked	   to	   chronic	   viral	   infection	   are	   the	   cause	   of	   HCC	  development	  and	  progression213,214.	  
Alcohol	   abuse.	   Additional	   to	   the	   above	   mentioned	   risk	   factors,	   excessive	   alcohol	  consumption,	   is	   another	   leading	   cause	  of	  HCC,	   especially	   in	  developed	   countries183,208.	  Chronic	   alcohol	   intake	   is	   linked	   to	   inflammation	   that	   increases	   hepatocyte	   turnover,	  oxidative	  stress	  and	  the	  risk	  to	  develop	  cirrhosis,	  eventually	  leading	  to	  HCC189,215	  (Figure	  7).	  
Metabolic	  syndrome	  and	  others.	  Recently,	  metabolic	  syndrome	  resulting	  from	  diabetes	  and	  obesity	  and	  the	  associated	  liver	  diseases	  non-­‐alcoholic	  fatty	  liver	  disease	  (NAFLD)	  and	   non-­‐alcoholic	   steatohepatits	   (NASH)	   became	   more	   important	   risk	   factors	   for	  HCC208,216,217.	   Furthermore,	   inherited	  metabolic	   disorders	   such	   as	   hemochromatosis218	  and	   alpha-­‐1	   antitrypsin	   deficiency219	   causing	   hepatocellular	   damage	   and	   necrosis	   can	  increase	  the	  risk	  of	  HCC	  development183,185.	  	  
Gender.	  HCC	  is	  three	  fold	  more	  common	  in	  men	  than	  women180,181,185.	  This	  phenomenon	  is	  not	  well	  understood.	  However,	  it	  has	  been	  hypothesized	  that	  differences	  in	  sex	  steroid	  hormones,	  immune	  responses	  and	  epigenetics	  could	  be	  the	  underlying	  cause188.	  Indeed,	  a	  positive	  association	  between	  high	  levels	  of	  circulating	  testosterone	  and	  HCC	  has	  been	  described	  in	  the	  context	  of	  HBV	  infected	  men220.	  	  Taken	   together,	   several	   etiologies,	   such	   as	   viral	   hepatitis,	   alcohol	   abuse,	   aflatoxin	   B1,	  NASH	  and	  NAFLD	  can	  lead	  to	  hepatocarcinogenesis.	  Some	  etiologies	  are	  prone	  to	  induce	  mutations	  with	   higher	   frequency	   in	   specific	   genes,	   as	   observed	   for	  HBV-­‐related	  HCCs	  that	  are	   frequently	  mutated	   in	  TP53221.	  However,	  although	  HCC	  risk	   factors	  are	  highly	  diverse,	   they	   induce	   several	   overlapping	   pathogenic	   pathways	   and	   processes.	   For	  example,	  inflammation	  and	  repeated	  cycles	  of	  liver	  damage	  and	  regeneration	  seem	  to	  be	  consistent	  among	  HBV-­‐,	  HCV-­‐	  and	  alcohol	  induced	  hepatocarcinogenesis.	  This	  suggests,	  that	  there	  are	  at	   least	  some	  common	  processes	  underlying	  HCC	  development	  and	  thus	  could	  represent	  important	  targets	  for	  drug	  development.	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Figure	   7.	   The	   different	   etiologies	   of	   HCC	   and	   the	   corresponding	   mechanisms	   of	  
hepatocarcinogenesis.	  Various	  etiologies	  have	  been	   linked	  to	  HCC	  development,	   including	  aflatoxin	  B1	  intake,	   hepatitis	   B	   virus	   (HBV)	   and	   hepatitis	   C	   virus	   (HCV)	   infection	   and	   chronic	   alcohol	   consumption,	  typically	   conditions	   that	   induce	   cirrhosis.	   In	   addition,	   HBV	   can	   integrate	   into	   the	   host	   genome,	   thus	  contributing	  to	  hepatocarcinogenesis.	  Modified	  from189.	  	  
2.2	  Prevention	  and	  treatment	  of	  hepatocellular	  carcinoma	  HCC	  is	  one	  of	  the	  deadliest	  cancers	  worldwide	  and	  its	  incidence	  is	  continuously	  rising185.	  Furthermore,	  therapies	  for	  advanced	  HCC	  are	  limited,	  showing	  a	  clear	  need	  for	  new	  and	  more	   effective	   drugs.	   The	   lack	   of	   curative	   treatment	   options	   for	   advanced	   stage	   HCC	  makes	   prevention	   even	  more	   important.	   The	   different	  HCC	   prevention	   and	   treatment	  options	  are	  described	  below.	  	  
2.2.1	  Prevention	  	  The	  best	  HCC	  prevention	  strategy	  is	  the	  reduction	  of	  the	  underlying	  etiological	  factors.	  A	  major	   breakthrough	   in	   the	   field	   of	   HCC	   prevention	   was	   the	   development	   of	   a	   HBV	  vaccine.	  National	  HBV	  vaccination	  programs	  reduced	  the	  burden	  of	  HBV	  infection,	  which	  in	  turn	   lowered	  the	   incidence	  rates	  of	  HCC222,223.	  However,	  240	  million	  people	  are	  still	  chronically	   infected	  with	  HBV	  and	  remain	  at	  risk	   for	   the	  development	  of	  cirrhosis	  and	  HCC202.	   In	   general,	   effective	   antiviral	   therapies	   in	   patients	  with	   chronic	  HBV	   and	  HCV	  infection	  are	  associated	  with	  reduced	  HCC	  incidence	  rates184,224.	  Cohort	  studies	  showed	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that	   the	   successful	   treatment	   of	   HCV	   reduces	   HCC	   incidence	   rates	   compared	   to	  untreated	   controls225,226.	   Furthermore,	   the	   reduction	   of	   aflatoxin	   1B	   exposure	   was	  proposed	  to	  be	  highly	  relevant	  for	  liver	  cancer	  prevention183.	  	  	  
2.2.2	  Treatment	  	  Staging	   of	   HCC	   patients	   according	   to	   prognosis	   and	   treatment	   options,	   is	   performed	  using	  the	  Barcelona	  Clinic	  Liver	  Cancer	  (BCLC)	  staging	  system227,	  recommended	  by	  the	  European	   and	   American	   clinical	   practice	   guidelines185,228.	   This	   staging	   system	   defines	  five	   prognostic	   subclasses	   (0,	   A,	   B,	   C	   and	   D)	   that	   link	   the	   disease	   stage	   to	   the	   most	  beneficial	  therapy	  option	  currently	  available184,185.	  Class	  0	  represents	  very	  early,	  A	  early,	  B	  intermediate,	  C	  advanced	  and	  D	  terminal	  stage	  disease	  (Figure	  8).	  Alternative	   staging	   systems	  were	   proposed	   including	   the	   Hong	   Kong	   classification229,	  the	  Cancer	  of	  the	  Liver	  Italian	  Program	  (CLIP)	  score230,	  the	  TNM	  system185	  and	  the	  Japan	  Integrated	   Staging	   (JIS)	   score231.	   But	   in	   contrast	   to	   the	   BCLC	   system,	   they	   are	   not	  globally	  used	  in	  the	  clinic185	  .	  	  To	  date,	   five	  different	   treatment	  options	  are	  available	   for	  patients	  with	  HCC,	   including	  surgical	   resection,	   liver	   transplantation,	   local	   ablation,	   chemoembolization	   and	   the	  multikinase	   inhibitor	   sorafenib184,185.	   Treatment	   options	   are	   divided	   into	   two	   groups,	  the	   potentially	   curative	   and	   the	   palliative	   treatments	   (Figure	   8).	   About	   30-­‐40%	   of	  patients	   are	   classified	   as	   BCLC	   0	   or	   A,	   representing	   asymptomatic,	   early	   stage	   HCCs.	  These	   patients	   are	   considered	   for	   potential	   curative	   therapies	   such	   as	   resection,	  transplantation	   or	   local	   ablation,	   resulting	   in	   a	   median	   survival	   rate	   of	   five	   years184.	  Patients	  with	   intermediate	  and	  advanced	  stage	  disease,	  BCLC	  B-­‐C,	  have	   two	  treatment	  options;	  chemoembolization	  and	  sorafenib.	  BCLC	  stage	  B	  patients	  with	  preserved	   liver	  functions	   benefit	   from	   chemoembolization	   whereas	   the	   standard	   of	   care	   for	   stage	   C	  patients	  is	  sorafenib,	  prolonging	  median	  survival	  by	  three	  months232.	  Patients	  with	  end	  stage	  disease,	  BCLC	  D,	  receive	  palliative	  treatment.	  These	  patients	  may	  need	  nutritional	  and	   psychological	   care	   and	   good	   pain	   management185.	   The	   different	   HCC	   treatment	  options,	   including	   liver	   transplantation,	   radiofrequency	  ablation,	   transcatheter	  arterial	  chemoembolization	  (TACE)	  and	  sorafenib,	  will	  be	  discussed	  in	  the	  following.	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Figure	   8.	   BCLC	   staging	   system	   and	   therapeutic	   strategy.	   The	   Barcelona	   Clinic	   Liver	   Cancer	   (BCLC)	  staging	  system	  encompasses	  five	  different	  stages	  (BCLC	  0,	  A,	  B,	  C	  and	  D)	  and	  is	  used	  to	  stratify	  patients	  according	   to	   their	   prognosis	   and	   treatment	   options.	   Curative	   treatments	   include	   resection,	  transplantation	  and	  ablation	  whereas	  transcatheter	  arterial	  chemoembolization	  (TACE)	  and	  sorafenib	  are	  used	   as	   palliative	   treatment	   in	   patients	   with	   intermediate	   and	   advanced	   stage	   disease,	   respectively.	  Modified	  from185.	  
	  
Liver	  Resection.	  Patients	  with	  single	  tumor	  nodules	  designated	  BCLC	  0	  or	  A,	  no	  portal	  hypertension	   and	  well-­‐preserved	   liver	   functions	   are	   considered	   for	   surgical	   resection.	  Tumor	   recurrence	   is	   the	  major	   complication	  of	   this	   treatment	  modality185.	  The	  5-­‐year	  recurrence	  rate	  of	  HCC	  is	  up	  to	  70%	  in	  these	  patients	  because	  of	  either	  metastasis	  or	  de	  
novo	  HCC	  development	  in	  the	  liver185,228.	  
Liver	  Transplantation.	  Patients	   that	  do	  not	  qualify	   for	   resection	  might	  be	   candidates	  for	  liver	  transplantation	  if	  the	  HCC	  is	  defined	  as	  BCLC	  A	  and	  some	  additional	  criteria	  are	  met.	   If	  only	  one	  nodule	   is	  present	   in	  the	   liver,	   its	  size	  has	  to	  be	  ≤	  5cm.	  If	  a	  patient	  has	  several	  nodules,	  their	  number	  cannot	  exceed	  three	  and	  their	  individual	  sizes	  cannot	  be	  larger	  than	  3cm.	  No	  vascular	  invasion	  should	  be	  present185.	  The	  5-­‐year	  recurrence	  rate	  of	  HCC	  is	  below	  15%,	  however	  the	  scarcity	  of	   liver	  donors	  is	  a	  major	  drawback	  of	  this	  treatment	  option185.	  



















less	   than	   5cm,	   whereas	   ethanol	   injection	   is	   used	   when	   radiofrequency	   ablation	   is	  technically	  not	  feasible.	  These	  patients	  have	  a	  5-­‐year	  survival	  rate	  of	  50-­‐70%184,185,233.	  
Transcatheter	  arterial	  chemoembolization	  (TACE).	  This	  technique	  is	  recommended	  in	  patients	  with	  an	   intermediate	   stage	  HCC	   (BCLC	  B).	  This	   stage	   is	  defined	  by	  preserved	  liver	   functions,	   several	   tumor	   nodules,	   no	   tumor-­‐related	   symptoms,	   no	   vascular	  invasion	   and	   no	   extrahepatic	   spread185.	   TACE	   is	   a	   minimal	   invasive	   technique.	  Embolizing	   particles	   loaded	   with	   chemotherapeutic	   drugs	   (e.g.	   doxorubicin	   and	  cisplatin)	  are	  injected	  into	  one	  or	  more	  branches	  of	  the	  hepatic	  artery	  in	  close	  proximity	  of	   the	   tumor.	   This	   enables	   the	   onsite	   delivery	   of	   the	   drug	   and	   restricts	   tumor	   blood	  supply.	   Patients	   that	   receive	   this	   treatment	   have	   a	   median	   survival	   of	   20-­‐26	  month184,185,234.	  
Sorafenib.	  The	  standard	  of	  care	  for	  patients	  with	  advanced	  HCC	  (BCLC	  C)	  is	  the	  multi-­‐kinase	   inhibitor	   sorafenib185.	   Its	   beneficial	   role	   was	   demonstrated	   in	   a	   randomized	  control	   trial	  with	  more	   than	  600	  patients	  with	  advanced	  HCC232.	  Patients	   treated	  with	  sorafenib	  benefit	   from	  an	  overall	   increased	  survival	  of	   three	  months	  (from	  7.9	   to	  10.7	  month).	  The	  effect	  of	  sorafenib	  was	  also	  confirmed	  in	  an	  Asian	  patient	  cohort	  with	  HBV	  background235.	  Despite	  its	  beneficial	  aspects,	  sorafenib	  has	  its	  limitations.	  Although	  it	  is	  the	  only	  first-­‐line	  treatment	  option	  for	  patients	  with	  advanced	  HCC,	  sorafenib	  treatment	  is	   not	   curative	   and	   cannot	   be	   used	   in	   patients	   with	   impaired	   liver	   function185,232.	  Furthermore,	   sorafenib	   is	   associated	   with	   potentially	   severe	   side	   effects,	   including	  diarrhea,	   fatigue,	   hand-­‐foot	   skin	   reactions	   and	   weight	   loss228,232,235.	   Sorafenib	   was	  originally	  identified	  as	  a	  Raf	  kinase	  inhibitor236	  that	  displayed	  anti-­‐tumor	  activity237.	  It	  is	  now	   known	   that	   sorafenib	   affects	   up	   to	   40	   different	   kinases,	   including	   Raf-­‐1,	   B-­‐Raf,	  vascular	  endothelial	  growth	  factor	  receptor	  2	  (VEGFR2),	  platelet-­‐derived	  growth	  factor	  receptor	   (PDGFR)	   and	   c-­‐Kit	   receptor	   kinases228.	   Sorafenib	   acts	   on	   tumor	   cells	   and	  stroma211	   and	   has	   antiangiogenic,	   antiproliferative	   and/or	   proapoptotic	   effects237.	  However,	  its	  molecular	  mode	  of	  action	  is	  not	  completely	  understood.	  	  Almost	  10	  years	  after	  the	  first	  therapy	  results	  of	  sorafenib	  were	  published232,	  all	  novel	  systemic	   drugs	   failed	   in	   clinical	   phase	   III	   trials,	   including	  brivanib,	   sunitinib,	   erlotinib	  and	  linifanib238-­‐242.	  None	  of	  these	  alternative	  treatments	  was	  superior	  to	  sorafenib	  in	  the	  first-­‐line	  setting.	  Of	  note,	  regorafenib	  -­‐	  another	  multikinase	  inhibitor	  –	  was	  the	  only	  drug	  with	   a	   beneficial	   outcome	   in	   a	   second-­‐line	   setting	   following	   sorafenib	   failure243.	  However,	  it	  is	  associated	  with	  several	  adverse	  effects	  and	  is	  not	  well	  tolerated	  by	  many	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patients244.	   Since	   the	   approval	   of	   checkpoint	   inhibitors	   such	   as	   tremelimumab	   and	  nivolumab,	   immunotherapy	  has	  recently	  gained	   interest	   in	   the	   treatment	  of	  HCC245.	   In	  general,	  cancer	  immunotherapy	  redirects	  the	  immune	  system	  of	  the	  patients	  against	  the	  cancer	   instead	   of	   targeting	   the	   cancer	   itself246.	   In	   the	   US,	   nivolumab	   an	   anti-­‐PD-­‐1	  (programmed	  cell	  death	  protein	  1)	  antibody	  has	  already	  been	  approved	  for	  the	  second-­‐line	   treatment	   of	   HCC	   and	   is	   currently	   tested	   in	   a	   Phase	   III	   trial	   against	   sorafenib	  (ClinicalTrials.	   gov	   registry	   number:	   NCT02576509)245.	   The	   results	   from	   the	   new	  checkpoint	   inhibitors	   are	   encouraging	   and	   hold	   promise	   for	   potential	   new	   HCC	  treatments.	  	  Taken	  together,	  despite	  a	  lot	  of	  potential	  therapeutic	  targets,	  sorafenib	  and	  regorafenib	  are	  the	  only	  drugs	  globally	  available	   for	   the	  management	  of	  advanced	  HCC.	  This	  could	  potentially	   be	   explained	   by	   the	   molecular	   heterogeneity	   of	   HCC,	   the	   lack	   of	   good	  biomarkers	  that	  help	  to	  stratify	  the	  patients	  into	  different	  treatment	  groups,	  the	  rapidly	  occurring	  resistance	  to	  chemotherapy	  and	  the	  toxicity	  of	  some	  compounds	  linked	  to	  the	  often	  bad	   liver	  condition	  of	   these	  patients.	  This	   indicates	  the	  urgent	  need	  for	  new	  and	  more	  effective	  drugs	  to	  treat	  HCC.	  	  	  
2.3	   Histopathological	   progression	   and	   molecular	   features	   of	   hepatocellular	  
carcinoma	  Although	  HCC	   is	  one	  of	   the	  most	   lethal	   cancer	   types	   in	  humans,	   the	  precise	  molecular	  mechanisms	  that	  drive	  tumor	  initiation	  and	  progression	  are	  far	  from	  being	  completely	  understood189,247.	   Several	   factors	   play	   a	   role	   in	   hepatocyte	   transformation,	   HCC	  development	  and	  progression	  including	  chronic	  inflammation,	  DNA	  damage,	  epigenetic	  modification,	  senescence,	  telomerase	  reactivation	  and	  early	  neoangiogenesis184,202.	  	  HCC	  development	  is	  a	  complex,	  multistep	  process	  that	  occurs	  in	  the	  majority	  of	  cases	  on	  a	   cirrhotic	   background	   linked	   to	   inflammatory	   conditions	   induced	   by	   different	  underlying	  etiologies,	  including	  viral	  hepatitis,	  alcohol	  abuse	  and	  metabolic	  syndrome248	  (Figure	   9).	   Each	   of	   the	   known	   risk	   factors	   can	   induce	   hepatic	   injury	   that	   leads	   to	  necrosis	   followed	   by	   regeneration	   due	   to	   hepatocyte	   proliferation.	   If	   this	   cycle	   of	  destruction	   and	   regeneration	   is	   repeated	   several	   times	   because	   of	   continuous	   liver	  damage	  it	  fosters	  a	  chronic	  liver	  disease,	  associated	  with	  cirrhosis.	  Typical	  for	  cirrhosis	  are	  the	  formation	  of	  collagen-­‐surrounded	  nodules	  and	  the	  scaring	  of	  the	  liver	  (Figure	  9).	  The	  early	  steps	  of	  HCC	  development,	   including	  chronic	   liver	  disease	  and	  cirrhosis,	   are	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associated	  with	  telomere	  shortening249	   that	  correlates	  with	  chromosomal	   instability250	  as	  indicated	  in	  Figure	  9.	  Of	  note,	  telomerase	  knock	  out	  mice	  showed	  an	  increased	  rate	  of	  liver	   cancer	   initiation251.	   A	   cirrhotic	   liver	   can	   subsequently	   develop	   hyperplastic	  nodules	  that	  further	  develop	  into	  dysplastic	  nodules	  and	  finally	  into	  HCC189	  (Figure	  9).	  	  In	   rare	   cases,	   HCC	   can	   also	   develop	   in	   normal	   livers	   without	   any	   sign	   of	   fibrosis,	  cirrhosis	  or	  inflammation.	  Some	  studies	  suggested	  that	  they	  might	  have	  developed	  in	  a	  pre-­‐existing	  hepatocellular	  adenoma217,252,253.	  However	  the	  exact	  pathogenesis	  of	  these	  HCCs	  remains	  unclear.	  	  
	  
Figure	  9.	  Histopathological	  progression	  and	  molecular	   features	  of	  HCC.	  The	  development	  of	  HCC	  is	  typically	  a	  multistep	  process	  occurring	  in	  most	  of	  the	  cases	  on	  a	  cirrhotic	  background.	  Chronic	  HBV	  and	  HCV	   infection,	   alcohol	  abuse	  and	   intake	  of	  aflatoxin	  B1	   induce	  hepatic	   injury	   leading	   to	  necrosis	   that	   is	  followed	  by	   regeneration	  due	   to	  proliferation	  of	   hepatocytes.	   In	   a	   chronic	   setting,	   this	   can	   lead	   to	   liver	  cirrhosis	   that	   further	   develops	   hyperplastic	   nodules,	   followed	   by	   dysplastic	   nodules	   and	   finally	   HCC.	  Chronic	  liver	  disease	  and	  liver	  cirrhosis	  is	  associated	  with	  telomere	  shortening,	  by	  contrast	  telomerase	  re-­‐activation	  seems	  to	  be	  involved	  in	  HCC	  development189.	  	  Furthermore,	  HCC	  development	  is	  the	  result	  of	  accumulation	  of	  mutations	  in	  passenger	  and	  driver	  cancer	  genes	  that	  leads	  to	  the	  alteration	  of	  multiple	  signaling	  cascades184.	  By	  definition,	  a	  cancer	  driver	  is	  a	  genetic	  event	  that	  contributes	  to	  tumor	  evolution	  at	  any	  stage	   by	   promoting	   functions	   including	   proliferation,	   survival,	   invasion	   or	   immune	  evasion254.	   In	   contrast,	   passenger	   mutations	   are	   of	   marginal	   relevance	   for	   cancer	  initiation	  and	  progression184.	  Molecular	  analysis	  of	  human	  HCC	  have	  helped	  to	  identify	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the	  main	   drivers	   responsible	   for	   HCC	   development	   and	   progression221,255.	   In	   general,	  each	   HCC	   nodule	   has	   approximately	   40	   somatic	   alterations	   of	   which	   only	   a	   few	   are	  considered	   as	   drivers184.	   At	   the	   top	   of	   the	   list	   of	   the	  most	   frequently	  mutated	   driver	  genes	  in	  HCC	  (Figure	  10)	  are	  TERT,	  CTNNB1	  and	  TP53	  that	  affect	  telomere	  maintenance,	  WNT	  pathway	  activation	  and	  inactivation	  of	  a	  tumor	  suppressor,	  respectively221.	  	  In	  90%	  of	  human	  HCCs	  Telomerase	  is	  overexpressed	  which	  is	  related	  to	  TERT	  promoter	  mutations	   in	   45-­‐60%	   of	   cases201,221,248	   (Figure	   10).	   This,	   and	   data	   from	   telomerase	  knockout	   mice251	   suggest	   that	   a	   re-­‐activation	   of	   telomerase	   is	   needed	   for	   HCC	  progression. Thus,	  telomere	  dysfunction	  seems	  to	  play	  an	  opposing	  role	  in	  the	  initiation	  versus	   progression	   of	   HCC.	   Early	   stages	   of	   HCC	   development	   are	   associated	   with	  telomere	  shortening,	  whereas	  telomerase	  re-­‐activation	  is	  an	  important	  feature	  in	  tumor	  progression	   linked	   to	   evasion	   of	   cellular	   senescence	   and	   promoting	   uncontrolled	  hepatocyte	  proliferation184,251	  (Figure	  9).	  With	  a	  frequency	  of	  11-­‐40%	  (Figure	  10),	  CTNNB1	  is	  one	  of	  the	  most	  frequently	  mutated	  genes	   in	   human	   HCCs,	   activating	   β-­‐catenin	   and	   therefore	   inducing	   the	   WNT-­‐pathway221,248,256.	  CTNNB1	  mutations	  are	  predominantly	  observed	  in	  well-­‐differentiated,	  non-­‐HBV-­‐related	   tumors257,258.	   However,	   inactivating	   mutations	   or	   deletion	   in	   AXIN1,	  
APC	  and	  ZNRF3	  can	  also	  result	  in	  activation	  of	  the	  WNT-­‐β-­‐catenin	  pathway184.	  






Figure	   10.	   Most	   frequently	   altered	   genes	   in	   HCC,	   based	   on	   exome	   sequencing	   analysis	   of	   243	  
human	   liver	   tumors.	  Genes	  that	  were	  altered	  in	  ≥4%	  of	  samples	  are	  shown,	  with	  TERT,	  CTNNB1,	  TP53	  being	   the	   most	   frequently	   mutated	   genes	   in	   HCC,	   affecting	   telomere	   maintenance,	   WNT	   pathway	  activation	  and	  inactivation	  of	  a	  tumor	  suppressor,	  respectively221.	  	  
2.4	  Classification	  of	  hepatocellular	  carcinoma	  HCCs	  have	  been	  classified	  in	  various	  ways,	  based	  on	  etiological	  and	  molecular	  features,	  mutational	   landscape,	   prognosis	   and	   histological	   appearance.	   The	   histological	   and	  immunohistological	  as	  well	  as	  the	  different	  molecular	  classifications	  will	  be	  discussed	  in	  more	  detail	  in	  the	  following.	  	  
2.4.1	  Histopathology	  and	  immunohistochemistry	  Until	   2000,	   the	   diagnosis	   of	   HCC	   was	   based	   only	   on	   biopsies.	   After	   that,	   the	   field	   of	  diagnosis	   has	   changed	   to	   a	   more	   non-­‐invasive	   radiological	   approach,	   including	  computed	   tomography	   (CT),	   magnetic	   resonance	   imaging	   (MRI)	   and	   ultrasound.	  However,	   the	   non-­‐invasive	   diagnosis	   of	   small	   lesions	   remains	   a	   challenging	   issue	   and	  often	  requires	  pathological	  confirmation	  on	  biopsy	  samples.	  Furthermore,	  biopsies	  are	  performed	   in	   cases	   with	   inconclusive	   or	   atypical	   imaging	   appearance	   in	   cirrhotic	  livers185.	  	  	  Histological	  assessment	  helps	  to	  confirm	  HCC	  and	  allows	  to	  define	  their	  differentiation	  grades	  and	  growth	  patterns260.	  Hematoxylin	  and	  Eosin	  staining	  of	  tumor	  sections	  allows	  for	   HCC	   growth	   pattern	   classification	   (f.e.	   trabecular,	   pseudoglandular	   and	   solid)	   and	  cytological	   subtypes	   (clear	   cell,	   giant	   cell,	   steato-­‐HCC	   and	   stem	   cell-­‐like)260,261.	   The	  Edmondson	  and	  Steiner	   system	   is	   the	  most	  widely	  used	  grading	   system	   for	  HCC262.	   It	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scales	   the	   tumors	   into	   four	   different	   groups;	   grade	   I-­‐IV.	   Grade	   I	   is	   the	   most	  differentiated	   group	   and	   is	   often	   difficult	   to	   distinguish	   from	   normal	   liver,	   whereas	  grade	  IV	  reflects	  highly	  dedifferentiated	  tumors.	   In	  general,	   the	  higher	  the	  Edmondson	  grade,	   the	   less	  differentiated	   the	   tumors	  are.	  Of	  note,	  a	  single	  nodule	  can	  have	  several	  differentiation	  grades.	  	  In	  cases	  where	  the	  histological	  interpretation	  and	  diagnosis	  is	  difficult,	  additional	  tissue	  markers	  are	  used	  to	  improve	  the	  diagnostic	  accuracy185,263.	  This	  is	  often	  necessary	  in	  the	  case	  of	  small	   liver	  nodules	   to	  discriminate	  between	  high-­‐grade	  dysplastic	  nodules	  and	  early	   grade	   I	   (i.e.	   well-­‐differentiated)	   HCCs264.	   Three	   immunohistochemical	   (IHC)	  markers	   –	   Glutamine	   Synthetase	   (GS),	   Glypican-­‐3	   (GPC3)	   and	   Heat	   Shock	   Protein	   70	  (HSP70)	   –	   are	   used	   for	   the	   diagnosis	   of	   resected	   and	   biopsied	   primary	   liver	  nodules185,264-­‐266.	   It	   is	   recommended	   that	   two	   out	   of	   the	   three	   markers	   should	   be	  positive	  for	  a	  pathological	  diagnosis	  of	  HCC265,267.	  	  	  GS	  catalyzes	  the	  synthesis	  of	  glutamine	  –	  the	  major	  energy	  source	  of	  cancer	  cells	  -­‐	  from	  glutamate	  and	  ammonia	  in	  the	  mammalian	  liver264.	  GS	  is	  upregulated	  in	  human	  HCC268	  and	  was	  shown	  to	  stepwise	  increase	  from	  pre-­‐cancerous	  lesions	  to	  early	  and	  further	  to	  advanced	  HCC269.	  However,	  this	  association	  of	  expression	  with	  tumor	  dedifferentiation	  was	   not	   observed	   in	   a	   newer	   study	   showing	   that	   early	   and	   late	   stage	   HCC	   similarly	  overexpress	  GS	  suggesting	  that	  the	  strong	  GS	  expression	  takes	  place	  in	  the	  early	  phases	  of	   malignant	   transformation264.	   Furthermore,	   GS	   is	   a	   target	   of	   β-­‐catenin	   and	   is	   often	  overexpressed	  in	  HCC	  associated	  with	  a	  CTNNB1	  mutation267.	  	  GPC3	   belongs	   to	   the	   family	   of	   Glypicans,	   is	   linked	   to	   the	   cell	   surface	   and	   is	  overexpressed	   in	  HCCs270,271.	   Typically,	   it	   is	   not	   expressed	   in	  normal,	   adult	   liver272,273.	  Furthermore,	  its	  expression	  is	  affected	  by	  the	  tumor	  grading	  with	  high	  expression	  levels	  in	  high	  grade	  nodules264.	  It	  is	  suggested,	  that	  GPC3	  plays	  a	  role	  in	  cell	  growth	  regulation,	  however,	  its	  role	  in	  the	  pathogenesis	  of	  HCC	  remains	  poorly	  understood274.	  HSP70	   is	  one	  of	   the	  most	  upregulated	  genes	   in	  HCC,	   induced	  by	  stress	   conditions	   like	  chronic	   inflammation	   and	   fibrosis275.	   Furthermore,	   HSP70	   is	   a	   potent	   anti-­‐apoptotic	  effector	   that	   allows	   the	   cells	   to	   survive	   under	   different	   conditions264.	   Of	   note,	   no	  correlation	   was	   observed	   between	   HSP70	   immunoreactivity	   and	   HCC	   differentiation	  grade,	   etiology,	   sex,	   cirrhosis	   or	   tumor	   size264.	   Taken	   together,	   IHC	   can	  be	  used	   as	   an	  additional	  tool	  to	  support	  the	  diagnostic	  conclusions	  driven	  from	  morphological	  analysis	  of	  HCC	  specimen.	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2.4.2	  Molecular	  classification	  Transcriptome-­‐based	   molecular	   classification	   studies	   of	   human	   HCC	   are	   aimed	   at	  identifying	  tumor	  specific	  druggable	  targets.	  If	  successful,	  this	  would	  allow	  to	  determine	  patients	  that	  could	  benefit	  from	  targeted	  therapies276.	  Several	  studies	  analysed	  the	  gene	  expression	  profiles	  of	  HCCs	   from	  resected	  specimens277-­‐280	  and	  biopsies276.	  Each	  study	  classified	   HCCs	   into	   different	   numbers	   of	   subclasses	   ranging	   from	   two	   to	   six	   and	  showing	   different	   transcriptomic	   profiles	   and	   clinicopathological	   features.	   However,	  molecular	  classification	  of	  HCC	  based	  on	  gene	  signatures	  or	  molecular	  abnormalities	  has	  not	  yet	  provided	  results	  suitable	   for	  clinical	  applications184,185,247,281.	  The	  major	  reason	  for	  this	  is	  probably	  that	  the	  most	  frequent	  mutations	  in	  HCC	  (TERT,	  CTNNB1	  and	  TP53)	  are	  not	   targetable.	  Nevertheless,	   the	  above	  mentioned	  molecular	  analysis	  showed	  that	  HCCs	  can	  be	  broadly	  divided	  into	  proliferative	  and	  non-­‐proliferative	  tumors.	  The	  class	  of	  proliferative	   tumors	   is	   typically	   more	   aggressive	   and	   less	   differentiated276,279.	  Furthermore,	   these	   tumors	   are	   often	   characterized	   by	   high	   serum	   alpha-­‐fetoprotein	  (AFP)	   levels,	   TP53	   mutations	   and	   are	   correlated	   with	   poor	   outcome256,277,279,280.	   The	  non-­‐proliferative	   subclass	   is	   highly	   heterogeneous	   and	   harbors	   tumors	   that	   tend	   to	  retain	   hepatocyte-­‐like	   features247,256.	   Around	   30%	  of	   these	  HCCs	   are	   characterized	   by	  mutations	   in	   CTNNB1	   and	   show	   β-­‐catenin	   pathway	   activation276-­‐279.	   However,	   the	  remaining	  non-­‐proliferative	  HCCs	  have	  no	  common	  distinguishing	  features.	  Taken	  together,	  despite	  substantial	  progress,	  the	  prognostic	  use	  of	  molecular	  subclasses	  of	  HCC	  in	  the	  clinics	  is	  still	  missing.	  Therefore,	  the	  prognostication	  and	  decision	  making	  for	  HCC	  patients	  still	  relies	  mainly	  on	  the	  BCLC	  staging	  system.	  	  
2.5	  Biomarkers	  of	  hepatocellular	  carcinoma	  Unfortunately,	  at	  the	  time	  when	  HCC	  symptoms	  are	  evident,	  the	  disease	  is	  typically	  too	  advanced	  to	  qualify	  for	  any	  curative	  treatment	  attempt185.	  Additionally,	   life	  expectancy	  for	  these	  patients	  is	  very	  short,	  with	  a	  median	  survival	  time	  of	  less	  than	  1	  year.	  To	  date,	  less	   than	   30%	   of	   HCC	   patients	   in	   Europe	   qualify	   for	   curative	   treatment	   like	   tumor	  resection	  or	  liver	  transplantation,	  mostly	  because	  of	  delayed	  HCC	  diagnosis185.	  In	  order	  to	   detect	   early-­‐stage	   tumors,	   guidelines	   for	   surveillance	   recommend	   ultrasonography	  every	  6	  months	  for	  patients	  at	  risk185,208.	  However,	  the	  diagnosis	  of	  early-­‐stage	  HCC	  by	  ultrasound,	  CT/MRI	  and/or	  liver	  biopsy	  is	  very	  challenging.	  Mainly	  because	  the	  lesions	  are	   very	   small,	   their	   radiological	   appearance	  might	  be	   atypical	   and	   the	  morphological	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changes	   compared	   to	   the	   dysplastic	   hepatocytes	   could	   be	  minor282.	   Thus,	   biomarkers	  that	  would	  help	   to	  detect	  early	   stage	  HCC	  are	  desirable.	   Importantly,	   such	  biomarkers	  would	  increase	  the	  possibility	  for	  curative	  treatment184,282.	  	  AFP	   is	   one	   of	   the	   most	   frequently	   tested	   serum	   biomarkers	   for	   the	   identification	   of	  HCC283.	  However,	   it	   has	  been	   shown	   that	   only	  10-­‐20%	  of	   early-­‐stage	  HCCs	   show	  high	  expression	  levels	  of	  AFP,	  whereas	  it	  is	  more	  often	  associated	  with	  advanced-­‐stage	  HCC.	  This	   makes	   it	   unsuitable	   for	   the	   detection	   of	   tumors	   at	   an	   early	   stage184,185,228,282.	  Therefore,	  AFP	  is	  suboptimal	  for	  routine	  clinical	  practice185.	  	  An	  ideal	  biomarker	  would	  not	  only	  be	  helpful	  for	  diagnosing	  early-­‐stage	  HCC	  but	  also	  for	  predicting	   response	   to	   sorafenib	   treatment.	   Thus,	   only	  patients	  would	  be	   treated	   that	  would	   benefit	   from	   this	   therapeutic	   approach.	   This	   would	   prevent	   patients	   to	   suffer	  from	   treatment	   side	   effects	   without	   having	   a	   therapeutic	   benefit.	   One	   study	   suggests	  that	   early	   increase	   in	   AFP	   levels	   is	   associated	   with	   disease	   progression	   and	   poorer	  outcome	   in	   patients	   treated	   with	   sorafenib284.	   However,	   these	   results	   have	   to	   be	  validated	   in	   a	   bigger	   cohort.	   Until	   now,	   no	   robust,	   predictive	   clinical	   or	   molecular	  biomarker	  for	  sorafenib	  response	  has	  been	  identified185,281,285.	  It	  is	  suggested,	  that	  a	  biomarker-­‐driven	  selection	  of	  patients	  for	  phase	  II	  and	  III	  clinical	  trials	   could	   improve	   their	   outcome286.	   The	   tested	   drug	   could	   be	   effective	   in	   a	   given	  molecular	  subgroup	  of	  HCC	  patients,	  but	  diluted	  if	  the	  complete	  patient	  cohort	  is	  used.	  Indeed,	  the	  phase	  II	  trial	  of	  tivantinib	  –	  a	  small	  molecule	  MET	  receptor	  tyrosine	  kinase	  inhibitor287	   -­‐	   versus	   placebo	   showed	   no	   effect	   when	   all	   patients	   were	   included.	  However,	   a	   significant	   effect	   was	   observed	   in	   the	   post	   hoc	   analysis	   when	   only	   a	  subgroup	  of	  patients	  with	  MET-­‐high	   tumors	  were	   included288.	  A	  phase	   III	   clinical	   trial	  with	  a	  subgroup	  of	  only	  MET-­‐positive	  HCC	  patients,	  that	  failed	  first	  line	  treatment	  with	  sorafenib,	   is	  currently	  ongoing	  (ClinicalTrials.	  gov	  registry	  number:	  NCT01755767).	   In	  general,	  a	  biomarker-­‐driven	  selection	  of	  HCC	  patients	  for	  drug	  testing	  could	  significantly	  improve	  the	  identification	  and	  application	  of	  drug	  candidates.	  	  
2.6	  Experimental	  models	  for	  hepatocellular	  carcinoma	  research	  As	   described	   above,	   HCC	   is	   one	   of	   the	   deadliest	   cancers	  worldwide	  with	   very	   limited	  treatment	   options	   for	   patients	   with	   advanced	   stage	   tumors185.	   Furthermore,	   despite	  tremendous	   efforts	   over	   the	   last	   10	   years,	   sorafenib	   still	   remains	   the	   only	   approved	  drug	  for	  the	  first-­‐line	  treatment	  of	  advanced	  HCC.	  There	  is	  a	  clear	  need	  for	  experimental	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models	   that	   recapitulate	   key	   features	   of	   human	   HCC	   and	   therefore	   advance	   the	  understanding	  of	  the	  molecular,	  cellular	  and	  pathophysiological	  mechanisms	  of	  HCC289.	  Accordingly,	   a	   variety	   of	   different	   in	   vitro	   and	   in	   vivo	   HCC	  model	   systems	   have	   been	  developed.	  However,	  because	  HCC	  is	  a	  very	  heterogeneous	  disease,	  it	  is	  very	  challenging	  to	  generate	  a	  model	  that	  fully	  mirrors	  the	  variability	  and	  complexity	  of	  human	  HCC.	  The	  different	  in	  vitro	  and	  in	  vivo	  models	  will	  be	  described	  in	  the	  following.	  	  
2.6.1	  In	  vitro	  models	  	  Current	   in	   vitro	   studies	   are	   mainly	   based	   on	   two-­‐dimensional	   hepatoma	   cell	   lines,	  derived	   from	   human	   or	   animal	   HCCs290.	   They	   mainly	   allow	   mechanistic	   studies	   of	  genetic	  alterations	  that	  could	  lead	  to	  abnormalities	  in	  signaling	  pathways.	  Furthermore,	  in	  the	  early	  steps	  of	  drug	  discovery,	  they	  are	  often	  used	  to	  evaluate	  the	  effect	  of	  potential	  anti-­‐cancer	  compounds	  on	  cell	  proliferation	  and	  apoptosis290,291.	  Although	  they	  are	  cost-­‐efficient,	   easy	   to	   handle	   and	  manipulate,	   they	   fail	   to	   recapitulate	   key	   features	   of	  HCC,	  including	   tumor	  architecture,	   cellular	  heterogeneity	   and	   cell-­‐to-­‐cell	   interactions.	  Thus,	  cancer	   cell	   lines	   do	   not	   represent	   the	   complexity	   of	   a	   tumor	   and	   its	  microenvironment292.	  Recently,	   the	  three-­‐dimensional	  organoid	  culture	  system	  has	  emerged	  as	  an	   important	  tool	  for	  basic	  and	  translational	  research293.	  This	  new	  technology	  allows	  the	  long-­‐term	  in	  
vitro	  maintenance	   and	   expansion	   of	   adult	   stem	   cells	   from	   human	   tissues	   that	   can	   be	  further	   differentiated	   into	   organ-­‐like	   structures294.	   Importantly,	   organoids	   can	   be	  generated	  from	  various	  patient-­‐derived	  tumors	  allowing	  to	  model	  human	  diseases	  and	  testing	  of	  therapeutic	  compounds	  in	  a	  personalized	  medicine	  approach295.	  Only	  recently,	  establishing	  of	  organoid	  cultures	  from	  human	  liver	  cancer	  became	  possible296(Nuciforo	  et	  al.,	  submitted).	  Although	  clearly	  useful,	  the	  organoid	  system	  has	  some	  limitations,	  as	  for	   example	   the	   lack	   of	   a	   microenvironment297.	   Thus,	   the	   usage	   of	   two	   and	   three-­‐dimensional	   cell	   culture	   systems	   are	   clearly	   helpful	   in	   the	   field	   of	   HCC	   research	   but	  some	   aspects	   of	   tumorigenesis,	   including	   angiogenesis	   and	   metastasis	   cannot	   be	  assessed292.	  	  	  
2.6.2	  In	  vivo	  models	   	  Experimental	   animal	  models	   that	   closely	  mimic	  human	  HCC	  are	   important	   to	  advance	  the	   knowledge	   about	   physiological,	   cellular	   and	   molecular	   mechanisms	   of	   this	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disease289.	   Furthermore,	   animal	   models	   may	   help	   to	   identify	   new	   therapeutic	  approaches	  to	  treat	  HCC.	  Although	  rats298,299,	  woodchucks300	  and	  pigs301	  have	  been	  used	  to	  study	  HCC,	  mice	  are	  the	  preferred	  model	  systems	  in	  the	  field	  of	  HCC	  research.	  This	  is	  mainly	  because	  of	   their	  physiologic	   and	  genetic	   similarity	   to	  humans,	   their	   small	   size,	  short	  lifespan	  and	  excellent	  breeding	  capacity292,302.	  However,	  the	  appropriate	  modeling	  of	   liver	   cancer	   is	   challenging	   due	   to	   its	   different	   underlying	   etiologies	   and	   the	   vast	  genetic	   landscape.	  Several	  HCC	  mouse	  models	  have	  been	  developed	  but	  depending	  on	  whether	   HCC	   is	   induced	   by	   genetic	   manipulations,	   chronic	   liver	   disease,	   or	  transplantation	  of	  cancer	  tissue,	  several	  differences	   in	  characteristics	  and	  complexities	  have	  been	  observed.	  For	  example,	  dependent	  on	  the	  mouse	  model,	  tumor	  development	  can	  take	  from	  few	  weeks	  to	  more	  than	  a	  year211,303.	  Each	  model	  has	  its	  own	  advantages	  and	  disadvantages,	   thus	   it	   is	  very	   important	  to	  choose	  the	  most	  appropriate	  system	  to	  address	   specific	  questions304.	  The	  different	  models	  will	   be	  discussed	   in	  more	  detail	   in	  the	  following.	  
	  
2.6.2.1	  Spontaneous	  mouse	  models	  Similar	   to	  humans,	  mice	   rarely	  develop	  HCCs	  spontaneously	   in	   the	  absence	  of	   chronic	  liver	   disease303.	   Interestingly,	   spontaneous	   cancer	   development	   in	   mice	   seems	   to	   be	  linked	  to	  the	  gender	  and	  the	  genetic	  background.	  Whereas	  C57BL/6	  mice	  rarely	  develop	  HCC	   in	   their	   normal	   life	   span,	   C3H	  mice	   spontaneously	   develop	   liver	   cancer	   starting	  from	  12	  months	  of	  age305.	  Because	  of	  the	  low	  incidence	  rate	  and	  the	  high	  variability	  of	  tumor	  occurrence,	  size	  and	  location	  dependent	  on	  strain	  and	  gender,	  these	  models	  are	  not	  ideal	  for	  experimentation306.	  	  	  
2.6.2.2	  Genetically	  engineered	  mouse	  models	  Genetically	  engineered	  mouse	  (GEM)	  models	  are	  powerful	  tools	  to	  study	  tumorigenesis,	  because	   they	   allow	   to	   model	   complex	   genetic	   alterations	   found	   in	   human	   HCCs,	  including	   point	   mutations,	   gene	   amplifications,	   deletions	   and	   translocations303.	   The	  most	   common	   GEM	   mice	   used	   to	   study	   liver	   carcinogenesis	   are	   generated	   either	   by	  overexpression	   (transgenic	   mice)	   or	   by	   deletion	   (knockout	   mice)	   of	   a	   specific	   gene.	  Furthermore,	  these	  gene	  modifications	  can	  target	  all	  organs	  (systemic)	  or	  only	  the	  liver	  (conditional),	  which	  may	  further	  be	  regulated	  in	  a	  time-­‐specific	  manner	  (inducible	  gene	  expression)303,307.	  Knockout	  mice	  are	  often	  used	  to	  identify	  the	  role	  of	  tumor	  suppressor	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genes	  on	  tumor	  development.	  For	  example,	  hepatocyte-­‐specific	  deletion	  of	  phosphatase	  and	  tensin	  homolog	  (PTEN)	  leads	  to	  steatosis,	  fibrosis	  and	  finally	  HCC	  in	  mice	  at	  74-­‐78	  weeks	  of	  age308.	  Similarly,	  deletion	  of	  Tak1	  and	  Mdr2	  leads	  to	  inflammation,	  fibrosis	  and	  eventually	  HCC	   after	   4	   and	  16	  months	   of	   age,	   respectively303,309,310.	  On	   the	   other	   side,	  constitutive	  overexpression	  of	  TGF-­‐α	   induces	  HCC	  development	   in	  mice	  after	  one	  year	  of	  age,	  with	  the	  incidence	  rate	  being	  dependent	  on	  the	  genetic	  background	  and	  gender	  of	  the	   transgenic	   mice307.	   Likewise,	   transgenic	   mice	   co-­‐expressing	   Tgfa	   and	   Myc	   show	  extensive	  chromosomal	  damage	  and	  develop	   tumors311	  with	  a	  gene	  expression	  profile	  similar	  to	  the	  subgroup	  of	  human	  HCCs	  with	  poor	  prognosis312.	  	  
	  
Transgenic	  models	  expressing	  viral	  genes	  Chronic	  HBV	  and	  HCV	  infections	  are	  major	  risk	  factors	  of	  HCC	  development185.	  However,	  besides	   chimpanzees213,313	   and	   humanized	   mice314,315	   no	   animal	   model	   is	   fully	  permissive	  for	  human	  HBV	  and	  HCV	  infection.	  Of	  note,	  a	  recent	  report	  shows	  that	  HCV-­‐related	   hepacivirus	   from	   Norway	   rats	   induces	   hepatotrophic	   infections	   in	   mice	   with	  similar	  immunological	  features	  observed	  in	  humans316.	  Immune	  competent	  mice	  mimic	  an	  acute	  infection	  with	  viral	  clearance	  after	  3-­‐5	  weeks,	  whereas	  immune	  compromised	  mice	   develop	   a	   chronic	   infection.	   The	   usefulness	   of	   this	   new	  model	   for	   studying	  HCC	  development	   remains	   to	   be	   investigated.	   The	   pathogenicity	   of	   HCV	   and	   HBV	   in	  chimpanzees	  is	  relatively	  low,	  the	  humanized	  mice	  lack	  a	  functional	  immune	  system	  and	  only	  immune	  compromised	  mice	  develop	  chronic	  infection	  from	  a	  HCV-­‐related	  rat	  virus,	  for	  which	   reasons	   they	   are	  poor	  models	   to	   study	   chronic	   liver	  disease	   and	  associated	  HCC	  development213.	  Thus,	  the	  study	  of	  HBV	  and	  HCV-­‐associated	  liver	  cancer	  remains	  a	  challenge.	  	  Transgenic	   mouse	   models	   expressing	   viral	   antigens	   of	   HBV	   or	   HCV	   have	   been	  established	  to	  study	  HBV-­‐	  and	  HCV-­‐induced	  liver	  carcinogenesis.	  For	  HBV,	  most	  of	  these	  models	   focus	   on	   the	  HBx	   gene	   that	   has	   been	   described	   to	   induce	   the	   expression	   of	   a	  broad	   range	   of	   oncogenes	   including	   c-­‐fos,	   c-­‐myc	   and	   c-­‐jun317.	  Kim	  et	  al.	   demonstrated	  that	  HBx	  transgenic	  mice	  died	  because	  of	  clear	  cell	  HCC	  within	  11-­‐15	  month	  of	  age318.	  Of	  note,	   in	   contrast	   to	   human	   HCC,	   cirrhosis	   and	   inflammation	   were	   absent	   in	   the	  preneoplastic	   stages	   of	   these	   mice.	   However,	   transgenic	   mice	   that	   overexpress	   HBV	  surface	   antigens319,320,	   develop	   necrosis	   and	   inflammation	   during	   HCC	   development,	  mimicking	  the	  features	  of	  chronic	  hepatitis	  in	  humans.	  Furthermore,	  the	  presence	  of	  the	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HBx	  gene	  plus	  an	  oncogene321	  or	  exposure	  to	  diethylnitrosamine	  (DEN)/aflatoxin	  B1322,	  resulted	  in	  an	  accelerated	  HCC	  formation	  in	  these	  transgenic	  mouse	  models.	  	  Similarly,	   several	   transgenic	   mouse	   models	   constitutively	   expressing	   HCV	   structural	  and/or	  non-­‐structural	  proteins	  under	  the	  control	  of	  liver	  specific	  promoters	  have	  been	  described323.	   In	   some	   of	   these	   models	   HCC	   develops	   primarily	   in	   older	   mice	   (>13	  month)	  and	  on	  an	  HCV	  mediated	  background	  of	  steatosis324,325.	   It	   is	   important	   to	  note	  however,	  that	  although	  these	  mouse	  models	  have	  a	  fully	  functional	  immune	  system,	  they	  are	   typically	   immune-­‐tolerant	   to	   the	   viral	   transgene	   and	   therefore	   lack	   the	  inflammatory	   phenotype	   observed	   in	   humans.	   Furthermore,	   the	   results	   from	   mouse	  models	  that	  ectopically	  express	  individual	  viral	  proteins	  have	  to	  be	  taken	  with	  caution	  as	   the	   expression	   level,	   trafficking	   and	   cellular	   localization	   of	   these	   proteins	   may	  significantly	  differ	  from	  what	  might	  occur	  in	  an	  infected	  hepatocyte213.	  	  Taken	  together,	  GEM	  models	  are	  frequently	  used	  to	  investigate	  pathophysiology	  of	  HCC,	  especially	   with	   the	   focus	   on	   the	   identification	   of	   pathways	   involved	   in	  hepatocarcinogenesis.	  The	  tumors	  are	  histologically	  similar	  to	  human	  HCCs	  and	  arise	  in	  a	  background	  of	  a	  fully	  active	  immune	  system.	  However,	  because	  the	  mice	  are	  normally	  immune-­‐tolerant	   to	   the	   viral	   transgene,	   they	   lack	   the	   immune	   response	   against	   the	  virus,	  which	  is	  very	  different	  from	  the	  human	  situation.	  Furthermore,	  the	  generation	  of	  GEM	   mice	   can	   be	   time	   consuming	   and	   the	   use	   of	   strong	   promoters	   results	   in	   gene	  overexpression	  not	  observed	  in	  the	  clinical	  setting.	  Furthermore,	  the	  knock	  out	  of	  tumor	  suppressor	  genes	  or	   the	  constant	  expression	  of	  oncogenes	  does	  not	  necessarily	  reflect	  the	  situation	  during	  natural	  cancer	  development	  in	  HCC	  patients.	  	  
	  
2.6.2.3	  Chemically	  induced	  mouse	  models	  Because	   the	   liver	   is	   the	   main	   organ	   responsible	   for	   detoxification,	   it	   is	   exposed	   to	  chemical	   compounds,	   including	   alcohol,	   aflatoxin	   B1	   and	   other	   toxins,	   which	   in	  constantly	  high	  concentrations	  can	  lead	  to	  liver	  damage	  and	  eventually	  HCC.	  Therefore,	  several	   models	   using	   genotoxic	   agents	   have	   been	   described	   to	   mimic	   the	   course	   of	  human	  HCC	  development	  induced	  by	  chemical	  compounds.	  DEN	  is	  the	  most	  frequently	  used	   carcinogen	   in	   the	   field	   of	   liver	   cancer	   research304.	   DEN-­‐induced	   tumorigenesis	  varies	  with	  dosage,	   age,	   sex	  and	  strain	  of	   the	  mice302,326	   and	   induces	   tumor	   formation	  mainly	  in	  the	  liver	  but	  also	  in	  the	  respiratory	  tract,	  kidney,	  upper	  digestive	  tract	  and	  in	  the	   hematopoietic	   system302,304.	  DEN	   is	  metabolized	   in	   the	   liver,	  where	   it	   causes	  DNA	  
I	  Introduction	  
	  36	  
damage307.	  When	  this	  damage	  happens	  in	  proliferating	  hepatocytes,	  either	  during	  liver	  development	   in	   the	   postnatal	   period	   or	   following	   liver	   injury,	   DNA	   damage	   is	  transmitted	   to	  daughter	   cells,	  which	  accelerates	  HCC	  development327-­‐329.	  DEN	   induced	  tumor	   development	   occurs	   in	   the	   absence	   of	   chronic	   liver	   injury,	   inflammation	   and	  fibrosis303.	  However,	   if	   it	   is	   combined	  with	  a	  promoting	  agent	  such	  as	   the	  hepatotoxin	  carbon	   tetrachloride	   (CCl4),	   it	   induces	   a	   multistep	   process,	   including	   liver	   injury,	  inflammation,	   fibrosis,	   cirrhosis	   and	   ultimately	   HCC	   development303.	   Genetically,	   the	  DEN	   model	   resembles	   the	   subclass	   of	   human	   HCCs	   with	   poor	   prognosis312,	  characterized	   by	   high	   proliferation	   rate,	   chromosomal	   instability	   and	   low	   levels	   of	  β-­‐catenin	  mutations.	  As	   previously	   described,	   aflatoxin	  B1	   induces	   genetic	   damage	   and	   its	   intake	   has	   been	  correlated	  with	  HCC	  development	  in	  humans185,203.	  Similarly,	  mice	  exposed	  to	  aflatoxin	  B1	  administration	  develop	  HCC	  after	  52	  weeks	  but	  with	  an	  incidence	  rate	  varying	  from	  25-­‐90%	  dependent	  on	  the	  mouse	  strain302,330.	  	  In	   general,	   chemically	   induced	   HCC	   mouse	   models	   can	   mimic	   the	   injury-­‐fibrosis-­‐malignancy	  cycle,	  the	  background	  on	  which	  the	  majority	  of	  HCC	  arise331.	  However,	  they	  mainly	   reflect	   toxin-­‐induced	   etiologies,	   which	   makes	   them	   suboptimal	   for	   preclinical	  drug	  screening303.	  	  
	  
2.6.2.4	  Xenograft	  mouse	  models	  For	  the	  generation	  of	  HCC	  xenograft	  mouse	  models,	  established	  hepatoma	  cell	   lines	  or	  fresh	  human	  tumor	  tissue	  is	  implanted	  into	  immunocompromised	  recipient	  mice292,306.	  According	   to	   tumor	   localization,	   ectopic	   and	   orthotopic	   models	   are	   distinguished.	   In	  ectopic	  models,	  tumor	  tissue	  is	  subcutaneously	  (s.c.)	  introduced,	  whereas	  in	  orthotopic	  models,	   tumor	  tissue	  is	  placed	  intrahepatically302.	  S.c.	  xenograft	  models	  are	  technically	  relatively	  easy	  to	  perform,	  reproducible	  and	  because	  the	  tumors	  are	  placed	  externally,	  size	  assessment	  is	  straightforward.	  This	  is	  of	  special	  interest	  for	  preclinical	  drug	  testing	  as	   it	   allows	   regular	   tumor	  volume	  measurements291.	   Indeed,	   s.c.	   xenograft	  models	   are	  most	  frequently	  used	  for	  pre-­‐clinical	  studies	  of	  anti-­‐cancer	  drugs	  in	  vivo.	  However,	  these	  tumors	   do	   not	   have	   a	   direct	   interaction	   with	   the	   liver	   tissue302,	   preventing	   the	  interaction	  of	  the	  tumor	  cells	  with	  the	  proper	  microenvironment292.	  On	  the	  other	  hand,	  tumors	   of	   orthotopic	   mouse	   models	   grow	   in	   their	   natural	   environment	   but	   are	  technically	  more	  challenging	  and	  require	   sophisticated	   imaging	   technologies	  or	   serum	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biomarkers	  to	  monitor	  tumor	  take	  rate,	  tumor	  growth	  and	  effects	  of	  therapy	  on	  tumor	  progression291.	   Furthermore,	   xenograft	  models	   lack	   a	   fully	   functional	   immune	   system.	  Thus,	  the	  process	  of	  hepatocarcinogenesis	  on	  an	  inflammatory	  and	  fibrotic	  background	  cannot	  easily	  be	  investigated	  in	  these	  mice303.	  	  Established	  cell	  lines	  are	  frequently	  used	  to	  generate	  xenograft	  models	  because	  they	  are	  easy	  to	  handle,	  can	  be	  indefinitely	  expanded,	  allow	  for	  genetic	  manipulation	  and	  induce	  rapid	  tumor	  growth	  when	  injected	   into	  mice.	  However,	   their	  clonal	  appearance	  hardly	  reflects	  the	  heterogeneity	  of	  human	  HCCs302.	  In	  contrast,	  fresh	  patient	  material	  reflects	  the	   true	   composition	   of	   human	   HCCs	   but	   is	   difficult	   to	   obtain	   with	   very	   limited	  possibilities	   of	   genetic	   manipulations.	   Importantly,	   patient-­‐derived	   xenograft	   models	  (PDX)	  are	  regarded	  as	  valuable	   tools	   in	   the	   field	  of	  anti-­‐cancer	  drug	  development	  and	  prediction	   of	   cancer	   therapy332,333.	   In	   the	   field	   of	   HCC,	   several	   s.c.334-­‐338	   and	  orthotopic339,340	  PDX	  models	  have	  been	  generated	  from	  fresh,	  surgically	  excised	  human	  HCC	   specimens.	   However,	   because	   only	   patients	   with	   early	   stage	   HCCs	   qualify	   for	  surgical	  tumor	  resection185,	  these	  models	  may	  not	  recapitulate	  the	  full	  spectrum	  of	  HCC	  including	  all	  clinical	  tumor	  stages.	  Furthermore,	  a	  comprehensive	  and	  in	  depth	  analysis	  of	  how	  well	  these	  PDX	  models	  recapitulate	  the	  original	  human	  HCC	  tissue	  on	  histologic,	  genetic	  and	  molecular	  level,	  is	  still	  missing.	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II	  Aims	  of	  Research	  	  
1.	  Project:	  Negative	  regulation	  of	  the	  IFN-­‐λ 	  induced	  JAK-­‐STAT	  pathway	  Although	   an	   immediate	   and	   strong	   activation	   of	   signaling	   pathways	   is	   necessary	   for	  optimal	  cytokine	  action,	   it	   is	  equally	  important	  to	  appropriately	  control	  the	  magnitude	  and	  duration	  of	  cellular	  responses	  to	  viral	  and	  bacterial	  infections	  in	  order	  to	  maintain	  tissue	  homeostasis.	  Although	  type	  I	  and	  III	  IFNs	  signal	  through	  distinct	  receptors,	  they	  induce	   a	   mostly	   overlapping	   set	   of	   ISGs	   in	   cells	   expressing	   both	   IFN-­‐α	   and	   IFN-­‐λ	  receptors100,341.	   However,	   the	   magnitude	   and	   duration	   of	   the	   induction	   remains	  different.	  While	   IFN-­‐α-­‐induced	  signaling	   is	   transient	  and	  completely	  shut	  down	  after	  a	  few	   hours,	   IFN-­‐λ-­‐induced	   signaling	   persists	   much	   longer100,342,343.	   USP18	   has	   been	  shown	  to	  be	  responsible	  for	  the	  strong	  regulation	  of	  IFN-­‐α	  signaling	  whereas	  its	  effect	  on	   IFN-­‐λ	   remains	   a	   matter	   of	   controversy.	   Importantly,	   the	   effect	   of	   the	   two	   known	  inducible	   negative	   regulators	   SOCS1	   and	   SOCS3	   on	   IFN-­‐λ	   needs	   further	   clarification.	  Currently	   available	   data	   is	   based	   primarily	   on	   overexpression	   studies	   in	   vitro	   and	  therefore	  lacks	  physiological	  relevance.	  With	  the	  current	  study,	  we	  aimed	  to	  investigate	  the	  physiological	  role	  of	  SOCS1,	  SOCS3	  and	  USP18	  on	  type	  III	   IFN-­‐induced	  signaling	   in	  
vitro	  and	  in	  vivo.	  	  
2.	   Project:	   Development	   of	   patient-­‐derived	   xenograft	  models	   from	   fresh	   human	  
HCC	  needle	  biopsies	  	  HCC	   is	   the	   second	   leading	   cause	   of	   cancer-­‐related	   death	   worldwide	   with	   increasing	  incidence	  rates.	  The	  prognosis	  of	  HCC	  is	  poor,	  despite	  massive	  efforts	  by	  experimental	  and	  clinical	  research.	  Less	  than	  30%	  of	  HCC	  patients	  qualify	  for	  curative	  treatment	  and	  therapeutic	   approaches	   for	  advanced	  stage	  HCC	  shows	  only	   limited	  efficacy.	  Thus,	   the	  identification	   and	   development	   of	   more	   efficient	   therapies	   for	   intermediate	   and	  advanced	   stage	  HCCs	   are	   required.	   Albeit	   PDX	  models	   are	   useful	   for	   pre-­‐clinical	   drug	  testing,	   until	   now,	   only	   resected	   HCC	   specimens	   were	   used	   to	   generate	   PDX	   mouse	  models.	   Because	   surgical	   resection	   is	   only	   applied	   to	   patients	   with	   early	   stage	   HCC,	  these	   models	   may	   not	   reflect	   the	   full	   spectrum	   of	   human	   HCC	   stages.	   Therefore,	   we	  aimed	  at	  establishing	  xenograft	  models	   from	  fresh	  human	  HCC	  needle	  biopsy	  material	  that	  also	  includes	  late	  stage	  HCCs.	  Using	  this	  approach	  we	  could	  generate	  a	  pre-­‐clinical	  tool	   suitable	   for	   personalized	   medicine	   including	   analysis	   of	   drug-­‐induced	   resistance	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SOCS1 is an inducible negative regulator of interferon !
(IFN-!)–induced gene expression in vivo
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Type I (" and #) and type III (!) IFNs are induced upon viral
infection through host sensory pathways that activate IFN reg-
ulatory factors (IRFs) and nuclear factor $B. Secreted IFNs
induce autocrine and paracrine signaling through the JAK-
STAT pathway, leading to the transcriptional induction of hun-
dreds of IFN-stimulated genes, among them sensory pathway
components such as cGAS, STING, RIG-I, MDA5, and the tran-
scription factor IRF7, which enhance the induction of IFN-"s
and IFN-!s. This positive feedback loop enables a very rapid and
strong host response that, at some point, has to be controlled by
negative regulators to maintain tissue homeostasis. Type I IFN
signaling is controlled by the inducible negative regulators sup-
pressor of cytokine signaling 1 (SOCS1), SOCS3, and ubiquitin-
specific peptidase 18 (USP18). The physiological role of these
proteins in IFN-% signaling has not been clarified. Here we used
knockout cell lines and mice to show that IFN-! signaling is
regulated by SOCS1 but not by SOCS3 or USP18. These differ-
ences were the basis for the distinct kinetic properties of type I
and III IFNs. We found that IFN-" signaling is transient and
becomes refractory after hours, whereas IFN-! provides a long-
lasting IFN-stimulated gene induction.
Type I and type III IFNs are induced in virus-infected cells
and provide an important first line of defense through the rapid
induction of hundreds of IFN-stimulated genes (ISGs)3 that
collectively establish an antiviral state. Type I IFNs (IFN-!s and
IFN-") bind to the ubiquitously expressed IFN-! receptor
(IFNAR), which consists of two major subunits: IFNAR1 and
IFNAR2c. Each receptor subunit constitutively binds to a single
specificmember of the JAK family: IFNAR1 to tyrosine kinase 2
(TYK2) and IFNAR2c to JAK1. Upon binding of the two chains
by type I IFNs, TYK2 and JAK1 transactivate each other by
mutual tyrosine phosphorylation and then initiate a cascade of
tyrosine phosphorylation events on the intracellular domains of
the receptors and on STAT1 and STAT2. STAT1 and STAT2
combinewith a third transcription factor, IFN regulatory factor
9 (IRF9), to form interferon-stimulated gene factor 3 (ISGF3).
ISGF3 binds to interferon-stimulated response elements
(ISREs) in the promoters of ISGs. Alternatively, IFN-activated
STAT1 can form homodimers. These STAT dimers bind a dif-
ferent class of response elements, the #-activated sequence ele-
ments (1). Activation of the JAK–STAT pathway is tightly con-
trolled by several negative regulatory mechanisms. SOCS1 and
3 are rapidly induced and inhibit STAT activation (2). Mecha-
nistically, SOCS proteins simultaneously bind the receptors
and the JAKs and prevent STATs from access to the receptor
kinase complex (3). Ubiquitin-specific peptidase 18 (USP18) is
induced later but remains highly expressed for days (4). USP18
is responsible for the long-lasting refractoriness of IFN-! sig-
naling in the liver (5). The physiological role of these inducible
negative feedback loops is to prevent tissue damage caused by
the potent pro-inflammatory effects of type I IFNs (6).
In humans, the type III IFN family consists of four members,
IFN-$1–4. They all bind to the IFN-$ receptor (IFNLR), con-
sisting of the ubiquitously expressed IL-10R2 chain (shared
with the IL-10 receptor) and a unique IFN-$ receptor chain
(IFN$R1) whose expression is mainly restricted to epithelial
cells (7–9). Activation of the IFNLR by ligand binding results in
the activation of ISGF3 and STAT1 homodimers, the same
transcription factor complexes that are induced by type I IFNs.
As a consequence, despite using different receptors, IFN-$s
induce highly similar sets of ISGs as IFN-!/"s (10–14). How-
ever, at least in cell culture, ISG induction followed distinct
kinetic profiles for IFN-! and IFN-$. Although gene induction
was rapid and transientwith IFN-!, IFN-$ induced a slower but
more sustained increase in ISG expression (15, 16). There is
indirect evidence that this difference could result from the lack
of USP18 binding to the IFNLR. In cell culture and in mice,
USP18 was induced by both IFN-! and IFN-$, but only IFN-!
signaling was inhibited by USP18 (17, 18). Contradictory to
these findings, amore recent report identified USP18 as a novel
inhibitor of IFN-$ signaling (19). The role of SOCS1 and
SOCS3 in regulating IFN-$ signaling remains to be clarified as
well. Overexpression of SOCS1 inHuh7 human hepatoma cells
inhibited the antiviral activity of both IFN-! and IFN-$ (20).
However, whether physiological expression levels of SOCS1
and/or SOCS3 can inhibit IFN-$ signaling remains to be
shown.
The IFN-$ system has been intensely studied in the context
of hepatitis C virus (HCV) infections because genetic variants of
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the IFN-! gene locus are strongly associated with the ability of
the host response to clear the viral infection in the acute phase
and with response to treatment with pegylated IFN-" and riba-
virin in chronic hepatitis C (21). Genetic evidence points to
IFN-!4 as the key regulator of the host response to HCV. A
variant allele (TT at position rs368234815) with an inactivating
frameshift mutation in exon 1 of the IFN-!4 gene is found with
a frequency that increases from Africa (0.29–0.44) to the New
World (0.51–0.65) and Europe (0.58–0.77) and reaches 0.94–
0.97 in East Asia (22). Homozygosity for the functionally inac-
tive IFN-!4 gene (TT/TT) is associated with spontaneous
clearance of HCV in the acute phase and a high cure rate of
therapies with pegylated IFN-" and ribavirin (23–25). It is not
entirely clear why the host benefits from lack of a functional
IFN-!4. A pertinent observation relates to the activation status
of the endogenous IFN system in the liver. Patients with wild-
type IFN-!4 (encoded by the rs368234815 !G allele) mount a
strong innate immune response and have a permanent and
strong expression of hundreds of ISGs in the liver (26). Among
these ISGs are also inducible negative regulators of IFN signal-
ing such as USP18. The continuous high expression of USP18
makes it highly unlikely that type I IFNs are drivers of the innate
immune response in chronic hepatitis C. Indeed, there is
genetic evidence that IFN-!4 is the driver of ISG expression in
chronic hepatitis C (25). To better understand themechanisms
of ISG induction in chronic hepatitis C, differences in negative
regulation of type I and type III interferons have to be
elucidated.
In this work, we investigated the role of SOCS1, SOCS3, and
USP18 in IFN-! signaling in cells with physiological IFNLR
expression anddeletion or overexpression of all three inhibitors
and in mice deficient for SOCS1 or USP18.We identify SOCS1
as a physiologically relevant inducible inhibitor of IFN-!–
induced JAK–STAT signaling. SOCS3 and USP18 are impor-
tant for regulating IFN-" but not IFN-! signaling.
Results
IFN-! induces sustained gene expression in cells despite strong
induction of USP18
The selective and restricted expression of IFNLR1 limits the
biological activity range of IFN-! primarily to mucosal epithe-
lial tissues (27). We have previously shown very low expression
of IFNLR1 in the human liver that can, however, be induced in
patients with chronic hepatitis C, particularly with the IFN-!4
wild-type genotype (TT/!G and !G/!G), to levels that make
hepatocytes responsive to IFN-! (28). To analyze IFN-! signal-
ing in a cell line with similar IFNLR1 expression, we used a
clone of Huh7 cells (a widely used human hepatoma cell line)
that has been stably transfected with IFNLR1, Huh7 LR clone 3
(designated Huh7 LR in this manuscript) (28). Huh7 LR cells
express around 10,000 copies of IFNLR1 per 40 ng of total RNA
(Fig. 1A). Huh7 LR cells were then stimulated with saturating
concentrations of human IFN-" and human IFN-!1 for up to
48 h. The kinetics of the activation of JAK–STAT signaling
were assessed with antibodies specific for tyrosine-phosphory-
lated STAT1 (p-STAT1), STAT2 (p-STAT2), and STAT3
(p-STAT3). IFN-" induced strong but transient STAT1 and
STAT2 activation (Fig. 1B). Induction of the two early ISGs,
RSAD2 and GBP5 (4), was also transient, with an expression
peak 8 h after IFN-" stimulation (Fig. 1C). IFN-!1 showed pro-
longed activation of STAT1 and STAT2 despite an even stron-
ger induction of USP18 at the 24 h time point (Fig. 1B). Consis-
tently, ISG induction was sustained and increased compared
with IFN-" (Fig. 1C). The induction of pSTAT3 was not signif-
icantly different between IFN-" and IFN-!1. These results are
in accordancewith published data obtainedwith other cell lines
and primary human hepatocytes (11, 15, 16).
IFN-! signaling is inhibited in cells overexpressing SOCS1,
SOCS3, or USP18
Huh7 LR cells were then transiently transfected with expres-
sion plasmids for SOCS1, SOCS3, and USP18 and stimulated
with saturating concentrations of IFN-" and IFN-!1 for 30min.
All three proteins were strongly expressed and inhibited both
IFN-"– and IFN-!1–induced STAT1 phosphorylation (Fig.
2A). The inhibitory effect of USP18 on IFN-! signaling was
unexpected, given the sustained p-STAT1 and ISG induction
shown in Fig. 1. We therefore systematically compared the
expression levels of the negative regulators obtained by physi-
ological stimulation with IFNs versus those obtained in cells
transfectedwith expression plasmid.As shown in Fig. 2B, trans-
fection resulted in expression levels that were 2–3 orders of
magnitude higher than those induced bymaximal physiological
stimulation with IFNs. The mRNA results were also confirmed
at the protein level (Fig. 2B). We conclude that all three inhib-
itors have the potential to inhibit both IFN-" and IFN-! signal-
ing at supraphysiological expression levels.
SOCS1-deficient cells are hyperresponsive to IFN-!
To assess the physiological relevance of SOCS1, SOCS3, and
USP18 for IFN-! signaling, we generated knockout cell lines
from Huh7 LR cells using the CRISPR-Cas9 technology (sup-
plemental Fig. 1). The rationale for this loss-of-function exper-
iment was the expectation that loss of a physiologically relevant
inhibitor of IFN signaling must result in hyperactivation of the
signal transduction pathway with increased ISG induction. By
definition, any inducible inhibitor of IFN signaling has to
restrict ISG induction at some point and to a relevant degree.
We first tested this hypothesis using a luciferase reporter gene
under the control of an ISRE promoter (i.e. the Mx1 promoter,
ISRE-Mx1-Luc). To do so, we transfected control and knockout
cells with the pGL3-ISRE-Mx1-Luc plasmid together with a
constitutively expressed Renilla luciferase construct for nor-
malization. 20 h after transfection, they were stimulated with
IFN-!1, IFN-!3, IFN-!4, IFN-", and IFN-# or left untreated,
and luciferase activity was quantified 4, 8, and 24 h later. The
luciferase activity in untreated cells did not differ significantly
between cell lines but increased at least 15-fold within 4 h after
IFN addition. At 4 h and 8 h, but not at 24 h, SOCS1 knockout
cells showed significantly higher expressionof the reporter con-
structs when stimulated with IFN-!1, IFN-!3, or IFN-!4 (Fig. 3
and supplemental Fig. 2). IFN-" signaling was enhanced in
USP18 knockout cells at all time points (Fig. 3), whereas IFN-#
signaling was enhanced at the 8 h time point only (supplemen-
tal Fig. 2). Type I IFN–induced expression of the reporter plas-
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mid was also significantly enhanced at some time points in
SOCS1 and SOCS3 knockout cells (Fig. 3 and supplemental Fig.
2). We confirmed these findings by quantifying the expression
levels of ISGs, including RSAD2,GBP5, and IFI27, as well as the
three inducible regulators, SOCS1, SOCS3, and USP18, in the
knockout cell lines after stimulation with IFN-!1 and IFN-"
(Fig. 4 and supplemental Fig. 3). Expression of RSAD2, GBP5,
and IFI27 in untreated control and knockout cells was detecta-
ble and did not differ significantly between the cell lines. The
same ISGs were up-regulated 10- to 100-fold 4 h after IFN-" or
IFN-!1 stimulation (Fig. 4). Importantly however, IFN-!1–
induced ISG expression was significantly enhanced in SOCS1
knockout cells at 8 and 24 h, but this increase was not observed
in SOCS3 or USP18 knockout cells. For GBP5, this enhance-
ment could already be observed 4 h after IFN-!1 stimulation,
although it did not reach statistical significance. Furthermore,
we confirmed the knownnegative regulatory effect ofUSP18 on
IFN-" signaling. We conclude that, in Huh7 LR cells, SOCS1 is
an inducible and physiologically relevant negative regulator of
IFN-!1, IFN-!3, and IFN-!4.
Figure 1. IFN-!– but not IFN-"–induced STAT1 phosphorylation becomes refractory to continuous stimulation. A, liver biopsies from chronic hepatitis
C patients (n! 16) were divided into three groups based on their IFNL4 genotype (rs368234815; TT/TT, TT/dG, and dG/dG). Total RNA frombiopsies and Huh7
andHuh7 LR cells were prepared. Expression of the IFNLR1 transcript was analyzed by quantitative PCR. Results (mean" S.D.) are shown as copy numbers per
40ngof total RNA.B andC, Huh7LR cellswere stimulatedwith1000 IU/ml IFN-"or 100ng/ml IFN-!1 for the indicated times.B, p-STAT1, STAT1, p-STAT2, STAT2,
p-STAT3, STAT3, USP18, SOCS1, SOCS3, and actin were visualized using specific antibodies. Shown are representative blots from two independent experi-
ments. C, transcripts of interferon-stimulated genes (RSAD2, IFI27, and GBP5) were quantified by PCR. Results (mean " S.D., n ! 3) are shown as relative
expression to GAPDH. ut, untreated.
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Figure 2. Overexpression of SOCS1, SOCS3, and USP18 leads to a reduction of IFN-!– and IFN-"–mediated STAT1 phosphorylation. A, Huh7 LR cells
were transiently transfected with control, SOCS1, SOCS3, or USP18 expression plasmids. 24 h later, cells were stimulated with 1000 IU/ml IFN-! or 100 ng/ml
IFN-"1 for 30 min, and p-STAT1, STAT1, SOCS1, SOCS3, USP18, and actin were visualized by immunoblotting. Shown are representative blots from three
independent experiments. B, Huh7 LR cells were transfectedwith SOCS1, SOCS3, or USP18 expression plasmids for 24 h. ThemRNAexpression levels of SOCS1,
SOCS3, andUSP18were analyzedbyquantitative PCR and comparedwith the endogenously induced SOCS1, SOCS3, orUSP18upon IFN-!or IFN-"1 stimulation
at the indicated time points. The results (mean! S.D., n" 3) are shown as relative expression to GAPDH. Protein levels of SOCS1, SOCS3, and USP18 and actin
were visualized using specific antibodies. ox, overexpression; ut, untreated.
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SOCS1 is a physiological inhibitor of IFN-! signaling in vivo
To test whether the results obtained in Huh7 LR cells are
valid in vivo, we analyzed IFN-! and IFN-" signaling in mice
deficient for Socs1 or Usp18 and their corresponding control
mice. Because Socs1 knockout mice suffer from IFN-#–
mediated lethal toxicity, they were bread as Ifng/Socs1 double
knockout mice, with Ifng knockout mice serving as controls, as
described previously (5, 29). The mice were sacrificed 4 and 8 h
after IFN injections, and the liver, lung, and gut were analyzed
for induction of seven different ISGs (Rsad2, Oas1, Stat1,
Usp18, Gbp5, and Ifi27). Socs1 knockout resulted in signifi-
cantly increased expression of all IFN-!2–induced ISGs at 8 h
in the lung and at 4 h in the gut, the two IFN-! responsive
organs, but not in the liver, which is devoid of IFNLR1 in mice
(Fig. 5). Although Socs1 knockout also resulted in enhanced
expression of three of six ISGs in the lung and gut upon IFN-"
injection (Fig. 5), it did not affect IFN-"–mediated ISG induc-
tion levels in the liver (Fig. 5 and supplemental Fig. 4A). In
contrast, IFN-" induced all tested ISGs to significantly higher
levels in the livers ofUsp18 knockoutmice compared with con-
trol mice at all time points (Fig. 6 and supplemental Fig. 4B).
The effect of Usp18 knockout on IFN-" signaling in the lung
occurred mainly at 8 h, and it was much less pronounced in the
gut. The effect ofUsp18 knockout on IFN-! signaling was min-
imal, with only Rsad2 and Ifi27 being significantly increased at
one time point in the gut and lung, respectively (Fig. 6 and
supplemental Fig. 4B). From these results, we conclude that
IFN-" signaling in these mice is predominantly inhibited by
Usp18, whereas IFN-! signaling is regulated by Socs1.
Discussion
Type I IFNs (IFN-"/$) are potent and critically important
cytokines that control innate and adaptive immune responses
to infection, cancer, and other inflammatory stimuli. Positive
feedback amplification through autocrine and paracrine induc-
tion of IFN-" gene transcription allows a very rapid and strong
host response to infections (30). The extent and duration of this
response is tightly controlled by several mechanisms to avoid
adverse effects on tissue homeostasis. The fact that several clin-
ically important autoimmune diseases, such as systemic lupus
erythematosus and Aicardi-Goutières syndrome, are associ-
ated with uncontrolled type I IFN activities demonstrates the
important role of negative regulators in keeping the system in
balance (6, 31). SOCS1 is an inducible negative regulator of
IFN-" signaling that transiently restricts phosphorylation of
STATs in the first hours. However, its role as a negative regu-
lator of IFN-" signaling is limited. The fact that the lethal phe-
notype of Socs1 knockout mice is rescued by additional knock-
out of Ifng demonstrates that themain role of SOCS1 in the IFN
system is to control IFN-# (29). Furthermore, deletion of Socs1
does not prevent the induction of refractoriness to IFN-" in the
mouse liver (5). The main negative regulator of IFN-" seems to
be USP18. This is demonstrated by this work, by previous work
that showed that refractoriness to IFN-" stimulation is abro-
gated in Usp18 knockout mice (5), and by a rare genetic inter-
feronopathy, pseudo-TORCH syndrome, which is caused by
human USP18 deficiency (32).
Negative regulation of type III IFNs is fundamentally differ-
ent from type I IFNs. The inducible up-regulation of USP18
does not induce refractoriness of IFN-! signaling (this work
andRefs. 11, 15–18).). Of note, as shown in Fig. 2, USP18 indeed
has the potential to inhibit IFN-! signaling, but only at expres-
sion levels that are not achieved by physiological induction
Figure 3. SOCS1 is a modulator of IFN-!-signaling. Control, SOCS1!/!,
SOCS3!/!, and USP18!/! cells were transfected with pGL3-ISRE-Mx1-Luc
and pGL4-CMV-Renilla-Luc plasmids and, 20 h later, stimulated with 100
ng/ml IFN-!1, 50 ng/ml IFN-!4, or 1000 IU/ml IFN-" for 4 h, 8 h, and 24hor left
untreated. The firefly luciferase values were normalized to Renilla luciferase,
and the results (mean " S.D., n # 2) are expressed as firefly/Renilla ratio.
Unpaired t test; *, p$ 0.05; **, p$ 0.01; ***, p$ 0.001.
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stimuli. We conclude that USP18 is not a physiological inhibi-
tor of IFN-! signaling. IFN-! signaling is rather controlled by
SOCS1, and contrary to IFN-", not only in the first hours of
stimulation but also at later time points (Fig. 4). Of note, a
long-lasting negative regulatory effect of SOCS1 on IFN-!1 sig-
naling has been found previously in shRNA knockdown exper-
iments in A549 human alveolar epithelial cells (33). SOCS1 not
only controls the closely related IFN-!1 and IFN-!3 but also
IFN-!4. We postulate that the prolonged inhibitory effects of
SOCS1 on IFN-! signaling result from its sustained up-regula-
tion for at least 48 h, which contrasts the transient induction of
SOCS1 by IFN-" (Fig. 2B).
In conclusion,we show that the IFN-" and the IFN-! systems
not only differ in terms of tissue distribution of their cognate
receptors (27) but are also controlled by distinct negative regu-
latory mechanisms of their signal transduction through the
JAK–STAT pathway. IFN-" signaling is transient and shut
down after 6–8 h by USP18, a very strong inhibitor of STAT
tyrosine phosphorylation at the IFNAR–kinase complex.
IFN-! signaling is not affected by USP18. It is controlled by
SOCS1, but SOCS1 does not shut down STATphosphorylation
completely, allowing long-lasting stimulation of ISG transcrip-
tion by IFN-!. We postulate that these differences between
IFN-" and IFN-! in the negative regulation of JAK–STAT sig-
naling are responsible for the previously described differences
in the kinetics of ISG induction. Long-lasting activation of
JAK–STAT signaling allows the IFN-! system to mount a sus-
tained antiviral state in mucosal epithelial cells that are con-
stantly exposed to pathogens. IFN-" is amore powerful defense
system that is activatedwhen pathogenic viruses have breached
Figure 4. SOCS1 is amodulator of IFN-!–induced ISGs expression in vitro. Control, SOCS1!/!, SOCS3!/!, and USP18!/! cells were stimulated with 1000
IU/ml IFN-" or 100 ng/ml IFN-!1 for 4 h, 8 h, and 24 h or left untreated, and the expression levels of RSAD2,GBP5, and IFI27were analyzed by quantitative PCR.
The results (mean" S.D., n# 2) are shown as relative expression to GAPDH. Unpaired t test; *, p$ 0.05; **, p$ 0.01; ***, p$ 0.001.
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the mucosal surfaces and invaded the systemic circulation and
other organs. In most instances, it is only transiently activated
because prolonged activation of IFN-! signaling is detrimental




A human hepatoma cell line (Huh7) was cultured in
DMEM (Gibco) supplemented with 10% heat-inactivated
FBS (Gibco) and 1% penicillin-streptomycin (Gibco). Huh7
Figure 5. Depletion of Socs-1 increased IFN-!–induced ISGs expression in vivo. Control and Socs1!/!mice were subcutaneously injected with PBS,
1000 units/g mouse IFN-!, or 50 ng/g mouse IFN-"2. The liver, the lung, and the gut were collected 4 h and 8 h after injection, and total RNA was
prepared. The expression of Rsad2, Oas1, Stat1, Usp18, and Socs1 was measured by quantitative PCR. The results (mean " S.D.) are shown as relative
expression to Rpl19. Three to four animals were used per time point and condition. Unpaired t test with Welch’s correction; *, p# 0.05; **, p# 0.01; ***,
p # 0.001. ut, untreated.
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LR cells constitutively overexpressing IFNLR1 (28) and
SOCS1!/!, SOCS3!/!, and USP18!/! cells were cultured in
DMEM-10% FBS, 1% penicillin-streptomycin (Gibco) sup-
plemented with 1 mg/ml G418 (Calbiochem).
Animals
Socs1!/! Ifng!/! (Socs1!/!), Ifng!/! (control), Ubp43!/!
(Usp18!/!), and FVB (control) mice were described previously
(29, 34–37). The animals were bred and maintained in the ani-
Figure 6. Depletion ofUsp18 increased IFN-!–induced ISGs expression in vivo. Control and Usp18!/!mice were subcutaneously injected with PBS,
1000 units/g mouse IFN-!, or 50 ng/g mouse IFN-"2. The liver, the lung, and the gut were collected 4 h and 8 h after injection, and total RNA was
prepared. The expression of Rsad2, Oas1, Stat1, Socs1, and Usp18 was measured by quantitative PCR. The results (mean " S.D.) are shown as relative
expression to Rpl19. Three to five animals were used per time point and condition. Unpaired t test with Welch’s correction; *, p# 0.05; **, p# 0.01; ***,
p # 0.001. ut, untreated.
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mal facility of the Department of Biomedicine of the University
Hospital Basel under specific-pathogen-free conditions on a
12-h day and 12-h night schedulewith ad libitum access to food
and drinking water. Experiments were conducted with the
approval of the Animal Care Committee of the Canton Basel-
Stadt, Switzerland. Six- to eight-week-oldmales were used, and
the animals were euthanized by CO2 narcosis. Resected organs
were immediately frozen in liquid nitrogen and kept at!70 °C
until further processing. Subcutaneous injections with PBS,
mouse IFN-!, ormouse IFN-"2were performedbetween 8 a.m.
and 5 p.m.
Human liver biopsies
Liver biopsies from chronic HCV-infected patients (n" 16,
patient characteristics are shown in supplemental Table 1)were
obtained in the outpatient clinic of theDivision of Gastroenter-
ology and Hepatology, University Hospital Basel, Switzerland.
Biopsymaterial that was not needed for routine histopathology
was used for research purposes after obtaining written
informed consent. The use of biopsy material for this project
was approved by the Ethikkommission Nordwest- und
Zentralschweiz, Basel, Switzerland, protocol numberM989/99.
Total DNA was isolated from liver biopsies using the DNeasy
Blood & Tissue Kit (Qiagen, Hombrechtikon, Switzerland)
according to the instructions of themanufacturer. IFN-"4 gen-
otype was determined as described previously (25).
Plasmids, antibodies, and reagents
Human IFN-! (Roferon-A) was purchased from Roche
Pharma SA (Reinach, Switzerland). Human IFN-# (Betaferon)
was obtained from Bayer HealthCare Pharmaceuticals (Bayer
Consumer Care AG, Basel, Switzerland). Human IFN-"1 and
mouse IFN-"2 were from PeproTech (LuBioScience GmbH,
Luzern, Switzerland), and human IFN-$ was from Biolegend
(Lucerna-ChemAG, Luzern, Switzerland). Human IFN-"3 and
human IFN-"4 were generated as described previously (9) by
Prof. Rune Hartmann (Aarhus University, Aarhus, Denmark),
andmouse IFN-!was a gift fromProf. Radek Skoda (University
Hospital Basel). Phospho-STAT1 (Tyr-701, 58D6), phospho-
STAT3 (Tyr-705, D3A7 XP), STAT3 (124H6), and USP18
(D4E7) antibodies were from Cell Signaling Technology (Bio-
Concept, Allschwil, Switzerland), and STAT1 (C-term) and
STAT2 antibodies were from BD Biosciences (Allschwil, Swit-
zerland). Phospho-STAT2 (Tyr689) and SOCS1 (4H1) anti-
bodies were from EMDMillipore (Merck & Co., Schaffhausen,
Switzerland). SOCS3 (H-103) and #-actin were from Santa
Cruz Biotechnology (LabForce AG, Muttenz, Switzerland)
and Sigma-Aldrich Chemie GmbH (Buchs, Switzerland),
respectively.
Whole-cell lysates andWestern blotting analysis
Whole-cell lysates and immunoblotswere prepared and used
as described previously (38).
Total RNA extraction and quantitative PCR
Total RNA from cell lines was isolated using NucleoSpin
RNA (Macherey-Nagel AG, Oensingen, Switzerland) accord-
ing to the instructions of the manufacturer. cDNA was gener-
ated from 1 %g of total RNA using Moloney murine leukemia
virus reverse transcriptase (Promega AG, Dübendorf, Switzer-
land). Total RNA fromhuman biopsies andmouse samples was
isolated using TRIzol according to the instructions of the man-
ufacturer. 1 %g of total RNAwas incubated with rDNaseI using
the DNA-free kit (Ambion). cDNA was generated using the
TaqMan reverse transcription reagent kit (Applied Biosystems)
according to the recommendations of the manufacturer. Real-
time quantitative PCRwas performed using FastStart Universal
SYBR Green Master Mix (Roche Diagnostics AG, Rotkreuz,
Switzerland) and the ABI 7500 detection system (Applied Bio-
systems, Thermo Fisher Scientific, Zug, Switzerland). Primers
are listed in supplemental Table 2. The specificity of the PCR
primers was assessed by sequencing the PCR product. Gene
transcript expression levels were calculated using the #Ct
method. To quantitate IFNLR1 transcript levels, dilutions of
plasmids containing the IFNLR1 ORF (28) were used as stan-
dard curves (dilutions ranged from 108 to 100 copies of
plasmid).
SOCS1, SOCS3, and USP18 overexpression
The pCMV6 plasmid containing the SOCS1 gene
(RC220847) was purchased from Origene Technologies Inc.
(Rockville, MD) and used to overexpress SOCS1. Human
USP18 and human SOCS3 coding sequences were cloned into
the pCMV6-entry and pCMV-MIR vectors, respectively, using
XhoI andBamHI restriction sites forUSP18 andXhoI andKpnI
restriction sites for SOCS3. Huh7 LR cells (2$ 105/well) were
seeded onto a 6-well plate, and 2 %g of expression plasmid was
transfected using JetPrimeTM (Polyplus Transfection, VWR
International GmbH, Dietikon, Switzerland) according to the
instructions of the manufacturer.
Generation of SOCS1, SOCS3, and USP18 knockout cell lines
Briefly, the CRISPR design tool from the Zhang laboratory
(http://crispr.mit.edu)4 was used to design single-guide RNA
constructs (supplemental Table 3). Phosphorylated and
annealed single-guide RNAs were cloned into pSpCas9(BB)-
2A-GFP (PX458) (Addgene, 48138, deposited by Feng Zhang)
using BbsI restriction sites. Plasmids were verified by sequenc-
ing. 48 h post-transfection, GFP-positive cells were single cell–
sorted by FACS. To confirm successful gene targeting in sorted
clones, genomic DNAwas extracted using the DNeasy Blood &
Tissue Kit (Qiagen AG) and subjected to PCR amplification
using specific primers for the region of interest (supplemental
Table 2). PCR fragments were then cloned into a pGEMT-easy
expression vector (Promega AG) and transformed into Esche-
richia coli TOP-10 chemically competent cells (Invitrogen).
Colonies were analyzed by sequencing using the T7 primer.
Finally, the absence of SOCS1, SOCS3, or USP18 protein was
confirmed by immunoblotting.
IFN activity reporter assay
The ISRE-Mx1 firefly luciferase reporter construct (pGL3-
Mx1P-FF-Luc, a gift from Rune Hartmann) and pGL4-CMV-
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party–hosted site.
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Renilla-Luc (a gift from Jacek Krol) were electroporated using
Cytomix (39, 40) into SOCS1!/!, SOCS3!/!, USP18!/!, or
control cells. 20 h after electroporation, cells were treated with
IFN-! (1000 UI/ml), IFN-" (1000 UI/ml), IFN-#1 (100 ng/ml),
IFN-#3 (200 ng/ml), or IFN-#4 (50 ng/ml) for 4, 8, and 24 h.
Cells were then lysed with passive lysis buffer (Promega AG),
and firefly luciferase levels were measured, followed by Renilla
luciferase levels, using a multimode microplate reader (Centro
XS3 LB960, Berthold Technologies GmbH & Co. KG, Bad
Wildbad, Germany). The firefly luciferase was normalized in
each well to Renilla luciferase.
Statistical analysis
Prism4 (GraphPad Software Inc., La Jolla, CA) was used for
statistical analysis.
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in! red!and!blue! respectively.! (B)!Huh7!LR!cells,! SOCS1,!SOCS3!and!USP18!knockout!clones!
were! stimulated!with!1000IU/ml! IFNRα!or!100ng/ml! IFNRγ!and! lysed!at! the! indicated! time!





and! pGL4RCMVRRenillaRLuc! plasmids! and! 20h! later! stimulated! with! 200ng/ml! IFNRλ3! or!
1000IU/ml! IFNRβ! for! 4h,! 8h! and! 24h! or! left! untreated.! The! Firefly! Luciferase! values!were!





100ng/ml! IFNRλ1! for!4h,!8h!and!24h!or! left!untreated!and!the!expression! levels!of!SOCS1,&






or! 50ng/g!mouse! IFNRλ2.! The! liver,! the! lung! and! the! gut! were! collected! 4h! and! 8h! post!
injection!and!total!RNA!was!prepared.!The!expression!of!Gbp5&and&Ifi27&was!measured!by!
quantitative! PCR.! The! results! (mean! ±! SD)! are! shown! as! relative! expression! to!Rpl19.! 3R4!
animals!were!used!per!time!point!and!condition.!Unpaired!tRtest!with!Welch’s!correction,!*!
p<0.05,! **! p<0.01,! ***! p<0.001.' (B)' Control! and! Usp18& 3/3! mice! were! subcutaneously!
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Supplementary table 1. CHC patients' characteristics
Patient's # Gender Age HCV genotype viral load L4 genotype IFNLR1 copies
1 m 58 1b 57'791 dG/dG 2750
2 m 60 1b 4'326'723 TT/dG 1181
3 m 45 1a 7'585'775 TT/dG 18699
4 m 43 3 1'445'439 TT/dG 1219
5 m 59 4 26'700 TT/dG 7787
6 f 48 1a n.d. TT/dG 7797
7 m 47 3 474'333 dG/dG 14082
8 m 52 3a 2'884'032 TT/dG 33324
9 m 24 1 64'646 dG/dG 9595
10 m 57 3 3'455'931 TT/dG 361
11 f 53 4 795'769 dG/dG 1084
12 f 47 1a 3'981'071 TT/TT 10
13 f 43 1 1'698'243 TT/TT 332
14 f 47 1 1'031'852 dG/dG 66
15 m 45 3 742'088 TT/TT 37
16 f 45 3 4'677'351 TT/dG 66
n.d: not determined 
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Supplementary table 2. Primer sequences for quantitative RT-PCR and PCR 














































Supplementary table 3. SgRNA sequences for CRISPR/Cas9
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Background & Aims: Hepatocellular carcinoma (HCC) is the second leading 2 
cause of cancer-related deaths worldwide with limited treatment options for 3 
patients with advanced stage disease. A major obstacle in preclinical drug 4 
development is the lack of an in vivo model that accurately reflects the broad 5 
spectrum of human HCC. Patient derived xenograft (PDX) mouse models 6 
could overcome the limitations of cancer cell lines. PDX models have been 7 
established from surgically resected HCCs. We aimed to establish and 8 
characterize PDX models from human HCC biopsies in order to expand the 9 
spectrum of HCC xenografts to advanced HCCs not amenable to surgery. 10 
Methods: Fifty-four human HCC needle biopsies were transplanted 11 
subcutaneously into immunodeficient NOD-SCID gamma-c (NSG) mice. 12 
Tumor growth rates, histopathological characteristics, RNA sequencing and 13 
whole exome sequencing were used to characterize the newly established 14 
mouse models and to compare them to the originating HCCs. 15 
Results: Eleven HCCs engrafted in NSG mice. They were derived from 16 
patients with various underlying liver diseases and tumor stages. All 17 
successfully transplanted HCCs were Edmondson grade III or IV. HCC PDX 18 
tumors retained the histopathological and transcriptomic characteristics of the 19 
original HCC biopsies over at least generations of re-transplantation, including 20 
Edmondson grade, expression of tumor markers, tumor gene signature and 21 
tumor-associated mutations. 22 
Conclusion: PDX mouse models can be established from undifferentiated 23 
HCCs with an overall success rate of about 33%. The transplanted tumors 24 
represent the entire spectrum of the molecular landscape of HCCs and 25 
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preserve the characteristics of the originating tumors. HCC PDX models are a 1 
promising tool for preclinical personalized drug development. 2 
 3 
Abstract words: 257 4 
 5 
Lay summary 6 
Needle biopsies of primary liver cancer can be transplanted and grown in 7 
immunodeficient mice. They maintain the original tumor characteristics and are 8 
promising new tools for pre-clinical drug screening. 9 



























































































HCC is the most common primary liver cancer and is the second most frequent 3 
cause of cancer-related mortality worldwide[1]. Current treatment options are 4 
limited with less than 30% of HCC patients in Europe qualifying for curative 5 
treatments[2]. The multikinase inhibitor sorafenib is the only first-line treatment 6 
for advanced HCC[3]. Sorafenib moderately improves survival of patients with 7 
advanced HCC but has adverse effects that preclude its use in patients with 8 
advanced cirrhosis[3, 4]. Novel therapies are urgently needed to improve 9 
treatment options for patients with advanced HCCs.  10 
 11 
Current in vitro cell culture models of HCC are based on conventional 12 
hepatoma cell lines that fail to recapitulate key features of tumor tissues such 13 
as three-dimensional tumor architecture, cellular heterogeneity and cell-cell 14 
interactions. Chemically induced HCC mouse models or genetically 15 
engineered mice better reflect in vivo tumor biology[5]. However, they do not 16 
recapitulate the different genetic alterations present in HCCs of different 17 
patients. Patient-derived xenograft (PDX) models have the potential to 18 
overcome these limitations and are considered valuable tools in the field of 19 
anti-cancer drug development and prediction of response to cancer therapy[6, 20 
7]. So far, all published HCC PDX models have been generated from surgically 21 
resected HCCs[8-13]. Because surgical resections are predominantly 22 
performed in patients with early stage tumors (typically BCLC stages 0/A), 23 
PDXs derived from resected tumors are heavily biased against advanced 24 
stage HCCs. Furthermore, from the published HCC PDX reports it is not clear 25 
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how much of the original tumor characteristics are preserved in the 1 
transplanted tumors. It is also not clear if successful engraftment was 2 
restricted to a subgroup of HCCs with distinct molecular characteristics. These 3 
questions need to be resolved before further developing PDX models for 4 
preclinical drug development. 5 
 6 
In the present study we report the results of a comprehensive comparative 7 
analysis of 11 newly generated PDX models and the originating human HCCs. 8 







































































Material and Methods 1 
 2 
Human HCC Tissues and Biopsy Procedure 3 
Fifty-four human HCC needle biopsies were obtained at the University Hospital 4 
Basel, Switzerland from 44 treatment naïve patients undergoing diagnostic 5 
liver biopsy (Table S1). A detailed description of the biopsy procedure is 6 
provided in Supplementary Material and Methods. Written informed consent 7 
was obtained from all patients. The study was approved by the Ethics 8 
committee of the north-western part of Switzerland (Protocol Number EKNZ 9 
2014-099). One biopsy cylinder was fixed in formalin and embedded in paraffin 10 
for diagnosis and staging. Additional cylinders were immediately snap-frozen 11 
in liquid nitrogen for later use in DNA/RNA extraction or embedded in O.C.T. 12 
(Tissue-Tek) and frozen using standard procedures. For PDX model 13 
generation, biopsy pieces were placed in PBS. An additional biopsy from non-14 
tumor liver parenchyma was also obtained from all patients. 15 
 16 
Mice and Xenotransplantation 17 
Needle biopsies of HCCs were transplanted subcutaneously into 6-10 weeks 18 
old NOD-SCID gamma-c (NSG) mice (Supplementary Methods). Experiments 19 
were conducted with the approval of the Ethics committee of the north-western 20 
part of Switzerland (Protocol Number EKNZ 2014-099) and the Animal Care 21 
Committee of the Canton Basel-Stadt, Switzerland. 22 
 23 
Tumor growth rate was assessed by weekly measurement using a caliper. S.c. 24 
transplantations and injections that did not yield any measurable tumor in the 25 
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mice within eight months after intervention were considered as failed 1 
engraftments. The animals were euthanized by CO2 narcosis as soon as the 2 
tumors reached a size of 1000-1500 mm3. Parts of the collected tumors were 3 
immediately frozen in liquid nitrogen and kept at −70°C until further 4 
processing; embedded in O.C.T. (Tissue-Tek) and frozen using standard 5 
procedures; fixed in formalin and embedded in paraffin using standard 6 
procedures; or cryopreserved for later usage. Tumor pieces of 2x2 mm were 7 
subsequently s.c. transplanted into new mice in order to expand the tumor 8 
material for further experiments.  9 
 10 
Lag phase and doubling time of patient-derived xenograft tumors 11 
The PDX tumor lag phase describes the time from s.c. transplantation or 12 
injection of tumor sample until tumor growth onset (measurable tumor size; 13 
2x2mm). Tumor doubling times were calculated based on the slope of the 14 
linear section of the log10 transformed growth curves of each tumor derived 15 
from a given biopsy. All results are shown as mean +/- SD (Figure 1B).  16 
 17 
Histology and Immunohistochemistry 18 
Paraffin-embedded tumor biopsies and PDX tumors were processed for 19 
Hematoxylin & Eosin or immunohistochemical staining using standard 20 
procedures (Supplementary Methods). Histopathology evaluation was carried 21 
out blindly by two board-certified hepatopathologists (L.T. and M.S.M.) at the 22 
Institute of Pathology of the University Hospital Basel. Disease stage was 23 
classified according to the BCLC staging system[14]. Histopathological grading 24 









































































O.C.T. (Tissue-Tek) embedded, frozen PDX tumors, mouse liver and human 3 
liver biopsy were used for vessel assessment (Supplementary Methods).  4 
 5 
Whole exome sequencing and analysis 6 
Paired-end 101bp sequencing was performed for the DNA extracted from 14 7 
engrafted HCC biopsies (derived from 12 patients) and the 12 matched non-8 
tumoral biopsies (Table S2), using the SureSelectXT Clinical Research Exome 9 
(Agilent) platform and sequenced on the Illumina HiSeq 2500 according to the 10 
manufacturers’ guidelines. HCC biopsies and the matched non-tumor biopsies 11 
were sequenced to a median depth of 93x (range 61x-159x) and 51x (range 12 
42x-75x), respectively. Whole exome data were analyzed as previously 13 
described[16], with some modifications (Supplementary Methods). 14 
 15 
RNA sequencing and analysis 16 
RNA extracted from 45 HCC biopsies derived from 37 patients (Table S2), 10 17 
HCC PDX tumors and 3 lymphoma PDX tumors from 12 models (1st 18 
generation tumors) and 8 HCC PDX tumors from two models (4th generation 19 
tumors) were sequenced. Nine HCC biopsies were excluded because of low 20 
tumor cell content. Tumors from PDX models D096 and D135 were not 21 
sequenced because they were generated recently. SR126 RNA sequencing 22 
was performed using the TruSeq Stranded Total RNA Library Prep Kit with 23 
Ribo-Zero Gold (lllumina) and sequenced on the Illumina HiSeq 2500 24 
according to the manufacturer’s guidelines (Supplementary Methods). 25 
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Sequence reads from the HCC biopsy samples were aligned by STAR[17] 2 
using the two-pass approach simultaneously to the human reference genome 3 
GRCh37, HBV strain ayw genome (NC 003977.2), HCV genotype 1 genome 4 
(NC 004102.1). Sequence reads from PDX tumors were aligned as above to 5 
human, HBV, HCV and mouse genomes (GRCm38). Median numbers of 6 
reads aligning to the human genome were 71 million (range 57-106 million) for 7 
the HCC biopsies and 78 million (range 64-101 million) for the PDX tumors. 8 
Transcript quantification for human genes was performed using RSEM[18]. 9 
Differential expression analysis was performed using the edgeR R 10 
package[19]. Pathway enrichment analysis was performed using 11 
hypergeometric test for the hallmark gene sets in the Molecular Signatures 12 
Database[20]. Cluster analysis was performed using hierarchical clustering. 13 
Batch effects associated with the process of PDX establishment were removed 14 
using the edgeR R package[19], which fits a linear model to the data and 15 
removes the component associated with xenografting. The expression of 16 
somatic mutations in RNA sequencing data was determined by GATK Unified 17 
Genotyper[21], given the somatic mutations identified by whole exome 18 
sequencing. For statistical comparisons, only missense and synonymous 19 
mutations were considered. Truncating, insertions and deletions and splice site 20 
mutations were excluded, as these mutations are likely to affect transcript 21 
stability. Transcriptomic classification was performed according to Hoshida et 22 
al.[22]. See Supplementary Methods for further details. 23 
 24 







































































For unsupervised cluster analysis of HCC biopsies and HCCs from TCGA, we 1 
merged our RNA sequencing dataset with the TCGA HCC dataset RNA 2 
sequencing data (“V2_MapSpliceRSEM”) retrieved from the Genomics Data 3 
Commons Data Portal[23] (Supplementary Methods). Clustering was 4 
performed as described above. Histological grading was performed according 5 
to the Edmondson grading system[15] as previously described[24] 6 
(Supplementary Methods). 7 
 8 
Statistical analysis 9 
Statistical analyses of the clinicopathological variables were performed in R 10 
v3.3.1. Comparisons of ordinal variables (BCLC, AFP, Edmondson grade, 11 
number of tumors, diameter of largest tumor, Hoshida subclass) were 12 
performed using Mann-Whitney U tests. Comparisons of categorical variables 13 
(all others) were performed using Fisher’s exact tests. All statistical tests were 14 
two-sided and P<0.05 was considered statistically significant. 15 
 16 
Data Availability 17 
Sequencing data are available at the NCBI Sequence Read Archive under the 18 
accession SRP111479 (experiments SRX3633744- SRX3633776). 19 
  20 
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Fresh human hepatocellular carcinoma needle biopsies generate 3 
xenograft tumors in immunocompromised mice. 4 
PDX models were generated from human HCC needle biopsies as described 5 
in Material and Methods. Fifty-four needle biopsies from 44 HCC patients were 6 
included in this study (Tables S1 and S2). The patient cohort covered all major 7 
HCC risk factors and the entire spectrum of Edmondson grades (I-IV)[15] 8 
(Table S1). Additionally, in contrast to the use of resected HCC tissue, which is 9 
limited to early stage disease[9, 12, 13], our cohort comprises all four classes 10 
of the Barcelona Clinic Liver Cancer (BCLC) staging system[14]. While we 11 
typically obtained a single biopsy sample per patient, there were nine patients 12 
that were simultaneously biopsied at two locations because of the presence of 13 
multiple lesions in the liver (indicated as -A/-B, Table S1). One patient was 14 
biopsied at two different locations within the same large tumor nodule (36-I and 15 
36-II, Table S1). In total, we successfully established eleven HCC-derived PDX 16 
models from ten patients (Table S1).  17 
The time from subcutaneous introduction of the HCC biopsy material to onset 18 
of tumor growth ranged from 4 to 28 weeks (Figures 1A and B). Time to onset 19 
of PDX tumor growth of Edmondson grade IV derived biopsies appeared to be 20 
somewhat shorter than that of grade III biopsies, but the difference did not 21 
reach statistical significance (Figure 1; p = 0.072; Mann-Whitney U test). 22 
Interestingly, PDX C078b derived from s.c. injection of a biopsy cell 23 
suspension showed the latest tumor growth onset (Figures 1A and B), 24 







































































tumor engraftment and growth onset. Finally, the onset of tumor growth varied 1 
between mice that were transplanted with tumor tissue derived from the same 2 
biopsy cylinder (Figure S1A), suggesting that, among other factors, the tumor 3 
cell content may also influence the lag time to tumor growth. Indeed, the lag 4 
time to tumor growth was very similar when a homogenous cell suspension, 5 
generated from one biopsy cylinder, was s.c. injected into two mice (Figure 6 
S1B).  7 
Taken together, these results demonstrate that human HCC tissue derived 8 
from fresh needle biopsies can generate xenografts upon s.c. transplantation 9 
and injection.  10 
 11 
Growth kinetics of hepatocellular carcinoma xenograft tumors remain 12 
stable over subsequent passages. 13 
Having successfully established eleven PDX models, we next investigated the 14 
re-transplantation capacity of the initial xenografts over at least four 15 
generations. Re-transplanted tumors showed a shortened lag phase until 16 
onset of tumor growth compared to the xenograft tumor derived from the 17 
biopsy tissue, and remained stable in subsequent PDX generations (Figures 18 
1B and C). However, while the doubling time of tumor growth differed between 19 
PDX models, it did not change between the 1st and all subsequent PDX 20 
generations (Figures 1B and C). These data indicate that once established, 21 
PDX tumors can be expanded for several generations with stable growth 22 
kinetics over time.  23 
 24 
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PDX tumors recapitulate the histopathological features of the original 1 
human HCC tumor. 2 
We next investigated whether the individual PDX tumors retained the histologic 3 
characteristics of the original human tumors. HCC PDX tumors maintained the 4 
differentiation grade[15], the growth pattern and the cytological subtype[25, 26] 5 
of the originating human HCC biopsies over at least four generations (Table 1, 6 
Figures 2 and S2A-J). As an example, Figure 2 shows that the PDX tumors 7 
originating from the tumor biopsy C942 displayed a solid-trabecular growth 8 
pattern with an Edmondson grade III as observed in the original tumor (Figure 9 
2 and Table 1). Of note, only in one case (PDX model of C284b) we observed 10 
the loss of the trabecular aspect of the growth pattern that was present in the 11 
original biopsy, however the solid growth pattern and differentiation grade were 12 
maintained over subsequent passages from mouse to mouse (Table 1, Figure 13 
S2B).  14 
 15 
Immunohistochemical analysis demonstrated that the expression and 16 
distribution of the tumoral marker alpha-fetoprotein[27] were maintained from 17 
the original tumor biopsies to the HCC xenografts over several passages 18 
(Figures 2 and S2A-J). Likewise, the expression pattern of the three most 19 
widely used markers for HCC diagnosis[28, 29], glypican 3, heat shock protein 20 
70 and glutamine-synthetase confirmed the histological stability of the 21 
xenograft tumors compared to the original HCC biopsy (Figures 2 and S2A-J).  22 
 23 
Taken together, these results show that the HCC PDX tumors retain the 24 








































































PDX tumors recapitulate the expression profile and expressed somatic 2 
mutations of the original human HCC tumors.  3 
To investigate the transcriptomic changes induced by PDX establishment and 4 
whether the PDX models recapitulate the gene expression pattern of the 5 
tumors from which they originated, we performed RNA sequencing of 9 PDX 6 
models and the originating HCC biopsies. Differential expression analysis 7 
revealed that 1,613 were up-regulated and 1,845 genes were down-regulated 8 
in the PDX tumors compared to their matched biopsies (Table S3). The down-9 
regulated genes were enriched in pathways of inflammatory response and 10 
angiogenesis (Figure 3A and Table S4), suggesting the loss of cells of the 11 
human immune system and vasculature. Indeed, the xenograft tumors were 12 
positive for mouse-specific CD31, suggesting that the human vascular system 13 
in the HCC tumors was replaced by mouse vessels in the xenografts (Figure 14 
S3). In contrast, up-regulated genes were associated with pathways related to 15 
cell cycle such as Myc and E2F target genes and mTORC1 signaling (Figure 16 
3A and Table S4), likely reflecting the enrichment of tumor cells in the PDX 17 
tumors compared to the biopsies. Importantly, unsupervised clustering after 18 
correcting for the systematic effects introduced by xenografting, in effect by 19 
fitting a linear model to the data and removing the effects, demonstrated that 20 
all PDX tumors stably clustered with their corresponding HCC tumors (Figure 21 
3B, stability as assessed by bootstrap resampling) and that the expression 22 
profile was maintained over at least four generations (Figure S4A).  23 
 24 
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To assess whether the PDX tumors retained the expression of the somatic 1 
mutations found in their originating tumors, we identified the repertoire of 2 
somatic mutations by performing whole exome sequencing (WES) of the 3 
original tumor biopsies and their non-tumoral counterparts. We then assessed 4 
the expression of these mutations by RNA sequencing in the HCC biopsies 5 
and the PDX tumors, focusing on missense and synonymous point mutations, 6 
as truncating mutations are likely to affect transcript stability. Based on WES, 7 
we identified a median of 120 (range 61-174) somatic missense and 8 
synonymous point mutations, of which 46% (range 26%-69%) were expressed 9 
in the corresponding HCC biopsies (Table S5). Of the expressed mutations in 10 
the HCC biopsies, a median of 80% (range 68%-93%) was also expressed in 11 
the respective PDX tumors (Figure 3C). Importantly, all missense mutations in 12 
HCC cancer genes, such as TP53, CTNNB1, ALB and KEAP1 were expressed 13 
in the corresponding PDX tumors and their expression was maintained over at 14 
least 4 generations (Figures 3C and S4B). These results indicate that the HCC 15 
PDX tumors maintained the expression profile and the expression of somatic 16 
mutations observed in their originating tumors. 17 
 18 
Engrafted HCC biopsies are broadly representative of the spectrum of 19 
poorly differentiated HCCs 20 
The success rate of engraftment was 20% (10 out of 50 biopsies) and 25% (1 21 
out of 4 biopsies) of all transplanted and injected biopsy tissues, respectively 22 
(Table S1). This success rate is in accordance with published data on s.c. PDX 23 
models derived from resected specimens[9, 11-13]. The use of HCC needle 24 







































































investigate the determinants of successful engraftment capacity into mice. 1 
When we compared the clinicopathological characteristics of the engrafted and 2 
non-engrafted biopsies we observed a clear correlation with histopathological 3 
grading; all HCC PDX tumors were derived from poorly differentiated tumors 4 
(Edmondson grades III/IV, Table S1 and Figure 4A). Indeed, differential 5 
expression analysis between engrafted and non-engrafted biopsies revealed 6 
2,401 up-regulated and 1,440 down-regulated genes. The up-regulated genes 7 
were enriched for pathways associated with cell cycle progression, epithelial-8 
to-mesenchymal transition, hypoxia and angiogenesis, while the down-9 
regulated genes were enriched for liver metabolic functions (Table S6). 10 
Furthermore, molecular subtyping based on the Hoshida subclasses[22] 11 
revealed that all engrafted HCC biopsies were of subclasses S1 and S2 12 
(Figure 4A), characterized by poor differentiation, high proliferation rate and 13 
poor survival compared to subclass S3. Besides Edmondson grading, no other 14 
available clinicopathological characteristics seemed to influence the 15 
engraftment success rate (Table S1 and Figure 4A). Indeed, when restricting 16 
the differential expression analysis to Edmondson grade III biopsies (the only 17 
histological grade that had variable successful engraftment rate), only two 18 
genes were differentially expressed (both FDR=0.04, data not shown), 19 
suggesting that, there was no systematic difference between engrafted and 20 
non-engrafted biopsies after accounting for histological grading. 21 
To assess the distribution of our samples within a reference set from 22 
TCGA[23], we performed an unsupervised hierarchical clustering analysis of 23 
the gene expression, combining our HCC biopsy cohort with TCGA[23]. We 24 
observed that the eleven engrafted biopsies preferentially clustered together in 25 
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a subclass located at the left end of the clustering tree (Figure S5). Since all 1 
our PDX models originated from poorly differentiated HCCs, we repeated the 2 
unsupervised clustering analysis using only the subset of poorly differentiated 3 
HCCs from the TCGA. In this scenario, both the eleven engrafted samples and 4 
the non-engrafted samples broadly represented the spectrum of poorly 5 
differentiated HCCs (Figure 4B). These results demonstrate that poorly 6 
differentiated tumor cells engraft more efficiently in mice and that the HCC 7 
biopsies that engrafted are broadly representative of the diversity of poorly 8 
differentiated HCCs.  9 
 10 
Transformation into human B-cell lymphoid neoplasms of patient-derived 11 
xenograft tumors 12 
During histological analyses of the engrafted tumors, we observed that three 13 
PDX tumors histologically differed from the originating tumors. Specifically, 14 
they primarily contained a population of middle-sized and large lymphoid 15 
mononuclear cells with diffuse growth pattern and high mitotic index that were 16 
not present in the corresponding HCC biopsies (Figure 5A).  17 
In fact, transcriptome-based unsupervised clustering showed that these PDX 18 
tumors did not cluster with their originating HCCs (Figure 5B) and did not 19 
express any of the mutations expressed in the corresponding biopsy (Figure 20 
5C and Table S5). Compared to the biopsies and the HCC PDXs, these three 21 
PDX tumors overexpressed genes consistent with immune infiltration, 22 
interferon-alpha and gamma responses and the NF-kB pathway and reduced 23 
expression of genes involved in liver metabolism and liver cancer (Table S7). 24 







































































has been reported in PDX studies of various cancers[30-33]. Indeed, these 1 
three PDX tumors stained positive for the human B-cell marker CD20 (Figure 2 
5D), consistent with the presence of a B-cell lymphoma. Importantly, species-3 
specific alignment demonstrated that CD20 mRNA expression was exclusively 4 
of human origin (Table S8). Of note, Chen et al. previously suggested that the 5 
reactivation of latent Epstein-Barr virus (EBV) of intratumoral passenger B 6 
lymphocytes led to the generation of lymphoid tumors in immunocompromised 7 
mice[30]. Consistent with this hypothesis, EBV transcripts were detected in all 8 
three of these PDX tumors, but were absent from the corresponding HCC and 9 
non-tumor biopsies, and were virtually absent from all the other PDX models 10 
(Table S8). Taken together, these results suggest that reactivation of latent 11 
EBV may lead to lymphomagenesis in some cases using our biopsy-derived 12 
xenograft system.  13 14 
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During the last 10 years after the introduction of sorafenib as a first line 2 
therapy for advanced HCC, a number of additional drugs have all failed in 3 
phase 2 or phase 3 trials[34]. A major obstacle for the development of new 4 
therapies is the lack of suitable animal models, specifically animal models that 5 
reflect the heterogeneity of HCCs. PDX mice derived from human tumors offer 6 
a tool for developing anticancer therapies and personalized medicine for 7 
patients with cancer[7]. PDX models have also been established for HCCs[8-8 
13]. However, these previously published HCC PDX mice were established 9 
from resected tumor specimens, and therefore predominantly from early stage 10 
HCCs. In the present study we expand the spectrum of HCC PDX models to 11 
advanced HCCs. 12 
 13 
As in previously published reports[9, 11-13], we also had a limited overall 14 
success rate of about 20%. From 54 transplanted HCCs, 11 could be grown 15 
and re-transplanted as xenografts. The reasons for this low success rate 16 
remain to be fully elucidated. However, we observed that none of the well-17 
differentiated (Edmondson grades I/II) HCCs could be engrafted in the mice. 18 
Of note, we stopped to monitor the mice for tumor growth 8 months after 19 
transplantation. Since low-grade tumors tend to grow slowly, we cannot 20 
exclude the possibility that they would have started growing beyond 8 months. 21 
However, we think that tumor cell intrinsic biological properties of 22 
undifferentiated HCCs such as growth factor independent proliferation or 23 
resistance to hypoxia are more likely reasons for the successful engraftment of 24 







































































tumor tissue architecture providing 3-dimensional oriented cell-cell contacts. 1 
We observed that compared to transplantations of small tumor pieces the 2 
injection of a cell suspension showed a delayed tumor growth onset. 3 
Interestingly, time to tumor growth onset was invariably shorter upon re-4 
transplantations of all PDX tumors and then remained constant over several 5 
passages. It is possible that the presence of a mouse-derived vascular system 6 
in the PDX tumors facilitated the accelerated engraftment upon re-7 
transplantation. Likewise, the consistent doubling time within a PDX model 8 
may reflect the intrinsic tumor growth rate once a murine vasculature system is 9 
established.  10 
 11 
The HCC biopsy-derived PDX models maintained a striking similarity with the 12 
original human HCCs with respect to differentiation grade, growth pattern, 13 
cytological subtype and the expression pattern of typical HCC markers. Of 14 
note, only one PDX model (C284b) lost part of the histological characteristics 15 
(i.e. trabecular growth pattern) observed in the originating human HCC. This 16 
may be due to heterogeneous growth patterns in different regions of the same 17 
tumor. RNA sequencing of the HCC PDX tumors and the corresponding 18 
human HCC biopsies revealed that pathways related to angiogenesis and 19 
immune cells were generally down-regulated in the PDX models, likely a 20 
consequence of the loss of human immune cells and the presence of a murine 21 
instead of human vasculature in these PDX models. By contrast, cell cycle-22 
related genes were up-regulated in the PDX models compared to the biopsies, 23 
suggesting an enrichment of cancer cells in the PDX tumors. Importantly, after 24 
accounting for these systematic differences, all PDX tumors clustered with 25 
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their corresponding human HCC demonstrating that they recapitulate the 1 
tumor-specific gene expression profiles. Furthermore, HCC-specific expression 2 
of somatic mutations in cancer genes was maintained in the corresponding 3 
PDX models. Of note, transcriptome-based analysis revealed that the PDX 4 
tumors are stable over several generations. Taken together, our results 5 
demonstrate that the PDX models faithfully recapitulate the histopathological 6 
and transcriptomic characteristics of the HCC tumors from which they were 7 
derived.  8 
 9 
The diversity of our patient cohort allowed us to identify potential determinants 10 
of tumor engraftment in mice. Differentiation grade was the major determinant 11 
for successful PDX development since only poorly differentiated biopsies 12 
(Edmondson grades III/IV) and those of molecular subclasses S1 and S2[22] 13 
formed tumors in mice. Accordingly, engrafted tumors overexpressed genes 14 
related to proliferation and epithelial-to-mesenchymal transition. However, 15 
within the group of poorly differentiated HCCs, we could not identify further 16 
clinical or transcriptomic characteristics affecting engraftment.  17 
 18 
Three HCC biopsies resulted in PDX models that did not resemble the 19 
corresponding HCC. The histological appearance of lymphocytes, the strong 20 
positivity for the human B-cell marker CD20, transcriptional up-regulation of 21 
immune cell signatures and loss of expression of the HCC-specific somatic 22 
mutations suggested that human B-cell lymphomas were formed in these PDX 23 
models. This phenomenon has already been described for PDX models 24 







































































that treatment with rituximab, an anti-CD20 monoclonal antibody, prevented 1 
lymphomatous outgrowth in early-passage ovarian xenografts[33]. Whether a 2 
similar strategy would improve the success rate of HCC PDX generation and 3 
prevent lymphomagenesis remains to be investigated.  4 
 5 
In conclusion, using needle biopsies instead of resected specimens allows to 6 
generate PDX models from advanced stages of HCC. Our model system is 7 
currently restricted to Edmondson grade III and IV tumors, but within this 8 
group, it is representative of the entire molecular spectrum of undifferentiated 9 
HCCs. The success rate is still limited to 20-30% for unknown reasons. The 10 
PDX tumors recapitulate the histopathological and transcriptomic features of 11 
the original human HCCs, and these features remain stable over at least 4 12 
generations of re-transplantation. We conclude that PDX models from HCC 13 
needle biopsies fulfill the requirements for preclinical drug development 14 
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Edmondson Grade Growth Pattern Cytological Subtype 
Biopsy PDX-1 PDX-4 Biopsy PDX-1 PDX-4 Biopsy PDX-1 PDX-4 
C078 III III III solid solid solid - - - 
C284 III III III solid-trabecular solid solid - - - 
C677 IV IV IV solid solid solid giant cells giant cells giant cells 
C678 IV IV IV solid solid solid giant cells giant cells giant cells 




trabecular - - - 




trabecular - - - 




trabecular - - - 
C965 III III III solid solid solid - - - 
C975 III III III solid solid solid - - - 
D096 IV IV IV solid solid solid - - - 











PDX-1: 1st generation tumor; PDX-4: 4th generation tumor 








































































Figure Legends 2 
 3 
Fig. 1. Xenograft tumor growth patterns 4 
(A) Lag phase and tumor growth rate of first generation xenografts. 5 
Edmondson grade III and IV are shown in green and red, respectively. Circles 6 
and diamonds represent transplanted solid pieces and cell suspensions, 7 
respectively. (B) Growth characteristics of PDX models. Lag phase until 8 
detectable tumor formation, doubling time of tumors from 1st, 2nd, 3rd and 4th 9 
generation PDX and number of transplanted tumors are indicated. (C) Tumor 10 
growth rate over several generations (1st to 4th) in one representative PDX 11 
model (C284b). Transplantation generations are color-coded. 12 
 13 
Fig. 2. HCC PDX mice recapitulate the histological characteristics as well 14 
as the expression patterns of HCC markers of the original tumor. 15 
Histological sections of the original HCC biopsies and their derivative PDX 16 
tumors (PDX-1 and PDX-4 corresponding to 1st and 4th transplantations, 17 
respectively) stained with Hematoxylin and Eosin (H&E), for alpha-fetoprotein 18 
(AFP) expression as well as for glypican 3 (GPC3), heat shock protein 70 19 
(HSP70) and glutamine synthetase (GS) detected by immunohistochemistry. 20 
Scale bar: 200 μm. Representative stainings are shown for PDX model C942.  21 
 22 
Fig. 3. HCC PDX mice recapitulate the transcriptomic features of their 23 
original tumors. (A) Heatmap of gene expression from selected differentially 24 
expressed pathways between HCC biopsies and PDX tumors (1st 25 
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transplantation). For each pathway, the top 5 genes, ranked by FDR, are 1 
shown. (B) Unsupervised clustering of HCC biopsies and PDX tumors, 2 
corrected for systemic biases between the two groups. (C) Barplot of the 3 
number of expressed somatic missense and synonymous mutations, and the 4 
repertoire of expressed somatic missense mutations affecting cancer 5 
genes[23, 35-37]. Multiple expressed mutations in the same gene are 6 
indicated by an asterisk. 7 
   8 
Fig. 4. Clinical, histopathological and molecular features of engrafted and 9 
not engrafted HCC biopsies. (A) Patient and biopsy characteristics of all 10 
transplanted biopsies, grouped by engraftment status. Calculations of 11 
significant differences (indicated in red) between engrafted versus not 12 
engrafted biopsies are shown underneath. Two-sided Fisher’s exact tests for 13 
categorical data and two-sided Mann-Whitney U tests for ordinal data. ALD: 14 
Alcoholic Liver Disease; AFP: Alpha-Fetoprotein; BCLC: Barcelona Clinic Liver 15 
Cancer; MVI: Macrovascular invasion; NAFLD: Non-Alcoholic Fatty Liver 16 
Disease. (B) Unsupervised hierarchical clustering analysis. Biopsy (PDX) 17 
cohort (this study) combined with high-grade (Edmondson III to IV) HCCs from 18 
the TCGA cohort. 19 
 20 
Fig. 5. Unintended lymphoid neoplasm transformation in PDX models. (A) 21 
H&E stained sections of original HCC biopsies and their derivative lymphoma 22 
PDX tumors (PDX-1). (B) Unsupervised clustering of 1st generation PDX and 23 
corresponding HCC biopsies. Lymphoma PDX tumors indicated in red. (C) 24 







































































synonymous mutations for the 9 HCC biopsies (mean) and the 10 1 
corresponding HCC PDX tumors (mean), and for C738, C948, C951 and their 2 
corresponding lymphoma PDX tumors (C738-PDX-1, C948-PDX-1 and C951-3 
PDX-1). (D) PDX tumors of the lymphoma models (C738-PDX-1, C948-PDX-1 4 
and C951-PDX-1) stained with hCD20. Scale bar: 200 μm.  5 
 6 
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Supplementary Material and Methods 1!
 2!
Human HCC Biopsy Procedure 3!
Ultrasound-guided (US) needle biopsies were obtained from tumor lesion(s) 4!
with a coaxial liver biopsy technique that allows taking several biopsy samples 5!
through a single biopsy needle tract. After local anaesthesia, the introducer 6!
needle was advanced 2-3 cm into the liver parenchyma. In case of a focal 7!
lesion, the needle was positioned precisely at the tumor border. The trocar of 8!
the introducer needle was removed, and up to five cylindrical biopsies of ~1 9!
mm diameter and 10-30 mm length were obtained with an automatic spring-10!
loaded biopsy needle (BioPince™). The introducer needle was kept in place 11!
during the entire procedure to ensure that all specimens came from the same 12!
area of the tumor. Finally, the needle tract was filled with absorbable gelatine 13!
sponge before removal of the introducer needle. 14!
 15!
Mice and Xenotransplantation 16!
NOD-SCID gamma-c (NSG) mice (The Jackson Laboratory) were bred and 17!
maintained in the animal facility of the Department of Biomedicine of the 18!
University Hospital Basel under specific-pathogen-free conditions, on a 12-h 19!
day and 12-h night schedule with ad libitum access to food and drinking 20!
water. The freshly obtained human HCC needle biopsy material was kept on 21!
ice during the whole procedure and was subcutaneously introduced into the 22!
mice either as pieces or cell suspension. For the subcutaneous (s.c.) 23!
transplantation of biopsy pieces, the biopsy cylinder was washed in PBS and 24!






transplanted into the hind flank of NSG mice. For the s.c. injection of the 1!
biopsy-derived cell suspension, the biopsy material was pressed through a 2!
70µm cell strainer (Falcon; 352350), followed by trypan blue analysis. The 3!
cells (30,000-300,000) were mixed with matrigel (BD Biosciences; 354234) 4!
and injected with a 25-gauge needle into the hind flank of NSG mice. 5!
 6!
Histology and Immunohistochemistry 7!
Tumor biopsies and PDX tumors were fixed in 4% phosphate buffered 8!
formalin and embedded in paraffin using standard procedures. The following 9!
primary antibodies were used for automated immunohistochemistry staining 10!
on a Benchmark XT device (Ventana Medical Systems, Inc.): Alpha-11!
Fetoprotein (Ventana Cat. Nr. 760-2603), Glypican 3 (Ventana Cat. Nr. 790-12!
4564), Glutamine Synthetase (Ventana Cat. Nr. 760-4898), Heat Shock 13!




Briefly, 10µm sections were fixed for 20 minutes in 4% formalin in phosphate-18!
buffered saline (PBS) and incubated over night with the primary rat anti-19!
mouse CD31 antibody (BD Pharmingen; 550274) at 4°C. Subsequently, 20!
slides were incubated with the secondary Alexa Fluor 488 donkey anti-rat 21!
antibody (Life technologies; A21208) for 1h at RT and mounted with DAPI-22!








Genomic DNA from biopsies was extracted using the ZR-Duet DNA/RNA 1!
MiniPrep Plus kit (Zymo Research) following the manufacturer’s instructions. 2!
Prior to extraction, biopsies were crushed in liquid nitrogen to facilitate lysis. 3!
Extracted DNA was quantified using the Qubit Fluorometer (Invitrogen).  4!
 5!
Whole exome sequence and analysis  6!
Whole exome sequencing was performed at the Genomics Facility of ETH 7!
Zurich Department of Biosystems Science and Engineering (Basel, 8!
Switzerland). Sequence reads were aligned to the reference human genome 9!
GRCh37 using Burrows-Wheeler Aligner (BWA, v0.7.12)[1]. Local 10!
realignment, duplicate removal and base quality adjustment were performed 11!
using the Genome Analysis Toolkit (GATK, v3.6)[2] and Picard 12!
(http://broadinstitute.github.io/picard/). Somatic single nucleotide variants 13!
(SNVs) and small insertions and deletions (indels) were detected using 14!
MuTect (v1.1.4)[3] and Strelka (v1.0.15)[4], respectively. We filtered out SNVs 15!
and indels outside of the target regions, those with variant allelic fraction 16!
(VAF) of <1% and/or those supported by <3 reads. We excluded variants for 17!
which the tumor VAF was <5 times that of the paired non-tumoral VAF. We 18!
further excluded variants identified in at least two of a panel of 123 non-19!
tumoral samples, including the 12 matched non-tumoral biopsies included in 20!
the current study, captured and sequenced using the same protocols using 21!
the artifact detection mode of MuTect2 implemented in GATK. All indels were 22!
manually inspected using the Integrative Genomics Viewer[5]. 23!
Whole exome data were analyzed as previously described[6], with some 24!






genome GRCh37 using Burrows-Wheeler Aligner (BWA, v0.7.12)[1]. Somatic 1!
single nucleotide variants (SNVs) and small insertions and deletions (indels) 2!
were detected using MuTect (v1.1.4)[3] and Strelka (v1.0.15)[4], respectively 3!
(Supplementary Methods). Cancer genes were annotated according to the 4!
cancer gene lists described by Kandoth et al. (127 significantly mutated 5!
genes)[7], Lawrence et al., (Cancer5000-S gene set)[8], Fujimoto et al.[9] and 6!
The Cancer Genome Atlas (TCGA)[10].!7!
 8!
RNA extraction 9!
RNA from human tumors and xenograft tumors was extracted using the 10!
RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. Extracted 11!
RNA was quantified using NanoDrop 2000 spectrophotometer (Thermo 12!
Scientific), and RNA quality/integrity was assessed with an Agilent 2100 13!
BioAnalyzer using RNA 6000 Nano Kit (Agilent Technologies). 14!
 15!
RNA sequencing  16!
200 ng total RNA were used for RNA sequencing library prep with the TruSeq 17!
Stranded Total RNA Library Prep Kit with Ribo-Zero Gold (lllumina) according 18!
to manufacturer’s specifications. SR126 sequencing was performed on an 19!
Illumina HiSeq 2500 using v4 SBS chemistry at the Genomics Facility Basel 20!
according to the manufacturer’s guidelines. Primary data analysis was 21!
performed with the Illumina RTA version 1.18.66.3.  22!
 23!






Differential expression analysis between HCC biopsies and PDX tumors was 1!
performed using the edgeR R package[11]. Specifically, genes with counts-2!
per-million <1 in more than 5 samples were removed. Normalization was 3!
performed using the “TMM” (weighted trimmed mean) method and differential 4!
expression was assessed using the quasi-likelihood F-test, accounting for the 5!
matched pairs of HCC biopsies and PDX tumors. Genes with false discovery 6!
rate (FDR)<0.05 were considered differentially expressed. Pathway 7!
enrichment of differentially expressed genes was performed using 8!
hypergeometric test for the hallmark gene sets in the Molecular Signatures 9!
Database[12]. Pathways with FDR<0.25 were considered enriched. 10!
 11!
For unsupervised cluster analysis of HCC biopsies and PDX tumors, we 12!
performed gene-level upper quartile normalization. Genes whose expression 13!
was quantified to be zero by RSEM[13] in >75% of the samples were 14!
removed. RSEM values were subsequently log2-transformed, adding 0.5 to 15!
RSEM values prior to transformation. To identify genes with variable 16!
expression for clustering, genes with standard deviation <2 were 17!
excluded[14]. Batch effects associated with the process of PDX establishment 18!
were removed using the edgeR R package[11], which fits a linear model to 19!
the data and removes the component associated with xenografting. Genes 20!
were centered prior to clustering. Cluster analysis was performed using 21!
hierarchical clustering using the Ward method and with a 1-Pearson 22!
correlation distance[10]. Cluster stability was assessed by bootstrap 23!







Aligned reads were further processed using the GATK SplitNCigarReads tool. 1!
The expression of somatic mutations in RNA sequencing data was 2!
determined by GATK Unified Genotyper using the 3!
GENOTYPE_GIVEN_ALLELES mode[2], given the list of somatic mutations 4!
identified by whole exome sequencing. Mutations supported by at least 2 5!
reads, VAF>1% at loci covered by at least 5 reads were considered 6!
expressed. For statistical comparisons, only missense and synonymous 7!
mutations were considered. Truncating, insertions and deletions and splice 8!
site mutations were excluded, as these mutations are likely to affect the 9!
stability of the transcripts. 10!
 11!
Transcriptomic classification was performed according to Hoshida et al.[16], 12!
using the Nearest Template Prediction algorithm 13!
(http://software.broadinstitute.org/cancer/software/genepattern), with RSEM 14!
gene-level quantification as input. 15!
 16!
CD20 and Epstein-Barr Virus transcripts 17!
Sequence reads from PDX tumors were aligned by QuasR (qAlign with 18!
Rbowtie)[17] to the human and mouse CD20 reference mRNA sequences 19!
NM_152866.2 and NM_007641.5, respectively. CD20 reads were normalized 20!
to the number of total reads per sample and transcript length and are 21!
expressed as RPKM (Reads Per Kilobase Million).  22!
Sequence reads from paired non-tumor and tumor biopsy and corresponding 23!
PDX tumors were aligned by QuasR (qAlign with Rbowtie)[17] to two Epstein-24!






reads were normalized to the number of total reads per sample and are 1!
expressed as RPM (Reads Per Million). 2!
 3!
TCGA data analysis  4!
For unsupervised cluster analysis of HCC biopsies and HCCs from TCGA, we 5!
merged our RNA sequencing dataset with the TCGA HCC dataset RNA-seq 6!
data (“V2_MapSpliceRSEM”) retrieved from the Genomics Data Commons 7!
Data Portal[10]. We performed gene-level upper quartile normalization of the 8!
combined dataset to the fixed threshold 1000 as described in the TCGA 9!
study[10]. Log2-transformation and gene filtering were performed as above. 10!
Batch correction using the edgeR R package[11] was performed to correct for 11!
systematic biases between the two datasets. Gene centering and clustering 12!
were performed as described above. 13!
 14!
For the TCGA cohort[10], images of diagnostic H&E slides were retrieved 15!
from the cbioportal (http://www.cbioportal.org; accessed December 2017)[18] 16!
and reviewed by two expert hepato-pathologists according to the Edmondson 17!

























Supplementary Fig. 1. Comparative tumor growth onset of one biopsy 
cylinder as piece or cell-suspension. (A-B) Comparative tumor growth 
onset between two subcutaneously transplanted pieces (A) or between two 




























































Supplementary Fig. 2A-J. HCC PDX mice retain the histology of the 
originating tumor. Histological sections of the original HCC biopsies and 






transplantation steps, respectively) stained with H&E, for alpha-fetoprotein 
(AFP) expression as well as for Glypican 3 (GPC3), Heat Shock Protein 70 
(HSP70) and Glutamine Synthetase (GS) detected by immunohistochemistry. 








Supplementary Fig. 3. Presence of mouse vessels in HCC PDX models. 
Human and mouse liver, and two representative PDX tumors from model 









Supplementary Fig. 4. HCC PDX models are stable over at least 4 
generations. (A) Unsupervised clustering of 1st and 4th transplantation PDX 
tumors. (B) Repertoire of somatic missense mutations affecting cancer genes 





Supplementary Fig. 5. Unsupervised hierarchical clustering analysis of 
engrafted and not engrafted HCC biopsy (PDX) cohort (this study) combined 

























Supplementary Table 1. Clinical annotation and histopathological data of 
transplanted HCC biopsies.  
	  
 
Patient Biopsy ID Gender Age [years] BCLC Cirrhosis Liver Disease(s) AFP [IU/ml] Edmondson PDX model
1 C078b F 58 A Yes HCV n.a. III yes
2 C255b M 60 A Yes HBV, ALD 1.5 II -
3 C272b F 67 A Yes HBV, ALD 3.9 III -
4 C284b M 78 C Yes HBV 5459 III yes
5  C316b F 76 A Yes NAFLD 144 II -
6 C334b M 79 A No no liver disease 27856 II -
7-A  C457b M 78 A No NAFLD 1.7 II -
7-B  C457c M 78 A No NAFLD 1.7 III -
8 C475b M 66 A Yes ALD 541 III -
9 C477b M 69 A No HCV 4.6 II -
10 C495 M 59 D Yes ALD 76 III -
11 C511 M 66 B Yes ALD 4352 III -
12 C532 F 67 A Yes ALD 125 II -
13 C605 M 48 A Yes ALD 1.7 II -
14 C613 M 67 A Yes NAFLD 1.6 II -
15 C628 F 75 B Yes HCV 0.8 II -
16 C638 M 69 B Yes ALD 3.2 II -
17-A C655 M 55 C No HCV, ALD 269 III -
17-B C656 M 55 C No HCV, ALD 269 III -
18-A C677 F 76 C No no liver disease 1.4 IV yes
18-B C678 F 76 C No no liver disease 1.4 IV yes
19 C696 M 63 A No HCV, HBV, ALD 1.5 II -
20 C710 M 55 B Yes HCV 8.4 I -
21 C738 F 72 B Yes ALD 7.9 III yes*
22 C753 F 54 D Yes ALD 82433 III -
23 C761 M 61 C Yes HCV, ALD 10278 III -
24 C769 M 59 C Yes HCV, ALD n.a. III -
25 C798 M 73 C No NAFLD 20377 III yes
26-A C850 M 77 C Yes ALD 1882 III -
26-B C851 M 77 C Yes ALD 1882 III -
27-A C878 M 61 D Yes ALD 1.8 I -
27-B C879 M 61 D Yes ALD 1.8 II -
28 C937 M 70 B Yes HBV 701 II -
29-A C942 M 77 C Yes NAFLD >100'000 III yes
29-B C944 M 77 C Yes NAFLD >100'000 III -
30-A C948 M 58 C Yes HCV, ALD 12054 III yes*
30-B C949 M 58 C Yes HCV, ALD 12054 III yes
31 C951 F 71 C Yes ALD 1745 III yes*
32-A C958 M 54 C Yes HCV, ALD 228 III -
33 C964 M 72 B Yes ALD 2.6 III -
32-B C965 M 54 C Yes HCV, ALD 228 III yes
34 C971 M 73 B Yes HCV 678 II -
35 C975 M 60 B Yes HCV, ALD 250 III yes
36-I D045 M 69 A No HCV 7852 III -
36-II D046 M 69 A No HCV 7852 III -
37 D051 M 86 B No ALD 4.3 II -
38 D070 F 49 A Yes HCV, ALD 3.1 II -
39 D096 M 75 A No no liver disease 2 IV yes
40-A D135 M 57 C Yes HCV 11 IV yes
40-B D136 M 57 C Yes HCV 11 IV -
41 D143 F 62 D Yes ALD 6.6 III -
42 D156 M 67 A Yes HBV 204 II -
43 D158 F 77 B Yes NAFLD 4.6 II -
44 D176 M 79 C No no liver disease 0.9 II -
-A/-B: different tumor nodules from same patient
-I/-II: different locations within same large tumor nodule
ALD: Alcoholic Liver Disease
AFP: Alpha-Fetoprotein
BCLC: Barcelona Clinic Liver Cancer
HCC: Hepatocellular Carcinoma
HBV: Hepatitis B Virus
HCV: Hepatitis C Virus
NAFLD: Nonalcoholic Fatty Liver Disease
n.a.: not available
* these biopsies established human B cell lymphomas in the mice
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Supplementary Table 2. Histopathological analysis of biopsies. Percentage of 
tumor content, immune infiltrates, necrosis and non-tumoral tissue were determined 
in each biopsy on H&E stained sections by an experienced hepato-pathologist 
(M.S.M.). Biopsies used for whole exome (WES) and RNA sequencing (RNAseq) are 
indicated. Immune infiltrates were summarized in four different categories: - = 0-1%; 
+ =  >1-5%; ++ = >5%-15%; and +++ = >15% of immune infiltrates in the whole 
biopsy cylinder. n.a.: not available 
	  
 
Patient Biopsy ID Tumor content  [%] Immune infiltrates Necrosis [%] Non-tumoral [%] WES RNAseq
1 C078b 90 n.a. n.a. n.a. yes yes
2 C255b 70 ++ 0 30 yes
3 C272b 90 + 5 5 yes
4 C284b 50 ++ 5 45 yes yes
5  C316b 90 + 2 8 yes
6 C334b 100 - 0 0 yes
7-A  C457b 60 - 0 40 yes
7-B  C457c 90 + 5 5 yes
8 C475b 95 + 0 5 yes
9 C477b 50 + 2 48 yes
10 C495 60 + 0 40 yes
11 C511 60 n.a. n.a. n.a. yes
12 C532 100 - 0 0 yes
13 C605 95 + 0 5 yes
14 C613 80 - 0 20 yes
15 C628 70 + 0 30 yes
16 C638 95 + 0 5 yes
17-A C655 10 + 80 10
17-B C656 5 n.a. n.a. n.a.
18-A C677 70 n.a. n.a. n.a. yes yes
18-B C678 30 + 50 20 yes yes
19 C696 80 + 2 18 yes
20 C710 95 + 0 5 yes
21 C738 60 +++ 0 40 yes yes
22 C753 10 - 0 90
23 C761 10 - 45 45
24 C769 80 + 0 20 yes
25 C798 70 - 5 25 yes yes
26-A C850 95 + 0 5 yes
26-B C851 95 + 0 5 yes
27-A C878 <5 - 25 70
27-B C879 <5 - 0 95
28 C937 100 + 0 5 yes
29-A C942 70 - 15 15 yes yes
29-B C944 30 ++ 0 70 yes
30-A C948 80 ++ 0 20 yes yes
30-B C949 40 - 30 30 yes yes
31 C951 80 ++ 0 20 yes yes
32-A C958 40 - 10 50 yes
33 C964 95 + 0 5 yes
32-B C965 50 ++ 40 10 yes yes
34 C971 20 ++ 0 80
35 C975 50 +++ 0 50 yes yes
36-I D045 80 ++ 10 10 yes
36-II D046 70 ++ 20 10 yes
37 D051 90 + 2 8 yes
38 D070 70 ++ 0 30 yes
39 D096 40 - 60 0 yes yes
40-A D135 80 + 0 20 yes yes
40-B D136 5 + 0 95
41 D143 40 +++ 0 60
42 D156 95 + 0 5 yes
43 D158 70 - 0 30 yes
44 D176 95 + 0 5 yes
III	  Results	  
	  125	  
Supplementary Table 3. List of differentially expressed genes in HCC PDX 
models compared to HCC biopsies. 
 





















Supplementary Table 4. Pathways enriched among genes down-regulated and 
up-regulated in HCC PDX tumors compared to HCC biopsies.	  
	  
	  
Pathway'name p,value FDR Pathway'description
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 9.33E429 4.66E427 Genes=defining=epithelial4mesenchymal=transition,=as=in=wound=healing,=fibrosis=and=metastasis.
HALLMARK_INFLAMMATORY_RESPONSE 8.01E423 2.00E421 Genes=defining=inflammatory=response.
HALLMARK_ALLOGRAFT_REJECTION 1.96E421 3.27E420 Genes=up4regulated=during=transplant=rejection.
HALLMARK_INTERFERON_GAMMA_RESPONSE 1.17E415 1.46E414 Genes=up4regulated=in=response=to=IFNG=[GeneID=3458].
HALLMARK_KRAS_SIGNALING_UP 4.55E415 4.55E414 Genes=up4regulated=by=KRAS=activation.
HALLMARK_IL2_STAT5_SIGNALING 8.36E413 6.97E412 Genes=up4regulated=by=STAT5=in=response=to=IL2=stimulation.
HALLMARK_IL6_JAK_STAT3_SIGNALING 1.41E410 1.00E409 Genes=up4regulated=by=IL6=[GeneID=3569]=via=STAT3=[GeneID=6774],=e.g.,=during=acute=phase=response.
HALLMARK_COMPLEMENT 9.98E410 6.24E409 Genes=encoding=components=of=the=complement=system,=which=is=part=of=the=innate=immune=system.
HALLMARK_COAGULATION 1.07E407 5.96E407 Genes=encoding=components=of=blood=coagulation=system;=also=up4regulated=in=platelets.
HALLMARK_UV_RESPONSE_DN 1.01E406 5.05E406 Genes=down4regulated=in=response=to=ultraviolet=(UV)=radiation.
HALLMARK_TNFA_SIGNALING_VIA_NFKB 2.94E406 1.34E405 Genes=regulated=by=NF4kB=in=response=to=TNF=[GeneID=7124].
HALLMARK_MYOGENESIS 7.05E406 2.94E405 Genes=involved=in=development=of=skeletal=muscle=(myogenesis).
HALLMARK_APICAL_JUNCTION 0.000174 0.00067 Genes=encoding=components=of=apical=junction=complex.
HALLMARK_APOPTOSIS 0.000451 0.0016108 Genes=mediating=programmed=cell=death=(apoptosis)=by=activation=of=caspases.
HALLMARK_ANGIOGENESIS 0.001032 0.0034392 Genes=up4regulated=during=formation=of=blood=vessels=(angiogenesis).
HALLMARK_INTERFERON_ALPHA_RESPONSE 0.003175 0.0099234 Genes=up4regulated=in=response=to=alpha=interferon=proteins.
HALLMARK_HYPOXIA 0.004843 0.0142442 Genes=up4regulated=in=response=to=low=oxygen=levels=(hypoxia).





HALLMARK_MITOTIC_SPINDLE 0.060029 0.1500716 Genes=important=for=mitotic=spindle=assembly.
Pathway'name p,value FDR Pathway'description
HALLMARK_E2F_TARGETS 1.36E448 6.82E447 Genes=encoding=cell=cycle=related=targets=of=E2F=transcription=factors.
HALLMARK_MYC_TARGETS_V1 1.35E447 3.37E446 A=subgroup=of=genes=regulated=by=MYC=4=version=1=(v1).
HALLMARK_G2M_CHECKPOINT 3.20E431 5.34E430 Genes=involved=in=the=G2/M=checkpoint,=as=in=progression=through=the=cell=division=cycle.
HALLMARK_OXIDATIVE_PHOSPHORYLATION 5.62E413 7.03E412 Genes=encoding=proteins=involved=in=oxidative=phosphorylation.
HALLMARK_MTORC1_SIGNALING 2.80E409 2.80E408 Genes=up4regulated=through=activation=of=mTORC1=complex.
HALLMARK_DNA_REPAIR 3.45E407 2.88E406 Genes=involved=in=DNA=repair.
HALLMARK_MYC_TARGETS_V2 3.57E406 2.55E405 A=subgroup=of=genes=regulated=by=MYC=4=version=2=(v2).
HALLMARK_MITOTIC_SPINDLE 0.001044 0.0065221 Genes=important=for=mitotic=spindle=assembly.





Supplementary Table 5. Expression of somatic mutations in human HCC 
biopsy and corresponding PDX tumors. Somatic mutations were identified in the 
human HCC biopsies by whole exome sequencing and their expression was 
assessed in the HCC biopsies and their corresponding PDX tumors using RNA 
sequencing data. WES: whole exome sequencing. SMG: significantly mutated genes.	  
	  



















Supplementary Table 6.	   Pathways enriched among genes up-regulated or 







Pathway'name p,value FDR Pathway'description
HALLMARK_E2F_TARGETS 2.49E152 1.24E150 Genes8encoding8cell8cycle8related8targets8of8E2F8transcription8factors.
HALLMARK_G2M_CHECKPOINT 2.30E150 5.75E149 Genes8involved8in8the8G2/M8checkpoint,8as8in8progression8through8the8cell8division8cycle.
HALLMARK_MITOTIC_SPINDLE 2.56E117 3.21E116 Genes8important8for8mitotic8spindle8assembly.
HALLMARK_MYC_TARGETS_V1 2.56E117 3.21E116 A8subgroup8of8genes8regulated8by8MYC818version818(v1).
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 6.61E114 6.61E113 Genes8defining8epithelial1mesenchymal8transition,8as8in8wound8healing,8fibrosis8and8metastasis.
HALLMARK_HYPOXIA 2.26E110 1.89E109 Genes8up1regulated8in8response8to8low8oxygen8levels8(hypoxia).
HALLMARK_MTORC1_SIGNALING 3.33E106 2.38E105 Genes8up1regulated8through8activation8of8mTORC18complex.
HALLMARK_MYC_TARGETS_V2 8.73E105 0.0005458 A8subgroup8of8genes8regulated8by8MYC818version828(v2).
HALLMARK_GLYCOLYSIS 0.00112945 0.00627471 Genes8encoding8proteins8involved8in8glycolysis8and8gluconeogenesis.
HALLMARK_ANGIOGENESIS 0.00144402 0.00722009 Genes8up1regulated8during8formation8of8blood8vessels8(angiogenesis).
HALLMARK_UV_RESPONSE_DN 0.00317294 0.01442248 Genes8down1regulated8in8response8to8ultraviolet8(UV)8radiation.
HALLMARK_TNFA_SIGNALING_VIA_NFKB 0.00367897 0.01532902 Genes8regulated8by8NF1kB8in8response8to8TNF8[GeneID=7124].
HALLMARK_ESTROGEN_RESPONSE_EARLY 0.00636121 0.0244662 Genes8defining8early8response8to8estrogen.
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 0.01029082 0.03675292 Genes8up1regulated8during8unfolded8protein8response,8a8cellular8stress8response8related8to8the8endoplasmic8reticulum.
HALLMARK_UV_RESPONSE_UP 0.01270011 0.04233369 Genes8up1regulated8in8response8to8ultraviolet8(UV)8radiation.
HALLMARK_APICAL_JUNCTION 0.01743279 0.05447747 Genes8encoding8components8of8apical8junction8complex.
HALLMARK_IL2_STAT5_SIGNALING 0.02761697 0.08122639 Genes8up1regulated8by8STAT58in8response8to8IL28stimulation.
HALLMARK_PI3K_AKT_MTOR_SIGNALING 0.02936448 0.081568 Genes8up1regulated8by8activation8of8the8PI3K/AKT/mTOR8pathway.
HALLMARK_WNT_BETA_CATENIN_SIGNALING 0.04055352 0.10618775 Genes8up1regulated8by8activation8of8WNT8signaling8through8accumulation8of8beta8catenin8CTNNB18[GeneID=1499].
HALLMARK_ESTROGEN_RESPONSE_LATE 0.0424751 0.10618775 Genes8defining8late8response8to8estrogen.
HALLMARK_TGF_BETA_SIGNALING 0.08688163 0.20686102 Genes8up1regulated8in8response8to8TGFB18[GeneID=7040].
Pathway'name p,value FDR Pathway'description
HALLMARK_XENOBIOTIC_METABOLISM 7.84E130 3.92E128 Genes8encoding8proteins8involved8in8processing8of8drugs8and8other8xenobiotics.
HALLMARK_FATTY_ACID_METABOLISM 1.86E121 4.65E120 Genes8encoding8proteins8involved8in8metabolism8of8fatty8acids.
HALLMARK_BILE_ACID_METABOLISM 7.49E118 1.25E116 Genes8involve8in8metabolism8of8bile8acids8and8salts.
HALLMARK_COAGULATION 1.58E113 1.97E112 Genes8encoding8components8of8blood8coagulation8system;8also8up1regulated8in8platelets.
HALLMARK_ADIPOGENESIS 3.75E113 3.13E112 Genes8up1regulated8during8adipocyte8differentiation8(adipogenesis).
HALLMARK_OXIDATIVE_PHOSPHORYLATION 3.75E113 3.13E112 Genes8encoding8proteins8involved8in8oxidative8phosphorylation.
HALLMARK_PEROXISOME 1.93E110 1.38E109 Genes8encoding8components8of8peroxisome.
HALLMARK_INTERFERON_ALPHA_RESPONSE 5.23E105 0.00032687 Genes8up1regulated8in8response8to8alpha8interferon8proteins.
HALLMARK_INTERFERON_GAMMA_RESPONSE 0.00019358 0.00107546 Genes8up1regulated8in8response8to8IFNG8[GeneID=3458].
HALLMARK_HEME_METABOLISM 0.00384143 0.01920713 Genes8involved8in8metabolism8of8heme8(a8cofactor8consisting8of8iron8and8porphyrin)8and8erythroblast8differentiation.





Supplementary Table 7. Pathways enriched among genes up-regulated or 
down-regulated in the lymphoid PDX tumor compared to HCC biopsies and 
HCC PDX tumors.	  
	  
Pathway'name p,value FDR Pathway'description
HALLMARK_INTERFERON_GAMMA_RESPONSE 5.22E425 2.61E423 Genes;up4regulated;in;response;to;IFNG;[GeneID=3458].
HALLMARK_ALLOGRAFT_REJECTION 2.79E424 6.97E423 Genes;up4regulated;during;transplant;rejection.
HALLMARK_INTERFERON_ALPHA_RESPONSE 1.35E412 2.25E411 Genes;up4regulated;in;response;to;alpha;interferon;proteins.
HALLMARK_TNFA_SIGNALING_VIA_NFKB 8.08E409 1.01E407 Genes;regulated;by;NF4kB;in;response;to;TNF;[GeneID=7124].
HALLMARK_E2F_TARGETS 2.29E408 2.29E407 Genes;encoding;cell;cycle;related;targets;of;E2F;transcription;factors.
HALLMARK_INFLAMMATORY_RESPONSE 4.42E407 3.68E406 Genes;defining;inflammatory;response.
HALLMARK_G2M_CHECKPOINT 6.67E406 4.76E405 Genes;involved;in;the;G2/M;checkpoint,;as;in;progression;through;the;cell;division;cycle.
HALLMARK_IL2_STAT5_SIGNALING 3.53E405 0.00022042 Genes;up4regulated;by;STAT5;in;response;to;IL2;stimulation.
HALLMARK_IL6_JAK_STAT3_SIGNALING 9.83E405 0.00054632 Genes;up4regulated;by;IL6;[GeneID=3569];via;STAT3;[GeneID=6774],;e.g.,;during;acute;phase;response.
HALLMARK_COMPLEMENT 0.00016591 0.00075412 Genes;encoding;components;of;the;complement;system,;which;is;part;of;the;innate;immune;system.
HALLMARK_P53_PATHWAY 0.00016591 0.00075412 Genes;involved;in;p53;pathways;and;networks.
HALLMARK_PI3K_AKT_MTOR_SIGNALING 0.00026204 0.00109182 Genes;up4regulated;by;activation;of;the;PI3K/AKT/mTOR;pathway.
HALLMARK_MYC_TARGETS_V1 0.00069163 0.00266012 A;subgroup;of;genes;regulated;by;MYC;4;version;1;(v1).
HALLMARK_APOPTOSIS 0.00091846 0.00328023 Genes;mediating;programmed;cell;death;(apoptosis);by;activation;of;caspases.
Pathway'name p,value FDR Pathway'description
HALLMARK_XENOBIOTIC_METABOLISM 7.31E426 3.66E424 Genes;encoding;proteins;involved;in;processing;of;drugs;and;other;xenobiotics.
HALLMARK_COAGULATION 8.58E425 2.15E423 Genes;encoding;components;of;blood;coagulation;system;;also;up4regulated;in;platelets.
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 8.87E422 1.48E420 Genes;defining;epithelial4mesenchymal;transition,;as;in;wound;healing,;fibrosis;and;metastasis.
HALLMARK_ESTROGEN_RESPONSE_EARLY 1.07E415 1.34E414 Genes;defining;early;response;to;estrogen.
HALLMARK_ESTROGEN_RESPONSE_LATE 5.02E411 5.02E410 Genes;defining;late;response;to;estrogen.
HALLMARK_BILE_ACID_METABOLISM 6.23E409 5.19E408 Genes;involve;in;metabolism;of;bile;acids;and;salts.
HALLMARK_HYPOXIA 8.94E409 6.39E408 Genes;up4regulated;in;response;to;low;oxygen;levels;(hypoxia).
HALLMARK_APICAL_JUNCTION 2.35E408 1.47E407 Genes;encoding;components;of;apical;junction;complex.
HALLMARK_GLYCOLYSIS 6.03E408 3.35E407 Genes;encoding;proteins;involved;in;glycolysis;and;gluconeogenesis.
HALLMARK_ANGIOGENESIS 2.85E407 1.42E406 Genes;up4regulated;during;formation;of;blood;vessels;(angiogenesis).
HALLMARK_ADIPOGENESIS 3.70E407 1.68E406 Genes;up4regulated;during;adipocyte;differentiation;(adipogenesis).
HALLMARK_UV_RESPONSE_DN 6.13E407 2.55E406 Genes;down4regulated;in;response;to;ultraviolet;(UV);radiation.
HALLMARK_MYOGENESIS 2.05E406 7.89E406 Genes;involved;in;development;of;skeletal;muscle;(myogenesis).
HALLMARK_ANDROGEN_RESPONSE 8.65E405 0.00030895 Genes;defining;response;to;androgens.
HALLMARK_KRAS_SIGNALING_UP 9.61E405 0.00032027 Genes;up4regulated;by;KRAS;activation.
HALLMARK_COMPLEMENT 0.00019191 0.00059972 Genes;encoding;components;of;the;complement;system,;which;is;part;of;the;innate;immune;system.
HALLMARK_UV_RESPONSE_UP 0.00022469 0.00066084 Genes;up4regulated;in;response;to;ultraviolet;(UV);radiation.
HALLMARK_CHOLESTEROL_HOMEOSTASIS 0.0003467 0.00096305 Genes;involved;in;cholesterol;homeostasis.
HALLMARK_PEROXISOME 0.00086454 0.00227511 Genes;encoding;components;of;peroxisome.
HALLMARK_FATTY_ACID_METABOLISM 0.00093519 0.00233798 Genes;encoding;proteins;involved;in;metabolism;of;fatty;acids.
HALLMARK_TGF_BETA_SIGNALING 0.00221892 0.00528314 Genes;up4regulated;in;response;to;TGFB1;[GeneID=7040].
HALLMARK_P53_PATHWAY 0.00408748 0.00928974 Genes;involved;in;p53;pathways;and;networks.
HALLMARK_APOPTOSIS 0.00469039 0.01019651 Genes;mediating;programmed;cell;death;(apoptosis);by;activation;of;caspases.
HALLMARK_APICAL_SURFACE 0.01514561 0.03155336 Genes;encoding;proteins;over4represented;on;the;apical;surface;of;epithelial;cells,;e.g.,;important;for;cell;polarity;(apical;area).
HALLMARK_HEME_METABOLISM 0.01843099 0.03544422 Genes;involved;in;metabolism;of;heme;(a;cofactor;consisting;of;iron;and;porphyrin);and;erythroblast;differentiation.
HALLMARK_IL2_STAT5_SIGNALING 0.01843099 0.03544422 Genes;up4regulated;by;STAT5;in;response;to;IL2;stimulation.
HALLMARK_NOTCH_SIGNALING 0.02746076 0.05085326 Genes;up4regulated;by;activation;of;Notch;signaling.
HALLMARK_REACTIVE_OXIGEN_SPECIES_PATHWAY 0.03428877 0.06122995 Genes;up4regulated;by;reactive;oxigen;species;(ROS).
HALLMARK_IL6_JAK_STAT3_SIGNALING 0.05438653 0.09376988 Genes;up4regulated;by;IL6;[GeneID=3569];via;STAT3;[GeneID=6774],;e.g.,;during;acute;phase;response.
HALLMARK_WNT_BETA_CATENIN_SIGNALING 0.06006921 0.10011536 Genes;up4regulated;by;activation;of;WNT;signaling;through;accumulation;of;beta;catenin;CTNNB1;[GeneID=1499].
HALLMARK_TNFA_SIGNALING_VIA_NFKB 0.06449537 0.10402479 Genes;regulated;by;NF4kB;in;response;to;TNF;[GeneID=7124].





Supplementary Table 8. Summary of RNA sequencing reads aligned against 
human and mouse CD20, and to the genome of EBV. 
	  
	  








Total Reads NC_009334 / NC_007605 RPM
C736 non Tumor 100'851'444 0 neg
C738 Tumor 78'938'981 0 neg
C738-PDX-1 Xenograft 50'203'401 12'760 254.17
C947 non Tumor 52'983'481 0 neg
C948 Tumor 60'538'859 0 neg
C948-PDX-1 Xenograft 45'460'391 6'210 136.60
C950 non Tumor 49'377'190 0 neg
C951 Tumor 51'071'193 0 neg
C951-PDX-1 Xenograft 56'915'236 2'098 36.86
C078-PDX-1a Xenograft 58'263'254 0 neg
C078-PDX-1b Xenograft 69'004'021 0 neg
C284-PDX-1 Xenograft 57'165'620 0 neg
C677-PDX-1 Xenograft 49'633'842 3 0.06
C678-PDX-1 Xenograft 40'100'082 1 0.02
C798-PDX-1 Xenograft 52'227'184 16 0.31
C942-PDX-1 Xenograft 47'495'346 0 neg
C949-PDX-1 Xenograft 43'840'074 1 0.02
C965-PDX-1 Xenograft 44'723'122 3 0.07
C975-PDX-1 Xenograft 49'521'217 1 0.02
Remarks:
- no alignment quality control
* alignment to EBV genomic DNA, spliced transcripts not included
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1	  Research	  article	  I	  IFNs	   are	   produced	   upon	   viral	   infection	   and	   induce	   an	   antiviral	   state	   to	   block	   viral	  replication	   and	   spread.	   Type	   I	   and	   III	   IFNs	   provide	   an	   important	   first	   line	   of	   defence	  through	   the	   fast	   induction	   of	   hundreds	   of	   ISGs	  who	   collectively	   establish	   an	   antiviral	  state100.	   This	   host	   response	   has	   to	   be	   negatively	   regulated	   at	   some	   point	   to	  maintain	  tissue	   homeostasis.	   Several	   clinical	   autoimmune	   diseases,	   such	   as	   Aicardi-­‐Goutieres	  syndrome,	   systemic	  erythematosus	  and	  pseudo-­‐TORCH	  syndrome,	  are	  associated	  with	  an	  uncontrolled	  type	  I	  IFN	  system	  highlighting	  the	  importance	  of	  negative	  regulation	  to	  maintain	  equiblibrium107,108,179.	  	  Despite	   extensive	   literature	   on	   the	   negative	   regulation	   of	   the	   IFN	   signaling,	   several	  aspects	  are	  still	  unclear	  or	  a	  matter	  of	  controversy,	  especially	  concerning	  the	  regulation	  of	  type	  III	  IFNs.	  For	  example,	  the	  role	  of	  SOCS1	  and	  SOCS3	  on	  IFN-­‐λ signaling	  was	  only	  addressed	  in	  overexpression	  experiments,	  showing	  that	  both	  are	  negative	  regulators	  of	  IFN-­‐λ	  signaling157-­‐159.	   However,	   whether	   physiological	   expression	   levels	   of	   SOCS1	  and/or	   SOCS3	   are	   sufficient	   to	   inhibit	   IFN-­‐λ	   signaling	   remained	   to	   be	   investigated.	  Furthermore,	   the	   role	  of	  USP18	  on	   type	   III	   IFN	   is	   still	   a	  matter	  of	  debate147,173,178	   and	  needed	   further	   clarification.	   In	   the	   present	   study,	   we	   investigated	   the	   negative	  regulatory	  role	  of	  SOCS1,	  SOCS3	  and	  USP18	  in	  type	  I	  and	  III	  IFN	  signaling.	  Although	  type	  I	  and	  type	  III	   IFNs	  signal	  through	  distinct	  receptors,	   they	  induce	  largely	  overlapping	  sets	  of	  ISGs342.	  However,	  at	  least	  in	  cell	  culture,	  IFN-­‐α	  and	  IFN-­‐λ	  mediated	  ISG	  induction	  followed	  distinct	  kinetic	  profiles.	  IFN-­‐α	  triggers	  an	  immediate	  and	  strong	  but	  very	  transient	  ISG	  response,	  while	  IFN-­‐λ	  provides	  long-­‐lasting	  JAK-­‐STAT	  activation	  and	  ISG	  induction100,342,343.	  The	  different	  activation	  patterns	  can	  in	  part	  be	  attributed	  to	  differences	   in	  negative	   regulation.	   SOCS1	  and	  SOCS3	  were	   shown	   to	  be	  early	  negative	  regulators	  of	  IFN-­‐α	  induced	  JAK-­‐STAT	  signaling145,153.	  Nevertheless,	  their	  role	  on	  IFN-­‐α	  induced	  signaling	  is	  limited	  as	  shown	  in	  the	  present	  study	  and	  by	  previous	  reports148,344.	  Using	   knockout	   cells,	   and	  mice,	  we	   demonstrated	   that	   USP18,	   rather	   than	   SOCS1	   and	  SOCS3	  play	  a	  major	  role	  in	  regulating	  the	  IFN-­‐α	  induced	  signaling	  cascade	  (Figures	  3,	  4,	  5	  and	  6,	  research	  article	  I).	  With	  a	  luciferase	  reporter	  assay,	  we	  demonstrated	  that	  IFN-­‐α	  signaling	   was	   enhanced	   in	   USP18	   knockout	   compared	   to	   control	   cells	   at	   4,	   8	   and	   24	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hours	   (Figure	   3,	   research	   article	   I).	   Furthermore,	   we	   show	   significantly	   higher	   ISG	  expression	   levels	   in	   USP18	   knockout	   cells	   compared	   to	   control	   cells	   upon	   IFN-­‐α	  stimulation	  at	  8	  and	  24	  hours	  (Figures	  4	  and	  S3,	  research	  article	  I).	  To	  further	  test	  if	  our	  results	  obtained	  in	  cell	  lines	  are	  also	  valid	  in	  vivo,	  we	  investigated	  the	  IFN-­‐α	  signaling	  in	  mice	   deficient	   for	   Usp18	   and	   the	   corresponding	   control	   mice.	   We	   analysed	   the	   ISG	  induction	   upon	   IFN-­‐α	   injection	   in	   the	  mouse	   liver,	   lung	   and	   gut.	   All	   tested	   ISGs	  were	  significantly	   higher	   expressed	   in	   the	   liver	   and	   the	   lung	   of	   Usp18	   deficient	   mice	  compared	  to	  control	  mice	  (Figures	  6	  and	  S4,	  research	  article	   I).	  This	  effect	  was	  visible	  but	   less	   pronounced	   in	   the	   gut.	   This	   could	   be	   explained	   by	   lower	   Usp18	   expression	  levels	   in	   the	   gut	   compared	   to	   the	   liver	   and	   the	   lung	   at	   the	   time	   points	   analyzed.	   In	  contrast	  to	  USP18,	  the	  effect	  of	  SOCS1	  on	  IFN-­‐α	  induced	  signaling	  was	  minor	  (Figures	  3,	  4	  and	  5,	  research	  article	  I).	  These	  results	  fit	  to	  the	  finding	  that	  Socs1	  knockout	  mice	  are	  hypersensitive	  to	  IFN-­‐γ,	  demonstrating	  the	  main	  role	  of	  SOCS1	  is	  the	  negative	  regulation	  of	  IFN-­‐γ	  signaling160,163.	  Furthermore,	  refractoriness	  to	  IFN-­‐α	  is	  not	  impaired	  in	  the	  liver	  of	  Socs1	  deficient	  mice,	  whereas	  deletion	  of	  Usp18	  completely	   restored	   the	   refractory	  phenotype	   to	   IFN-­‐α	   stimulation148.	   Of	   note,	   the	   previously	   mentioned	   type	   I	  interferonopathy	  pseudo-­‐TORCH	  syndrome	   is	  caused	  by	  a	  human	  USP18	  deficiency179.	  Thus,	  our	  results	  together	  with	  the	  previously	  published	  data	  define	  USP18	  as	  the	  main	  negative	  regulator	  of	  the	  IFN-­‐α	  induced	  signaling	  cascade	  in	  vitro	  and	  in	  vivo.	  	  In	  contrast	  to	  IFN-­‐α,	  the	  effect	  of	  USP18	  on	  IFN-­‐β	  was	  marginal	  and	  only	  significant	  at	  8	  hours	   post	   stimulation	   in	  vitro	   (Figure	   S2,	   research	   article	   I).	   Of	   note,	   although	   IFN-­‐β	  belongs	   to	   the	   type	   I	   IFNs	   and	   signals	   through	   the	   same	   receptor	   as	   IFN-­‐α,	   the	   long-­‐lasting	   refractoriness	   was	   not	   observed	   for	   IFN-­‐β	   stimulation147,173.	   This	   goes	   in	   line	  with	  the	  fact	  that	  IFN-­‐β	  was	  effective	   in	  some	  chronic	  hepatitis	  C	  patients	  who	  did	  not	  respond	   to	   previous	   therapies	   with	   IFN-­‐α345.	   Furthermore,	   IFN-­‐α	   and	   IFN-­‐β	   induce	  distinct	  mRNA	  expression	  profiles	  in	  human	  cells100,342,346,347.	  In	  contrast	  to	  IFN-­‐α,	  IFN-­‐β	  induces	  long-­‐lasting	  ISG	  expression342.	  This	  and	  the	  data	  from	  our	  study	  suggest	  that	  the	  negative	   regulatory	   role	  of	  USP18	  on	   IFN-­‐β	   is	  much	  weaker	   compared	   to	   its	   effect	   on	  IFN-­‐α	   signaling.	  The	  reason	   for	   that	   is	  not	  entirely	  clear;	  especially	  given	   the	   fact	   that	  USP18	  inhibits	  the	  IFN-­‐α	  signaling	  by	  binding	  to	  the	  IFNAR2109	  chain	  that	  is	  also	  used	  by	  IFN-­‐β.	   It	   can	  be	   speculated,	   that	   the	   interaction	  of	  USP18	  with	   the	   IFNAR2	   chain	  may	  lead	  to	  reorganization	  of	  the	  type	  I	  IFN	  receptor	  that	  could	  weaken	  the	  interaction	  with	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IFN-­‐α,	   while	   not	   affecting	   the	   binding	   of	   IFN-­‐β	   that	   has	   a	   higher	   receptor	  affinity173,348,349.	   This	   would	   allow	   IFN-­‐β	   to	   maintain	   activity	   in	   cells	   desensitized	   for	  IFN-­‐α,	   which	   could	   be	   important	   for	   the	   stimulation	   of	   adaptive	   immune	   responses,	  critical	   to	   eradicate	   pathogen	   infest	   cells.	   However,	   solid	   experimental	   evidence	  supporting	   such	   a	  model	   is	   still	   lacking.	   Taken	   together,	   IFN-­‐α	   and	   IFN-­‐β	   induce	   the	  same	  set	  of	  ISGs	  but	  only	  IFN-­‐α	  response	  is	  subject	  to	  a	  significant	  negative	  feedback	  by	  USP18.	  The	   negative	   regulation	   of	   IFN-­‐λs	   is	   fundamentally	   different	   from	   that	   of	   IFN-­‐
α	  signaling.	  The	  upregulation	  of	  USP18	  does	  not	  induce	  refractoriness	  of	  IFN-­‐λ signaling	  as	   shown	   in	   the	   present	   study	   and	   in	   previous	   studies147,173.	  We	   demonstrate	   that	   in	  contrast	   to	   IFN-­‐α,	   IFN-­‐λ	   induces	   a	   prolonged	   activation	   of	   STAT1	   and	   2	   as	   well	   as	  sustained	   ISG	   expression	   despite	   strong	   induction	   of	   USP18	   (Figures	   1B	   and	   1C,	  research	  article	   I).	   Importantly,	  we	  used	  a	  hepatoma	  cell	   line	  with	   IFNLR1	  expression	  levels	   comparable	   to	   the	   expression	   levels	   in	   the	   liver	   of	   chronic	   hepatitis	   C	   patients,	  especially	  with	  the	  IFN-­‐λ4	  wildtype	  genotype	  (TT/ΔG	  and	  ΔG/ΔG)	  (Figure	  1A,	  research	  article	   I).	   We	   have	   previously	   demonstrated	   that	   the	   initially	   very	   low	   IFNLR1	  expression	  in	  human	  livers	  seems	  to	  be	   induced	  to	   levels	  sufficient	   for	  IFN-­‐λ	  signaling	  during	  chronic	  hepatitis	  C	  infection350.	  Again	  using	  USP18	  knockout	  cells,	  we	  show	  that	  USP18,	  while	  being	  the	  main	  negative	  regulator	  of	  the	  IFN-­‐α	  signaling,	  has	  no	  effect	  on	  IFN-­‐λ	  signaling	   (Figure	  3,	  4,	  S2	  and	  S3	  of	  research	  article	  I).	   Of	   note,	   USP18	   has	   the	  potential	  to	  inhibit	  IFN-­‐λ	  signaling	  but	  only	  at	  supra-­‐physiological	  expression	  levels	  as	  demonstrated	   in	  our	  overexpression	  experiments	   (Figure	  2,	   research	  article	   I).	   In	   this	  setting,	   the	   transiently	   transfected	   cells	   showed	  USP18	   expression	   levels	   2-­‐3	   order	   of	  magnitude	  higher	  than	  those	  induced	  by	  maximal	  physiological	  stimulation	  with	  IFN-­‐λ.	  These	   experiments	   showed	   that	   the	   results	   from	   overexpression	   studies	   have	   to	   be	  cautiously	  interpreted,	  especially	  in	  the	  case	  of	  the	  inducible	  SOCS	  and	  USP18	  proteins.	  Not	  only	  can	  the	  negative	  regulators	  be	  expressed	  at	  non-­‐physiological	  levels,	  but	  also	  in	  a	  temporally	   inappropriate	  manner	  (i.e.	  already	  present	  prior	  to	  the	  onset	  of	  signaling	  rather	   than	   induced	   as	   a	   consequence	   of	   signal	   transduction).	   Indeed,	   while	   several	  SOCS	  proteins	   inhibit	   a	  number	  of	  different	   cytokines	  when	  artificially	  overexpressed,	  under	   normal	   conditions	   their	   activity	   is	   usually	   highly	   specific	   for	   only	   a	   few	  cytokines152.	  This	  was	  shown	  for	  example	   for	  SOCS1	  that,	  despite	  being	  discovered	  on	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the	  basis	  of	  its	  ability	  to	  inhibit	  IL-­‐6	  when	  overexpressed129,131,	  has	  little,	  if	  any,	  role	  in	  inhibiting	  IL-­‐6	  in	  vivo	  based	  on	  studies	  in	  knockout	  mice165.	  Thus,	  knockout	  experiments	  are	  more	   reliable	   for	   investigating	   the	   negative	   regulatory	   role	   of	   SOCS1,	   SOCS3	   and	  USP18	   on	   the	   IFN-­‐λ	  induced	  signaling	  cascade.	   Accordingly,	   we	   show	   that	   SOCS1	  deficient	  cells	  are	  hyper-­‐responsive	  to	  type	  III	  IFNs	  in	  vitro	  whereas	  IFN-­‐λ	  signaling	  was	  not	  affected	  in	  SOCS3	  and	  USP18	  knockout	  cells	  (Figures	  3,	  4,	  S2	  and	  S3,	  research	  article	  I).	  This	  led	  us	  to	  conclude	  that	  SOCS1	  is	  an	  inducible	  and	  physiological	  relevant	  negative	  regulator	   of	   IFN-­‐λ1,	   IFN-­‐λ3	   and	   IFN-­‐λ4	   in	   human	   hepatoma	   cells.	   Furthermore,	   we	  confirmed	   this	   inhibitory	   role	   of	   SOCS1	   on	   IFN-­‐λ	   signaling	   in	   vivo.	   IFN-­‐λ-­‐induced	   ISG	  expression	   in	   the	   lung	   and	   the	   gut,	   tissues	   known	   to	   express	   IFNLR138,351,	   was	  significantly	  increased	  in	  Socs1	  knockout	  mice	  compared	  to	  control	  mice	  (Figures	  5	  and	  S4,	  research	  article	  I).	  	  We	  demonstrated	  that	  the	  IFN-­‐α	  and	  IFN-­‐λ	  systems	  are	  negatively	  regulated	  in	  different	  ways.	  Whereas	  USP18	  is	  the	  main	  negative	  regulator	  of	  the	  IFN-­‐α	  signaling	  cascade,	  IFN-­‐
λ	  signaling	  is	  regulated	  by	  SOCS1.	  However,	  not	  only	  the	  regulation	  is	  different	  but	  also	  the	  distribution	  of	  their	  cognate	  receptors.	  Almost	  all	  nucleated	  cells	  express	  the	  IFNAR,	  whereas	  the	  IFNLR1	  expression	  is	  mostly	  restricted	  to	  epithelial	  cells	  of	  the	  respiratory	  and	  gastrointestinal	  tracts10,36,38.	  This	  leads	  to	  the	  hypothesis	  that	  type	  III	  IFNs	  serve	  as	  the	  first	  line	  of	  defense	  at	  the	  borders	  where	  viral	  infection	  is	  a	  frequent	  challenge.	  Our	  data	  also	   shows	   that	  SOCS1,	  while	  negatively	   regulating	   IFN-­‐λ	   induced	  signaling,	  does	  not	   completely	   abolish	   it.	   This	   probably	   enables	   a	   long-­‐lasting	   activation	   of	   the	   JAK-­‐STAT	   signaling,	   crucial	   for	   a	   sustained	   antiviral	   state	   at	   mucosal	   surfaces	   that	   are	  constantly	  exposed	  to	  pathogens.	  In	  contrast,	  IFN-­‐α	  is	  a	  more	  powerful	  defense	  system	  that	   is	   induced	   fast	   but	   only	   transiently5.	   It	   is	   induced	   after	   viruses	   breached	   the	  mucosal	   surfaces	   and	   invade	   the	   systemic	   circulation	   and	   other	   organs.	   Although	  powerful	   in	   fighting	   invading	   pathogens,	   IFN-­‐α	   induced	   signaling	   needs	   to	   be	   tightly	  controlled	   to	  maintain	   tissue	   homeostasis.	   This	   could	   explain	  why	  USP18	   shuts	   down	  IFN-­‐α	  signaling	  completely.	  Taken	  together,	  we	  demonstrate	  SOCS1	  as	  a	  physiologically	  relevant	  inducible	  inhibitor	  of	  the	  IFN-­‐λ	  signaling,	  whereas	  USP18	  represents	  the	  main	  negative	  regulator	  of	  IFN-­‐α	  induced	  JAK-­‐STAT	  signaling.	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1.	  Research	  article	  II	  HCC	  is	  the	  second	  deadliest	  cancer	  worldwide	  with	  yearly	  increasing	  incidence181,182,185.	  Treatment	  options	  for	  HCC	  patients	  are	  unsatisfactory	  with	  less	  than	  30	  percent	  of	  HCC	  patients	   in	   Europe	   qualifying	   for	   curative	   treatment	   such	   as	   resection	   and	  transplantation185. Due	  to	  advanced	  disease	  stages	  and	  unfavorable	  patient	  conditions	  at	  the	   time	  of	   diagnosis,	   the	  majority	   of	  HCC	   cases	   are	  unresectable.	   The	  only	   treatment	  option	   for	   patients	   with	   advanced	   disease	   is	   the	   multikinase	   inhibitor	   sorafenib,	  prolonging	  median	   survival	   by	   three	  months232.	   Although	   beneficial,	   sorafenib	   has	   its	  limitations	  mostly	  because	  of	  its	  side	  effects	  and	  resistance	  to	  treatment,	  showing	  a	  clear	  need	  for	  new	  and	  more	  effective	  drugs.	  Novel	  systemic	  drugs	  developed	  after	  sorafenib	  was	  approved	  for	   the	  treatment	  of	  advanced	  HCC	  failed	   in	  clinical	  phase	  II	  or	   III	   trials	  because	   of	   liver	   toxicity	   or	   marginal	   antitumor	   potency286.	   A	   major	   obstacle	   for	   the	  understanding	   of	   the	   pathogenesis	   of	   HCC	   and	   the	   molecular	   mechanisms	   leading	   to	  drug	  resistance	  is	  the	  lack	  of	  in	  vivo	  models	  that	  recapitulate	  key	  features	  of	  human	  HCC.	  In	  recent	  years,	  PDX	  models	  have	  gained	  interest	  and	  are	  regarded	  as	  valuable	  tools	  in	  the	   field	   of	   pre-­‐clinical	   drug	   testing	   and	   prediction	   of	   cancer	   therapy332,333.	   Indeed,	  several	  HCC	  PDX	  mouse	  models	  have	  been	  described334-­‐340.	  However,	  all	  of	  these	  models	  have	   been	   generated	   from	   surgically	   removed	  HCC	   tumors.	   Because	   liver	   resection	   is	  typically	   performed	   in	   patients	   with	   early	   stage	   disease,	   these	   models	   may	   not	  recapitulate	  the	  full	  spectrum	  of	  HCC	  stages.	  Importantly,	  none	  of	  the	  above	  mentioned	  PDX	  models	  includes	  advanced	  stage	  HCC,	  although	  this	  would	  be	  desired	  as	  sorafenib	  treatment	  is	  mainly	  used	  in	  patients	  with	  advanced	  stage	  disease.	  	  We	  report	  here	  for	  the	  first	  time	  the	  establishment	  of	  s.c.	  PDX	  models	  from	  fresh	  human	  HCC	  needle	  biopsies	   that	  cover	  early	  and	   late	  stage	   tumors.	  We	  generated	  eleven	  PDX	  models	  from	  tumor	  biopsies	  of	  HCC	  patients	  with	  different	  etiologies	  and	  disease	  stages	  (Table	   S1,	   research	   article	   II)	  with	   an	   engraftment	   success	   rate	   of	   20%	   (11	   out	   of	   54	  biopsies).	   This	   is	   in	   accordance	   with	   published	   data	   from	   HCC	   PDX	   models	   from	  resected	   specimens334,337,338.	   The	   use	   of	   HCC	   biopsies	   covering	   the	   full	   spectrum	   of	  disease	   stages	   and	   etiologies	   enabled	   us	   to	   assess	   potential	   determinants	   for	   the	  generation	  of	  PDX	  models.	  We	  show	   that	   the	   tumor	  differentiation	  grade	  according	   to	  Edmondson262	  was	   a	   clear	  determinant	   for	   engraftment	   success,	  with	  only	  high	   grade	  biopsies	   (grades	   III	   and	   IV)	   engrafting	   in	   the	  mice	   (Table	   S1	   and	   Figure	   4A,	   research	  article	   II).	   Besides	   the	   differentiation	   grade,	   no	   other	   clinical	   patient	   characteristics	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seemed	   to	   influence	   the	  engraftment	  success	   rate (Figure	  4A,	   research	  article	   II).	  This	  suggests,	   that	  mainly	  dedifferentiated	  and	  thus	  more	  aggressive	  HCCs	  are	  able	  to	  form	  tumors	   in	   mice	   whereas	   those	   of	   low	   Edmondson	   grade	   (i.e.	   retaining	   hepatocyte	  differentiation)	  do	  not.	  This	  is	  supported	  by	  the	  fact	  that	  previously	  reported	  HCC	  PDX	  models,	  generated	  from	  early	  stage	  tumors,	  were	  mainly	  derived	  from	  high	  Edmondson	  grade	   samples335-­‐338.	   Furthermore,	   in	   the	   case	  of	  well	   differentiated	  originating	   tumor	  samples,	   the	   corresponding	   PDX	   were	   of	   poor	   differentiation	   grades340.	   This	   is	  consistent	   with	   our	   finding	   that	   according	   to	   the	   Hoshida	   classification279,	   all	   our	  engrafted	   biopsies	   were	   of	   molecular	   subtype	   S1	   and	   S2,	   characterized	   by	   poor	  differentiation,	  high	  proliferation	  rate	  and	  poor	  survival	  (Figure	  4A,	  research	  article	  II).	  In	  contrast,	  none	  of	  the	  subtype	  S3	  biopsies,	  characterized	  as	  well	  differentiated	  tumors	  retaining	   a	   hepatocyte-­‐like	   phenotype	   and	   associated	  with	   good	   survival	   gave	   rise	   to	  PDX	  models.	  However,	  although	  only	  high	  grade	  HCC	  biopsies	  resulted	  in	  PDX	  models,	  they	   largely	   represented	   the	   entire	   spectrum	   of	   poorly	   differentiated	   HCCs	   by	  unsupervised	   clustering	   against	   the	   poorly	   differentiated	   HCCs	   from	   the	   TCGA	   HCC	  reference	  cohort248	  (Figure	  4B,	  research	  article	  II).	  	  Of	  note,	  because	  we	  consider	  all	  transplanted	  biopsies	  as	  failed	  engraftments	  if	  no	  tumor	  growth	  was	  visible	  within	  eight	  months	  after	   transplantation,	  we	  can	  not	  exclude	   that	  slow-­‐growing,	   low-­‐grade	   tumors	  would	  have	   started	  growing	  after	   the	   cut	  off	  of	   eight	  months.	  This	  potential	  scenario	  is	  further	  supported	  by	  the	  observation	  that	  Edmondson	  grade	   IV	   biopsies	   tend	   to	   have	   an	   earlier	   tumor	   growth	   onset	   compared	   to	   grade	   III	  biopsies	  (Figure	  1A,	  research	  article	  II).	  Furthermore,	  while	  transplantation	  of	  different	  pieces	  obtained	  from	  the	  same	  biopsy	  cylinder	  showed	  different	  tumor	  growth	  onsets	  in	  the	  mice	  (Figure	  S1A,	  research	  article	  II),	   injection	  of	  equal	  amounts	  of	  biopsy-­‐derived	  cell	  suspension	  led	  to	   identical,	  but	  delayed	  tumor	  growth	  onset	  (Figure	  S1B,	  research	  article	   II).	   Although	   not	   proven,	   these	   data	   suggest	   that	   the	   cell	   number	   and	   tissue	  integrity	  of	   the	   tumor	   tissue	  used	  probably	   influence	   the	   time	   to	   tumor	  growth	  onset.	  The	  use	  of	   a	   cell-­‐suspension	  generated	  by	  disruption	  of	   the	   tumor	   could	  promote	   cell	  death	  because	  of	  matrix	  detachment340,352	  and	  also	  requires	  complete	  revascularization,	  thus	  leading	  to	  a	  delayed	  tumor	  growth	  onset.	  	  	  First	   generation	   PDX	   tumors	   were	   re-­‐transplanted	   in	   order	   to	   expand	   the	   tumor	  material	  and	  maintain	  the	  models	  for	  further	  analysis.	  The	  lag	  phase	  to	  onset	  of	  tumor	  growth	  in	  the	  second	  PDX	  generations	  was	  shorter	  for	  all	  models	  and	  remained	  constant	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over	  several	  generations	  (Figures	  1B	  and	  1C,	  research	  article	  II).	  The	  finding	  of	  a	  shifted	  onset	  of	  tumor	  growth	  in	  the	  second	  PDX	  generation	  is	  in	  line	  with	  a	  report	  of	  PDX	  mice	  derived	   from	   resected	   HCC	   specimens334.	   It	   can	   be	   speculated	   that	   the	   presence	   of	   a	  mouse	   derived	   vascular	   system	   in	   the	   PDX	   tumors	   facilitates	   the	   accelerated	  engraftment	  upon	  re-­‐transplantation.	  Furthermore,	  the	  doubling	  time	  of	  the	  PDX	  tumors	  was	  consistent	   in	  all	  generations	  within	  a	  given	  model	   (Figure	  1B,	   research	  article	   II).	  Thus,	   tumor	   growth	  might	   be	   primarily	   dependent	   on	   the	   tumor	   cells	   once	   a	  murine	  vasculature	  system	  is	  established.	  	  The	   established	   PDX	   tumors	   were	   highly	   similar	   to	   their	   originating	   human	   tumors.	  They	  maintained	  the	  tumor	  differentiation	  grade,	  growth	  pattern,	  cytological	  subtype	  as	  well	  as	  the	  expression	  of	  AFP	  and	  typical	  HCC	  markers	  such	  as	  GPC3,	  HSP70	  and	  GS	  over	  at	  least	  four	  generations	  (Figures	  2,	  S2A-­‐J	  and	  Table	  1,	  research	  article	  II).	  Of	  note,	  only	  one	  PDX	  model	   (C284b)	   lost	  part	  of	   the	  histological	   characteristics	   (i.e.	   the	   trabecular	  growth	   pattern)	   observed	   in	   the	   originating	   human	   HCC.	   This	   may	   be	   due	   to	  heterogeneous	  growth	  patterns	  in	  different	  regions	  of	  the	  same	  tumor.	  Three	   xenografts	   however,	   differed	   histologically	   from	   the	   corresponding	   human	  tumors	   (Figure	   5A,	   research	   article	   II).	   Further	   analysis	   revealed	   the	   histological	  appearance	   of	   lymphocytes,	   strong	   positivity	   for	   the	   human	   B-­‐cell	   marker	   CD20,	  transcriptional	  up-­‐regulation	  of	  human	  immune	  cell	  signatures	  and	  loss	  of	  expression	  of	  HCC	  specific	   somatic	  mutations	   in	   these	  PDX	   tumors	   (Figure	  5	  and	  Table	  S7,	   research	  article	   II).	   This	   suggests	   that	   human	   B-­‐cell	   lymphomas	  were	   formed	   in	   these	  models.	  This	  phenomena	  has	  been	  previously	  described	  for	  PDX	  models	  derived	  from	  a	  number	  of	   human	   cancer	   tissues353,	   including	   HCC354.	   It	   was	   previously	   suggested	   that	   the	  reactivation	  of	  latent	  EBV	  of	  intratumoral	  passenger	  B	  lymphocytes	  may	  be	  the	  cause	  of	  lymphoma	  development	   in	  PDX	  mice353,354.	   Indeed,	  we	  detected	  EBV	   transcripts	   in	   all	  three	   lymphoma	  PDX	  models,	   but	   not	   in	   the	   originating	  HCC	   and	  matched	  non-­‐tumor	  biopsies	  (Table	  S8,	  research	  article	  II).	  The	  effect	  of	  EBV	  reactivation	  may	  be	  linked	  to	  the	  level	  of	  immunodeficiency	  of	  the	  mice,	  as	  the	  percentage	  of	  lymphoma	  development	  was	   high	   in	   NSG,	   NOG	   and	   NOD/SCID	  mice,	   whereas	   no	   lymphoma	   development	   has	  been	  described	   in	  nude	  mice355,356.	  Therefore,	   the	  use	  of	  nude	   instead	  of	  NSG	  mice	   for	  PDX	   development	  might	   help	   to	   avoid	   lymphoma	   generation	   probably	   because	   of	   the	  presence	   of	   functional	   NK	   cells355.	   Interestingly,	   two	   biopsies	   derived	   from	   the	   same	  patient	  but	  from	  two	  distinct	  HCC	  nodules	  gave	  rise	  to	  one	  HCC	  and	  one	  lymphoma	  PDX	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model	   (C948	   and	   C949	   of	   Table	   S1,	   research	   article	   II).	   This	   is	   in	   accordance	   with	   a	  report	  for	  breast	  and	  pancreatic	  cancer	  PDX	  models,	  where	  transplantation	  of	  the	  tumor	  pieces	   from	   the	   same	   human	   tumor	   graft	   could	   grow	   as	   a	   lymphocytic	   tumor	   in	   one	  mouse	   and	   as	   an	   adenocarcinoma	   in	   another	   mouse355.	   Butler	   et	   al.	   reported	   that	  treatment	   with	   rituximab,	   an	   anti-­‐CD20	   monoclonal	   antibody,	   at	   the	   time	   of	  transplantation,	  prevented	  the	  occurrence	  of	  lymphomatous	  outgrowth	  in	  early-­‐passage	  ovarian	   xenografts353.	   If	   this	   strategy	   could	   be	   applied	   to	   prevent	   lymphoma	  development	   and	   improve	   the	   success	   rate	   of	   HCC	   PDX	   generation	   has	   to	   be	  investigated.	  	  Because	  PDX	  models	  are	   frequently	  used	   in	  pre-­‐clinical	  drug	  testing,	   it	   is	   important	   to	  understand	  to	  what	  extent	  they	  recapitulate	  the	  human	  tumor	  signatures.	  Based	  on	  RNA	  sequencing	   data,	  we	   showed	   that	   pathways	   related	   to	   immune	   cells	   and	   angiogenesis	  were	  generally	  down-­‐regulated	  in	  the	  PDX	  models	  compared	  to	  their	  originating	  human	  HCC	  biopsies	  (Figure	  3A	  and	  Table	  S4,	  research	  article	  II),	  most	  likely	  a	  consequence	  of	  the	   loss	   of	   human	   immune	   cells	   and	   the	   presence	   of	   a	   murine	   instead	   of	   human	  vasculature	   in	   these	   PDX	   models	   (Figure	   S3	   and	   Table	   S4,	   research	   article	   II).	   In	  contrast,	  pathways	  related	  to	  cell	  cycle	  were	  up-­‐regulated	  in	  the	  PDX	  models	  compared	  to	  the	  human	  HCC	  biopsies,	  suggesting	  an	  enrichment	  of	  cancer	  cells	  in	  the	  PDX	  tumors	  (Figure	  3A	  and	  Table	   S4,	   research	  article	   II).	  Martinez-­‐Garcia	   et	   al.	   suggested	   that	   the	  lack	  of	  human	  stromal	  components	  in	  PDX	  models	  is	  most	  probably	  the	  major	  difference	  between	  them	  and	  their	  originating	  human	  tumor357.	  After	  accounting	  for	  the	  systemic	  differences	  mentioned	  above,	  all	  PDX	  tumors	  clustered	  together	  with	  the	  corresponding	  HCC	  biopsy.	  This	  demonstrates	  that	  the	  HCC	  PDX	  models	  recapitulate	  the	  tumor-­‐specific	  gene	   expression	   profile	   of	   the	   originating	   tumor	   (Figure	   3B,	   research	   article	   II).	  Furthermore,	  we	  demonstrated	  that	  the	  HCC	  specific	  expression	  of	  somatic	  mutations	  in	  cancer	   genes	   was	   maintained	   in	   the	   corresponding	   PDX	  models	   (Figure	   3C,	   research	  article	   II).	   Moreover,	   transcriptome	   based	   analysis	   revealed	   that	   the	   PDX	   tumors	   are	  stable	   over	   several	   generations	   and	   retain	   expression	   of	   somatic	   mutations	   of	   the	  biopsied	   tumor	   (Figures	  S4A	  and	  S4B,	   research	  article	   II).	  This	   suggests	   that	   the	  gene	  expression	   differences	   between	   the	   PDX	   tumors	   and	   their	   corresponding	   biopsies	   is	  mainly	  due	  to	  the	  substitution	  of	  human	  by	  mouse	  stromal	  cells	  and	  that	  this	  adaptation	  happens	  in	  an	  early	  phase	  of	  PDX	  establishment357.	  	  
IV	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Taken	   together,	   we	   successfully	   generated	   PDX	   models	   from	   human	   HCC	   needle	  biopsies	  of	  early	  and	  late-­‐stage	  disease,	  including	  unresectable	  tumors.	  Importantly,	  the	  HCC	  PDX	  models	  maintain	  the	  histologic	   features	  and	  transcriptomic	  characteristics	  of	  the	   originating	   tumors.	   Thus,	   these	   models	   will	   not	   only	   serve	   as	   valuable	   tools	   for	  investigating	   HCC	   biology	   but	   will	   also	   be	   very	   useful	   in	   studying	   drug-­‐induced	  resistance	  mechanisms	  and	  identification	  of	  novel	  drug	  targets.	  	   	  






	  1	   Krause,	  C.	  D.	  &	  Pestka,	   S.	  Evolution	  of	   the	  Class	  2	   cytokines	  and	   receptors,	   and	  discovery	   of	   new	   friends	   and	   relatives.	   Pharmacol	   Ther	   106,	   299-­‐346,	  doi:10.1016/j.pharmthera.2004.12.002	  (2005).	  2	   Isaacs,	  A.	  &	  Lindenmann,	  J.	  Virus	  interference.	  I.	  The	  interferon.	  Proc	  R	  Soc	  Lond	  B	  
Biol	  Sci	  147,	  258-­‐267	  (1957).	  3	   Stark,	  G.	  R.,	  Kerr,	  I.	  M.,	  Williams,	  B.	  R.,	  Silverman,	  R.	  H.	  &	  Schreiber,	  R.	  D.	  How	  cells	  respond	   to	   interferons.	   Annu	   Rev	   Biochem	   67,	   227-­‐264,	  doi:10.1146/annurev.biochem.67.1.227	  (1998).	  4	   Pestka,	  S.,	  Langer,	   J.	  A.,	  Zoon,	  K.	  C.	  &	  Samuel,	  C.	  E.	   Interferons	  and	  their	  actions.	  
Annu	   Rev	   Biochem	   56,	   727-­‐777,	   doi:10.1146/annurev.bi.56.070187.003455	  (1987).	  5	   Pestka,	  S.,	  Krause,	  C.	  D.	  &	  Walter,	  M.	  R.	  Interferons,	  interferon-­‐like	  cytokines,	  and	  their	   receptors.	   Immunol	  Rev	  202,	   8-­‐32,	  doi:10.1111/j.0105-­‐2896.2004.00204.x	  (2004).	  6	   Pestka,	  S.	  The	  interferons:	  50	  years	  after	  their	  discovery,	  there	  is	  much	  more	  to	  learn.	  J	  Biol	  Chem	  282,	  20047-­‐20051,	  doi:10.1074/jbc.R700004200	  (2007).	  7	   Heim,	   M.	   H.	   Interferons	   and	   hepatitis	   C	   virus.	   Swiss	   Med	   Wkly	   142,	   w13586,	  doi:10.4414/smw.2012.13586	  (2012).	  8	   Donnelly,	   R.	   P.	   &	   Kotenko,	   S.	   V.	   Interferon-­‐lambda:	   a	   new	   addition	   to	   an	   old	  family.	  J	  Interferon	  Cytokine	  Res	  30,	  555-­‐564,	  doi:10.1089/jir.2010.0078	  (2010).	  9	   Kotenko,	  S.	  V.	  et	  al.	   IFN-­‐lambdas	  mediate	  antiviral	  protection	  through	  a	  distinct	  class	   II	   cytokine	   receptor	   complex.	   Nat	   Immunol	   4,	   69-­‐77,	   doi:10.1038/ni875	  (2003).	  10	   Hall,	   J.	   C.	   &	   Rosen,	   A.	   Type	   I	   interferons:	   crucial	   participants	   in	   disease	  amplification	   in	   autoimmunity.	   Nat	   Rev	   Rheumatol	   6,	   40-­‐49,	  doi:10.1038/nrrheum.2009.237	  (2010).	  11	   Liu,	   Y.	   J.	   IPC:	   professional	   type	   1	   interferon-­‐producing	   cells	   and	   plasmacytoid	  dendritic	   cell	   precursors.	   Annu	   Rev	   Immunol	   23,	   275-­‐306,	  doi:10.1146/annurev.immunol.23.021704.115633	  (2005).	  12	   Siegal,	  F.	  P.	  et	  al.	  The	  nature	  of	  the	  principal	  type	  1	  interferon-­‐producing	  cells	  in	  human	  blood.	  Science	  284,	  1835-­‐1837	  (1999).	  13	   Heim,	   M.	   H.	   Innate	   immunity	   and	   HCV.	   J	   Hepatol	   58,	   564-­‐574,	  doi:10.1016/j.jhep.2012.10.005	  (2013).	  14	   Asselin-­‐Paturel,	  C.	  &	  Trinchieri,	  G.	  Production	  of	  type	  I	  interferons:	  plasmacytoid	  dendritic	  cells	  and	  beyond.	  J	  Exp	  Med	  202,	  461-­‐465,	  doi:10.1084/jem.20051395	  (2005).	  15	   Muller,	   U.	   et	   al.	   Functional	   role	   of	   type	   I	   and	   type	   II	   interferons	   in	   antiviral	  defense.	  Science	  264,	  1918-­‐1921	  (1994).	  16	   Dupuis,	   S.	   et	   al.	   Impaired	   response	   to	   interferon-­‐alpha/beta	   and	   lethal	   viral	  disease	  in	  human	  STAT1	  deficiency.	  Nat	  Genet	  33,	  388-­‐391,	  doi:10.1038/ng1097	  (2003).	  17	   Lu,	  B.	  et	  al.	  Targeted	  disruption	  of	  the	  interferon-­‐gamma	  receptor	  2	  gene	  results	  in	  severe	  immune	  defects	  in	  mice.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  95,	  8233-­‐8238	  (1998).	  
V	  References	  	  
	  142	  
18	   Bach,	  E.	  A.,	  Aguet,	  M.	  &	  Schreiber,	  R.	  D.	  The	  IFN	  gamma	  receptor:	  a	  paradigm	  for	  cytokine	   receptor	   signaling.	   Annu	   Rev	   Immunol	   15,	   563-­‐591,	  doi:10.1146/annurev.immunol.15.1.563	  (1997).	  19	   Walter,	  M.	  R.	  et	  al.	  Crystal	  structure	  of	  a	  complex	  between	  interferon-­‐gamma	  and	  its	   soluble	   high-­‐affinity	   receptor.	  Nature	  376,	   230-­‐235,	   doi:10.1038/376230a0	  (1995).	  20	   Lasfar,	   A.	   et	   al.	   Characterization	   of	   the	   mouse	   IFN-­‐lambda	   ligand-­‐receptor	  system:	   IFN-­‐lambdas	   exhibit	   antitumor	   activity	   against	   B16	  melanoma.	   Cancer	  
Res	  66,	  4468-­‐4477,	  doi:10.1158/0008-­‐5472.CAN-­‐05-­‐3653	  (2006).	  21	   Darnell,	  J.	  E.,	  Jr.,	  Kerr,	  I.	  M.	  &	  Stark,	  G.	  R.	  Jak-­‐STAT	  pathways	  and	  transcriptional	  activation	  in	  response	  to	  IFNs	  and	  other	  extracellular	  signaling	  proteins.	  Science	  
264,	  1415-­‐1421	  (1994).	  22	   Dalton,	  D.	  K.	  et	  al.	  Multiple	  defects	  of	  immune	  cell	  function	  in	  mice	  with	  disrupted	  interferon-­‐gamma	  genes.	  Science	  259,	  1739-­‐1742	  (1993).	  23	   Heim,	  M.	  H.	   Intracellular	  signalling	  and	  antiviral	  effects	  of	   interferons.	  Dig	  Liver	  
Dis	  32,	  257-­‐263	  (2000).	  24	   Huang,	   S.	   et	   al.	   Immune	   response	   in	   mice	   that	   lack	   the	   interferon-­‐gamma	  receptor.	  Science	  259,	  1742-­‐1745	  (1993).	  25	   Sheppard,	   P.	   et	  al.	   IL-­‐28,	   IL-­‐29	   and	   their	   class	   II	   cytokine	   receptor	   IL-­‐28R.	  Nat	  
Immunol	  4,	  63-­‐68,	  doi:10.1038/ni873	  (2003).	  26	   Ank,	   N.	   et	   al.	   Lambda	   interferon	   (IFN-­‐lambda),	   a	   type	   III	   IFN,	   is	   induced	   by	  viruses	   and	   IFNs	   and	   displays	   potent	   antiviral	   activity	   against	   select	   virus	  infections	   in	   vivo.	   J	   Virol	  80,	   4501-­‐4509,	   doi:10.1128/JVI.80.9.4501-­‐4509.2006	  (2006).	  27	   Prokunina-­‐Olsson,	  L.	  et	  al.	  A	  variant	  upstream	  of	   IFNL3	  (IL28B)	  creating	  a	  new	  interferon	  gene	  IFNL4	  is	  associated	  with	  impaired	  clearance	  of	  hepatitis	  C	  virus.	  
Nat	  Genet	  45,	  164-­‐171,	  doi:10.1038/ng.2521	  (2013).	  28	   Heim,	  M.	  H.,	  Bochud,	  P.	  Y.	  &	  George,	   J.	  Host	   -­‐	  hepatitis	  C	  viral	   interactions:	  The	  role	  of	  genetics.	  J	  Hepatol	  65,	  S22-­‐32,	  doi:10.1016/j.jhep.2016.07.037	  (2016).	  29	   Osterlund,	   P.	   I.,	   Pietila,	   T.	   E.,	   Veckman,	   V.,	   Kotenko,	   S.	   V.	   &	   Julkunen,	   I.	   IFN	  regulatory	  factor	  family	  members	  differentially	  regulate	  the	  expression	  of	  type	  III	  IFN	  (IFN-­‐lambda)	  genes.	  J	  Immunol	  179,	  3434-­‐3442	  (2007).	  30	   Onoguchi,	   K.	   et	   al.	   Viral	   infections	   activate	   types	   I	   and	   III	   interferon	   genes	  through	   a	   common	   mechanism.	   J	   Biol	   Chem	   282,	   7576-­‐7581,	  doi:10.1074/jbc.M608618200	  (2007).	  31	   Coccia,	   E.	   M.	   et	   al.	   Viral	   infection	   and	   Toll-­‐like	   receptor	   agonists	   induce	   a	  differential	  expression	  of	   type	  I	  and	   lambda	   interferons	   in	  human	  plasmacytoid	  and	   monocyte-­‐derived	   dendritic	   cells.	   Eur	   J	   Immunol	   34,	   796-­‐805,	  doi:10.1002/eji.200324610	  (2004).	  32	   Heim,	   M.	   H.	   &	   Thimme,	   R.	   Innate	   and	   adaptive	   immune	   responses	   in	   HCV	  infections.	  J	  Hepatol	  61,	  S14-­‐25,	  doi:10.1016/j.jhep.2014.06.035	  (2014).	  33	   Hermant,	   P.	   &	  Michiels,	   T.	   Interferon-­‐lambda	   in	   the	   context	   of	   viral	   infections:	  production,	   response	   and	   therapeutic	   implications.	   J	   Innate	   Immun	  6,	   563-­‐574,	  doi:10.1159/000360084	  (2014).	  34	   Hamming,	  O.	   J.	  et	  al.	   Interferon	   lambda	  4	  signals	  via	   the	   IFNlambda	  receptor	   to	  regulate	  antiviral	  activity	  against	  HCV	  and	  coronaviruses.	  EMBO	  J	  32,	  3055-­‐3065,	  doi:10.1038/emboj.2013.232	  (2013).	  
V	  References	  
	  143	  
35	   Donnelly,	  R.	  P.,	  Sheikh,	  F.,	  Kotenko,	  S.	  V.	  &	  Dickensheets,	  H.	  The	  expanded	  family	  of	  class	  II	  cytokines	  that	  share	  the	  IL-­‐10	  receptor-­‐2	  (IL-­‐10R2)	  chain.	  J	  Leukoc	  Biol	  
76,	  314-­‐321,	  doi:10.1189/jlb.0204117	  (2004).	  36	   Mordstein,	  M.	  et	  al.	  Lambda	  interferon	  renders	  epithelial	  cells	  of	  the	  respiratory	  and	   gastrointestinal	   tracts	   resistant	   to	   viral	   infections.	   J	   Virol	   84,	   5670-­‐5677,	  doi:10.1128/JVI.00272-­‐10	  (2010).	  37	   Mordstein,	   M.,	   Michiels,	   T.	   &	   Staeheli,	   P.	  What	   have	  we	   learned	   from	   the	   IL28	  receptor	   knockout	   mouse?	   J	   Interferon	   Cytokine	   Res	   30,	   579-­‐584,	  doi:10.1089/jir.2010.0061	  (2010).	  38	   Sommereyns,	   C.,	   Paul,	   S.,	   Staeheli,	   P.	  &	  Michiels,	  T.	   IFN-­‐lambda	   (IFN-­‐lambda)	   is	  expressed	  in	  a	  tissue-­‐dependent	  fashion	  and	  primarily	  acts	  on	  epithelial	  cells	   in	  vivo.	  PLoS	  Pathog	  4,	  e1000017,	  doi:10.1371/journal.ppat.1000017	  (2008).	  39	   Wack,	  A.,	  Terczynska-­‐Dyla,	  E.	  &	  Hartmann,	  R.	  Guarding	  the	  frontiers:	  the	  biology	  of	  type	  III	  interferons.	  Nat	  Immunol	  16,	  802-­‐809,	  doi:10.1038/ni.3212	  (2015).	  40	   Muir,	  A.	  J.	  et	  al.	  A	  randomized	  phase	  2b	  study	  of	  peginterferon	  lambda-­‐1a	  for	  the	  treatment	   of	   chronic	   HCV	   infection.	   J	   Hepatol	   61,	   1238-­‐1246,	  doi:10.1016/j.jhep.2014.07.022	  (2014).	  41	   Doyle,	  S.	  E.	  et	  al.	  Interleukin-­‐29	  uses	  a	  type	  1	  interferon-­‐like	  program	  to	  promote	  antiviral	   responses	   in	   human	   hepatocytes.	   Hepatology	   44,	   896-­‐906,	  doi:10.1002/hep.21312	  (2006).	  42	   Key,	  F.	  M.	  et	  al.	   Selection	  on	  a	  variant	  associated	  with	   improved	  viral	   clearance	  drives	   local,	   adaptive	   pseudogenization	   of	   interferon	   lambda	   4	   (IFNL4).	   PLoS	  
Genet	  10,	  e1004681,	  doi:10.1371/journal.pgen.1004681	  (2014).	  43	   Uze,	   G.	   &	   Monneron,	   D.	   IL-­‐28	   and	   IL-­‐29:	   newcomers	   to	   the	   interferon	   family.	  
Biochimie	  89,	  729-­‐734,	  doi:10.1016/j.biochi.2007.01.008	  (2007).	  44	   Hermant,	   P.	   et	   al.	   Human	   but	   not	   mouse	   hepatocytes	   respond	   to	   interferon-­‐lambda	  in	  vivo.	  PLoS	  One	  9,	  e87906,	  doi:10.1371/journal.pone.0087906	  (2014).	  45	   Pestka,	   S.	   The	   human	   interferon	   alpha	   species	   and	   receptors.	   Biopolymers	   55,	  254-­‐287,	   doi:10.1002/1097-­‐0282(2000)55:4<254::AID-­‐BIP1001>3.0.CO;2-­‐1	  (2000).	  46	   Galani,	   I.	   E.,	   Koltsida,	   O.	   &	   Andreakos,	   E.	   Type	   III	   interferons	   (IFNs):	   Emerging	  Master	  Regulators	  of	  Immunity.	  Adv	  Exp	  Med	  Biol	  850,	  1-­‐15,	  doi:10.1007/978-­‐3-­‐319-­‐15774-­‐0_1	  (2015).	  47	   Tyrrell,	   D.	   A.	   Interferon	   produced	   by	   cultures	   of	   calf	   kidney	   cells.	   Nature	  
184(Suppl	  7),	  452-­‐453	  (1959).	  48	   Friedman,	   R.	   M.	   Clinical	   uses	   of	   interferons.	   Br	   J	   Clin	   Pharmacol	   65,	   158-­‐162,	  doi:10.1111/j.1365-­‐2125.2007.03055.x	  (2008).	  49	   Hoofnagle,	   J.	   H.	   et	   al.	   Treatment	   of	   chronic	   non-­‐A,non-­‐B	   hepatitis	   with	  recombinant	   human	   alpha	   interferon.	   A	   preliminary	   report.	  N	  Engl	   J	  Med	  315,	  1575-­‐1578,	  doi:10.1056/NEJM198612183152503	  (1986).	  50	   Hoofnagle,	  J.	  H.	  &	  Seeff,	  L.	  B.	  Peginterferon	  and	  ribavirin	  for	  chronic	  hepatitis	  C.	  N	  
Engl	  J	  Med	  355,	  2444-­‐2451,	  doi:10.1056/NEJMct061675	  (2006).	  51	   McHutchison,	  J.	  G.	  et	  al.	  Interferon	  alfa-­‐2b	  alone	  or	  in	  combination	  with	  ribavirin	  as	   initial	   treatment	   for	   chronic	   hepatitis	   C.	   Hepatitis	   Interventional	   Therapy	  Group.	   N	   Engl	   J	   Med	   339,	   1485-­‐1492,	   doi:10.1056/NEJM199811193392101	  (1998).	  52	   Poynard,	   T.	   et	   al.	   Randomised	   trial	   of	   interferon	   alpha2b	   plus	   ribavirin	   for	   48	  weeks	  or	  for	  24	  weeks	  versus	  interferon	  alpha2b	  plus	  placebo	  for	  48	  weeks	  for	  
V	  References	  	  
	  144	  
treatment	   of	   chronic	   infection	   with	   hepatitis	   C	   virus.	   International	   Hepatitis	  Interventional	  Therapy	  Group	  (IHIT).	  Lancet	  352,	  1426-­‐1432	  (1998).	  53	   Manns,	  M.	  P.	  et	  al.	  Peginterferon	  alfa-­‐2b	  plus	  ribavirin	  compared	  with	  interferon	  alfa-­‐2b	   plus	   ribavirin	   for	   initial	   treatment	   of	   chronic	   hepatitis	   C:	   a	   randomised	  trial.	  Lancet	  358,	  958-­‐965	  (2001).	  54	   Holmes,	   J.	   A.	   &	   Thompson,	   A.	   J.	   Interferon-­‐free	   combination	   therapies	   for	   the	  treatment	   of	   hepatitis	   C:	   current	   insights.	   Hepat	   Med	   7,	   51-­‐70,	  doi:10.2147/HMER.S55864	  (2015).	  55	   Quesada,	   J.	   R.,	   Reuben,	   J.,	   Manning,	   J.	   T.,	   Hersh,	   E.	   M.	   &	   Gutterman,	   J.	   U.	   Alpha	  interferon	  for	  induction	  of	  remission	  in	  hairy-­‐cell	  leukemia.	  N	  Engl	  J	  Med	  310,	  15-­‐18,	  doi:10.1056/NEJM198401053100104	  (1984).	  56	   Tsao,	  H.,	  Atkins,	  M.	  B.	  &	  Sober,	  A.	  J.	  Management	  of	  cutaneous	  melanoma.	  N	  Engl	  J	  
Med	  351,	  998-­‐1012,	  doi:10.1056/NEJMra041245	  (2004).	  57	   Ganem,	  D.	  &	  Prince,	  A.	  M.	  Hepatitis	  B	  virus	  infection-­‐-­‐natural	  history	  and	  clinical	  consequences.	   N	   Engl	   J	   Med	   350,	   1118-­‐1129,	   doi:10.1056/NEJMra031087	  (2004).	  58	   Jacobs,	  L.	  D.	  et	  al.	  Intramuscular	  interferon	  beta-­‐1a	  therapy	  initiated	  during	  a	  first	  demyelinating	   event	   in	  multiple	   sclerosis.	   CHAMPS	   Study	   Group.	  N	  Engl	   J	  Med	  
343,	  898-­‐904,	  doi:10.1056/NEJM200009283431301	  (2000).	  59	   Errante,	   P.	   R.,	   Frazao,	   J.	   B.	   &	   Condino-­‐Neto,	   A.	   The	   use	   of	   interferon-­‐gamma	  therapy	   in	   chronic	   granulomatous	   disease.	  Recent	  Pat	  Antiinfect	  Drug	  Discov	  3,	  225-­‐230	  (2008).	  60	   Lasfar,	  A.,	  Zloza,	  A.	  &	  Cohen-­‐Solal,	  K.	  A.	   IFN-­‐lambda	  therapy:	  current	  status	  and	  future	   perspectives.	   Drug	   Discov	   Today	   21,	   167-­‐171,	  doi:10.1016/j.drudis.2015.10.021	  (2016).	  61	   Ghany,	  M.	  G.,	  Strader,	  D.	  B.,	  Thomas,	  D.	  L.,	  Seeff,	  L.	  B.	  &	  American	  Association	  for	  the	   Study	   of	   Liver,	   D.	   Diagnosis,	  management,	   and	   treatment	   of	   hepatitis	   C:	   an	  update.	  Hepatology	  49,	  1335-­‐1374,	  doi:10.1002/hep.22759	  (2009).	  62	   Muir,	  A.	  J.	  et	  al.	  Phase	  1b	  study	  of	  pegylated	  interferon	  lambda	  1	  with	  or	  without	  ribavirin	   in	   patients	   with	   chronic	   genotype	   1	   hepatitis	   C	   virus	   infection.	  
Hepatology	  52,	  822-­‐832,	  doi:10.1002/hep.23743	  (2010).	  63	   Flisiak,	   R.	  et	  al.	   A	  Randomized	   Study	   of	   Peginterferon	  Lambda-­‐1a	  Compared	   to	  Peginterferon	  Alfa-­‐2a	   in	  Combination	  with	  Ribavirin	   and	  Telaprevir	   in	  Patients	  with	   Genotype-­‐1	   Chronic	   Hepatitis	   C.	   PLoS	   One	   11,	   e0164563,	  doi:10.1371/journal.pone.0164563	  (2016).	  64	   Stark,	   G.	   R.	   &	  Darnell,	   J.	   E.,	   Jr.	   The	   JAK-­‐STAT	   pathway	   at	   twenty.	   Immunity	  36,	  503-­‐514,	  doi:10.1016/j.immuni.2012.03.013	  (2012).	  65	   Larner,	  A.	  C.	  et	  al.	  Transcriptional	  induction	  of	  two	  genes	  in	  human	  cells	  by	  beta	  interferon.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  81,	  6733-­‐6737	  (1984).	  66	   Levy,	  D.	  E.	  &	  Darnell,	  J.	  E.,	  Jr.	  Stats:	  transcriptional	  control	  and	  biological	  impact.	  
Nat	  Rev	  Mol	  Cell	  Biol	  3,	  651-­‐662,	  doi:10.1038/nrm909	  (2002).	  67	   Aaronson,	  D.	  S.	  &	  Horvath,	  C.	  M.	  A	  road	  map	  for	  those	  who	  don't	  know	  JAK-­‐STAT.	  
Science	  296,	  1653-­‐1655,	  doi:10.1126/science.1071545	  (2002).	  68	   Heim,	  M.	  H.	  The	  Jak-­‐STAT	  pathway:	  cytokine	  signalling	  from	  the	  receptor	  to	  the	  nucleus.	   J	   Recept	   Signal	   Transduct	   Res	   19,	   75-­‐120,	  doi:10.3109/10799899909036638	  (1999).	  69	   Darnell,	  J.	  E.,	  Jr.	  STATs	  and	  gene	  regulation.	  Science	  277,	  1630-­‐1635	  (1997).	  70	   Wilks,	  A.	  F.	  Two	  putative	  protein-­‐tyrosine	  kinases	  identified	  by	  application	  of	  the	  polymerase	  chain	  reaction.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  86,	  1603-­‐1607	  (1989).	  
V	  References	  
	  145	  
71	   Wilks,	   A.	   F.	   et	   al.	   Two	   novel	   protein-­‐tyrosine	   kinases,	   each	   with	   a	   second	  phosphotransferase-­‐related	   catalytic	   domain,	   define	   a	   new	   class	   of	   protein	  kinase.	  Mol	  Cell	  Biol	  11,	  2057-­‐2065	  (1991).	  72	   Firmbach-­‐Kraft,	   I.,	   Byers,	  M.,	   Shows,	   T.,	   Dalla-­‐Favera,	   R.	   &	   Krolewski,	   J.	   J.	   tyk2,	  prototype	   of	   a	   novel	   class	   of	   non-­‐receptor	   tyrosine	   kinase	   genes.	  Oncogene	   5,	  1329-­‐1336	  (1990).	  73	   Velazquez,	  L.,	  Fellous,	  M.,	  Stark,	  G.	  R.	  &	  Pellegrini,	  S.	  A	  protein	  tyrosine	  kinase	  in	  the	  interferon	  alpha/beta	  signaling	  pathway.	  Cell	  70,	  313-­‐322	  (1992).	  74	   Johnston,	   J.	  A.	  et	  al.	  Phosphorylation	  and	  activation	  of	   the	   Jak-­‐3	   Janus	  kinase	   in	  response	  to	  interleukin-­‐2.	  Nature	  370,	  151-­‐153,	  doi:10.1038/370151a0	  (1994).	  75	   Rane,	   S.	   G.	   &	   Reddy,	   E.	   P.	   JAK3:	   a	   novel	   JAK	   kinase	   associated	   with	   terminal	  differentiation	  of	  hematopoietic	  cells.	  Oncogene	  9,	  2415-­‐2423	  (1994).	  76	   Witthuhn,	   B.	   A.	   et	   al.	   Involvement	   of	   the	   Jak-­‐3	   Janus	   kinase	   in	   signalling	   by	  interleukins	   2	   and	   4	   in	   lymphoid	   and	   myeloid	   cells.	   Nature	   370,	   153-­‐157,	  doi:10.1038/370153a0	  (1994).	  77	   Muller,	   M.	   et	   al.	   The	   protein	   tyrosine	   kinase	   JAK1	   complements	   defects	   in	  interferon-­‐alpha/beta	   and	   -­‐gamma	   signal	   transduction.	   Nature	   366,	   129-­‐135,	  doi:10.1038/366129a0	  (1993).	  78	   Colamonici,	   O.	   R.,	   Uyttendaele,	   H.,	   Domanski,	   P.,	   Yan,	   H.	   &	   Krolewski,	   J.	   J.	  p135tyk2,	  an	  interferon-­‐alpha-­‐activated	  tyrosine	  kinase,	  is	  physically	  associated	  with	  an	  interferon-­‐alpha	  receptor.	  J	  Biol	  Chem	  269,	  3518-­‐3522	  (1994).	  79	   Kotenko,	   S.	   V.	   &	   Durbin,	   J.	   E.	   Contribution	   of	   Type	   III	   Interferons	   to	   Antiviral	  Immunity;	   Location,	   Location,	   Location.	   J	   Biol	   Chem,	  doi:10.1074/jbc.R117.777102	  (2017).	  80	   Kotenko,	   S.	   V.	   et	   al.	   Identification	   and	   functional	   characterization	   of	   a	   second	  chain	   of	   the	   interleukin-­‐10	   receptor	   complex.	   EMBO	   J	   16,	   5894-­‐5903,	  doi:10.1093/emboj/16.19.5894	  (1997).	  81	   Igarashi,	   K.	   et	   al.	   Interferon-­‐gamma	   induces	   tyrosine	   phosphorylation	   of	  interferon-­‐gamma	  receptor	  and	  regulated	  association	  of	  protein	  tyrosine	  kinases,	  Jak1	  and	  Jak2,	  with	  its	  receptor.	  J	  Biol	  Chem	  269,	  14333-­‐14336	  (1994).	  82	   Kotenko,	  S.	  V.	  et	  al.	  Interaction	  between	  the	  components	  of	  the	  interferon	  gamma	  receptor	  complex.	  J	  Biol	  Chem	  270,	  20915-­‐20921	  (1995).	  83	   Copeland,	  N.	   G.	  et	  al.	   Distribution	   of	   the	  mammalian	   Stat	   gene	   family	   in	  mouse	  chromosomes.	  Genomics	  29,	  225-­‐228	  (1995).	  84	   Schindler,	   C.,	   Fu,	   X.	   Y.,	   Improta,	   T.,	   Aebersold,	   R.	   &	  Darnell,	   J.	   E.,	   Jr.	   Proteins	   of	  transcription	  factor	  ISGF-­‐3:	  one	  gene	  encodes	  the	  91-­‐and	  84-­‐kDa	  ISGF-­‐3	  proteins	  that	   are	   activated	   by	   interferon	   alpha.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  89,	   7836-­‐7839	  (1992).	  85	   Zhong,	  Z.,	  Wen,	  Z.	  &	  Darnell,	   J.	  E.,	   Jr.	   Stat3:	  a	  STAT	   family	  member	  activated	  by	  tyrosine	   phosphorylation	   in	   response	   to	   epidermal	   growth	   factor	   and	  interleukin-­‐6.	  Science	  264,	  95-­‐98	  (1994).	  86	   Zhong,	   Z.,	  Wen,	  Z.	  &	  Darnell,	   J.	   E.,	   Jr.	   Stat3	  and	  Stat4:	  members	  of	   the	   family	  of	  signal	   transducers	   and	   activators	   of	   transcription.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  91,	  4806-­‐4810	  (1994).	  87	   Yamamoto,	   K.	   et	   al.	   Stat4,	   a	   novel	   gamma	   interferon	   activation	   site-­‐binding	  protein	   expressed	   in	   early	  myeloid	   differentiation.	  Mol	  Cell	  Biol	  14,	   4342-­‐4349	  (1994).	  
V	  References	  	  
	  146	  
88	   Wakao,	   H.,	   Gouilleux,	   F.	   &	   Groner,	   B.	   Mammary	   gland	   factor	   (MGF)	   is	   a	   novel	  member	   of	   the	   cytokine	   regulated	   transcription	   factor	   gene	   family	   and	   confers	  the	  prolactin	  response.	  EMBO	  J	  13,	  2182-­‐2191	  (1994).	  89	   Mui,	   A.	   L.,	  Wakao,	   H.,	   O'Farrell,	   A.	   M.,	   Harada,	   N.	   &	  Miyajima,	   A.	   Interleukin-­‐3,	  granulocyte-­‐macrophage	   colony	   stimulating	   factor	   and	   interleukin-­‐5	   transduce	  signals	  through	  two	  STAT5	  homologs.	  EMBO	  J	  14,	  1166-­‐1175	  (1995).	  90	   Hou,	  J.	  et	  al.	  An	  interleukin-­‐4-­‐induced	  transcription	  factor:	  IL-­‐4	  Stat.	  Science	  265,	  1701-­‐1706	  (1994).	  91	   Shuai,	   K.,	   Stark,	   G.	   R.,	   Kerr,	   I.	   M.	   &	   Darnell,	   J.	   E.,	   Jr.	   A	   single	   phosphotyrosine	  residue	  of	  Stat91	  required	  for	  gene	  activation	  by	  interferon-­‐gamma.	  Science	  261,	  1744-­‐1746	  (1993).	  92	   Heim,	  M.	  H.,	  Kerr,	   I.	  M.,	  Stark,	  G.	  R.	  &	  Darnell,	   J.	  E.,	   Jr.	  Contribution	  of	  STAT	  SH2	  groups	   to	   specific	   interferon	   signaling	   by	   the	   Jak-­‐STAT	   pathway.	   Science	   267,	  1347-­‐1349	  (1995).	  93	   Schindler,	   C.,	   Shuai,	   K.,	   Prezioso,	   V.	   R.	   &	   Darnell,	   J.	   E.,	   Jr.	   Interferon-­‐dependent	  tyrosine	   phosphorylation	   of	   a	   latent	   cytoplasmic	   transcription	   factor.	   Science	  
257,	  809-­‐813	  (1992).	  94	   Shuai,	   K.	   et	   al.	   Interferon	   activation	   of	   the	   transcription	   factor	   Stat91	   involves	  dimerization	  through	  SH2-­‐phosphotyrosyl	  peptide	  interactions.	  Cell	  76,	  821-­‐828	  (1994).	  95	   Zhou,	   Z.	   et	  al.	   Type	   III	   interferon	   (IFN)	   induces	   a	   type	   I	   IFN-­‐like	   response	   in	   a	  restricted	  subset	  of	  cells	  through	  signaling	  pathways	  involving	  both	  the	  Jak-­‐STAT	  pathway	   and	   the	   mitogen-­‐activated	   protein	   kinases.	   J	   Virol	   81,	   7749-­‐7758,	  doi:10.1128/JVI.02438-­‐06	  (2007).	  96	   Veals,	  S.	  A.	  et	  al.	  Subunit	  of	  an	  alpha-­‐interferon-­‐responsive	  transcription	  factor	  is	  related	  to	  interferon	  regulatory	  factor	  and	  Myb	  families	  of	  DNA-­‐binding	  proteins.	  
Mol	  Cell	  Biol	  12,	  3315-­‐3324	  (1992).	  97	   Levy,	  D.	  E.,	  Kessler,	  D.	  S.,	  Pine,	  R.,	  Reich,	  N.	  &	  Darnell,	  J.	  E.,	  Jr.	  Interferon-­‐induced	  nuclear	  factors	  that	  bind	  a	  shared	  promoter	  element	  correlate	  with	  positive	  and	  negative	  transcriptional	  control.	  Genes	  Dev	  2,	  383-­‐393	  (1988).	  98	   Levy,	   D.	   E.,	   Kessler,	   D.	   S.,	   Pine,	   R.	   &	   Darnell,	   J.	   E.,	   Jr.	   Cytoplasmic	   activation	   of	  ISGF3,	   the	   positive	   regulator	   of	   interferon-­‐alpha-­‐stimulated	   transcription,	  reconstituted	  in	  vitro.	  Genes	  Dev	  3,	  1362-­‐1371	  (1989).	  99	   Levy,	   D.,	   Larner,	   A.,	   Chaudhuri,	   A.,	   Babiss,	   L.	   E.	   &	   Darnell,	   J.	   E.,	   Jr.	   Interferon-­‐stimulated	   transcription:	   isolation	   of	   an	   inducible	   gene	   and	   identification	   of	   its	  regulatory	  region.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  83,	  8929-­‐8933	  (1986).	  100	   Marcello,	   T.	   et	   al.	   Interferons	   alpha	   and	   lambda	   inhibit	   hepatitis	   C	   virus	  replication	   with	   distinct	   signal	   transduction	   and	   gene	   regulation	   kinetics.	  
Gastroenterology	  131,	  1887-­‐1898,	  doi:10.1053/j.gastro.2006.09.052	  (2006).	  101	   Decker,	  T.,	   Lew,	  D.	   J.,	  Mirkovitch,	   J.	  &	  Darnell,	   J.	   E.,	   Jr.	   Cytoplasmic	  activation	  of	  GAF,	  an	  IFN-­‐gamma-­‐regulated	  DNA-­‐binding	  factor.	  EMBO	  J	  10,	  927-­‐932	  (1991).	  102	   Meraz,	   M.	   A.	   et	   al.	   Targeted	   disruption	   of	   the	   Stat1	   gene	   in	   mice	   reveals	  unexpected	   physiologic	   specificity	   in	   the	   JAK-­‐STAT	   signaling	   pathway.	   Cell	  84,	  431-­‐442	  (1996).	  103	   Durbin,	   J.	  E.,	  Hackenmiller,	  R.,	   Simon,	  M.	  C.	  &	  Levy,	  D.	  E.	  Targeted	  disruption	  of	  the	  mouse	  Stat1	  gene	  results	   in	  compromised	   innate	   immunity	   to	  viral	  disease.	  
Cell	  84,	  443-­‐450	  (1996).	  104	   Dickensheets,	  H.,	  Sheikh,	  F.,	  Park,	  O.,	  Gao,	  B.	  &	  Donnelly,	  R.	  P.	  Interferon-­‐lambda	  (IFN-­‐lambda)	   induces	   signal	   transduction	   and	   gene	   expression	   in	   human	  
V	  References	  
	  147	  
hepatocytes,	   but	   not	   in	   lymphocytes	   or	   monocytes.	   J	   Leukoc	   Biol	   93,	   377-­‐385,	  doi:10.1189/jlb.0812395	  (2013).	  105	   Ronnblom,	   L.	   The	   type	   I	   interferon	   system	   in	   the	   etiopathogenesis	   of	  autoimmune	   diseases.	   Ups	   J	   Med	   Sci	   116,	   227-­‐237,	  doi:10.3109/03009734.2011.624649	  (2011).	  106	   Ronnblom,	   L.	   The	   importance	   of	   the	   type	   I	   interferon	   system	   in	   autoimmunity.	  
Clin	  Exp	  Rheumatol	  34,	  21-­‐24	  (2016).	  107	   Porritt,	   R.	   A.	   &	   Hertzog,	   P.	   J.	   Dynamic	   control	   of	   type	   I	   IFN	   signalling	   by	   an	  integrated	   network	   of	   negative	   regulators.	   Trends	   Immunol	   36,	   150-­‐160,	  doi:10.1016/j.it.2015.02.002	  (2015).	  108	   Lee-­‐Kirsch,	   M.	   A.	   The	   Type	   I	   Interferonopathies.	   Annu	   Rev	   Med	   68,	   297-­‐315,	  doi:10.1146/annurev-­‐med-­‐050715-­‐104506	  (2017).	  109	   Malakhova,	   O.	   A.	   et	   al.	   UBP43	   is	   a	   novel	   regulator	   of	   interferon	   signaling	  independent	   of	   its	   ISG15	   isopeptidase	   activity.	   EMBO	   J	   25,	   2358-­‐2367,	  doi:10.1038/sj.emboj.7601149	  (2006).	  110	   Wormald,	  S.	  &	  Hilton,	  D.	  J.	  Inhibitors	  of	  cytokine	  signal	  transduction.	  J	  Biol	  Chem	  
279,	  821-­‐824,	  doi:10.1074/jbc.R300030200	  (2004).	  111	   Shuai,	  K.	  &	  Liu,	  B.	  Regulation	  of	  JAK-­‐STAT	  signalling	  in	  the	  immune	  system.	  Nat	  
Rev	  Immunol	  3,	  900-­‐911,	  doi:10.1038/nri1226	  (2003).	  112	   Greenhalgh,	  C.	  J.	  &	  Hilton,	  D.	  J.	  Negative	  regulation	  of	  cytokine	  signaling.	  J	  Leukoc	  
Biol	  70,	  348-­‐356	  (2001).	  113	   Greenhalgh,	  C.	   J.,	  Miller,	  M.	  E.,	  Hilton,	  D.	   J.	  &	  Lund,	  P.	  K.	  Suppressors	  of	  cytokine	  signaling:	   Relevance	   to	   gastrointestinal	   function	   and	   disease.	   Gastroenterology	  
123,	  2064-­‐2081,	  doi:10.1053/gast.2002.37068	  (2002).	  114	   Myers,	  M.	  P.	  et	  al.	  TYK2	  and	  JAK2	  are	  substrates	  of	  protein-­‐tyrosine	  phosphatase	  1B.	  J	  Biol	  Chem	  276,	  47771-­‐47774,	  doi:10.1074/jbc.C100583200	  (2001).	  115	   Feldhammer,	   M.,	   Uetani,	   N.,	   Miranda-­‐Saavedra,	   D.	   &	   Tremblay,	   M.	   L.	   PTP1B:	   a	  simple	   enzyme	   for	   a	   complex	   world.	   Crit	   Rev	   Biochem	   Mol	   Biol	   48,	   430-­‐445,	  doi:10.3109/10409238.2013.819830	  (2013).	  116	   Abram,	   C.	   L.	   &	   Lowell,	   C.	   A.	   Shp1	   function	   in	   myeloid	   cells.	   J	   Leukoc	   Biol,	  doi:10.1189/jlb.2MR0317-­‐105R	  (2017).	  117	   Neel,	  B.	  G.,	  Gu,	  H.	  &	  Pao,	  L.	  The	   'Shp'ing	  news:	  SH2	  domain-­‐containing	   tyrosine	  phosphatases	   in	   cell	   signaling.	   Trends	   Biochem	   Sci	   28,	   284-­‐293,	  doi:10.1016/S0968-­‐0004(03)00091-­‐4	  (2003).	  118	   You,	  M.,	  Yu,	  D.	  H.	  &	  Feng,	  G.	  S.	  Shp-­‐2	  tyrosine	  phosphatase	  functions	  as	  a	  negative	  regulator	  of	  the	  interferon-­‐stimulated	  Jak/STAT	  pathway.	  Mol	  Cell	  Biol	  19,	  2416-­‐2424	  (1999).	  119	   Qu,	   C.	   K.	   Role	   of	   the	   SHP-­‐2	   tyrosine	   phosphatase	   in	   cytokine-­‐induced	   signaling	  and	  cellular	  response.	  Biochim	  Biophys	  Acta	  1592,	  297-­‐301	  (2002).	  120	   Bourdeau,	   A.,	   Dube,	   N.	   &	   Tremblay,	   M.	   L.	   Cytoplasmic	   protein	   tyrosine	  phosphatases,	  regulation	  and	  function:	  the	  roles	  of	  PTP1B	  and	  TC-­‐PTP.	  Curr	  Opin	  
Cell	  Biol	  17,	  203-­‐209,	  doi:10.1016/j.ceb.2005.02.001	  (2005).	  121	   Simoncic,	  P.	  D.,	  Lee-­‐Loy,	  A.,	  Barber,	  D.	  L.,	  Tremblay,	  M.	  L.	  &	  McGlade,	  C.	   J.	  The	  T	  cell	  protein	  tyrosine	  phosphatase	  is	  a	  negative	  regulator	  of	  janus	  family	  kinases	  1	  and	  3.	  Curr	  Biol	  12,	  446-­‐453	  (2002).	  122	   Heinonen,	   K.	   M.	   et	   al.	   T-­‐cell	   protein	   tyrosine	   phosphatase	   deletion	   results	   in	  progressive	   systemic	   inflammatory	   disease.	   Blood	   103,	   3457-­‐3464,	  doi:10.1182/blood-­‐2003-­‐09-­‐3153	  (2004).	  
V	  References	  	  
	  148	  
123	   ten	  Hoeve,	  J.	  et	  al.	  Identification	  of	  a	  nuclear	  Stat1	  protein	  tyrosine	  phosphatase.	  
Mol	  Cell	  Biol	  22,	  5662-­‐5668	  (2002).	  124	   Irie-­‐Sasaki,	  J.	  et	  al.	  CD45	  is	  a	  JAK	  phosphatase	  and	  negatively	  regulates	  cytokine	  receptor	  signalling.	  Nature	  409,	  349-­‐354,	  doi:10.1038/35053086	  (2001).	  125	   Ratei,	   R.	   et	   al.	   Immunophenotype	   and	   clinical	   characteristics	   of	   CD45-­‐negative	  and	   CD45-­‐positive	   childhood	   acute	   lymphoblastic	   leukemia.	   Ann	   Hematol	   77,	  107-­‐114	  (1998).	  126	   Liu,	  B.	  et	  al.	  Inhibition	  of	  Stat1-­‐mediated	  gene	  activation	  by	  PIAS1.	  Proc	  Natl	  Acad	  
Sci	  U	  S	  A	  95,	  10626-­‐10631	  (1998).	  127	   Chung,	  C.	  D.	  et	  al.	  Specific	  inhibition	  of	  Stat3	  signal	  transduction	  by	  PIAS3.	  Science	  
278,	  1803-­‐1805	  (1997).	  128	   Yoshimura,	   A.	   et	   al.	   A	   novel	   cytokine-­‐inducible	   gene	   CIS	   encodes	   an	   SH2-­‐containing	   protein	   that	   binds	   to	   tyrosine-­‐phosphorylated	   interleukin	   3	   and	  erythropoietin	  receptors.	  EMBO	  J	  14,	  2816-­‐2826	  (1995).	  129	   Starr,	  R.	  et	  al.	  A	  family	  of	  cytokine-­‐inducible	  inhibitors	  of	  signalling.	  Nature	  387,	  917-­‐921,	  doi:10.1038/43206	  (1997).	  130	   Endo,	   T.	   A.	   et	   al.	   A	   new	   protein	   containing	   an	   SH2	   domain	   that	   inhibits	   JAK	  kinases.	  Nature	  387,	  921-­‐924,	  doi:10.1038/43213	  (1997).	  131	   Naka,	   T.	   et	   al.	   Structure	   and	   function	   of	   a	   new	   STAT-­‐induced	   STAT	   inhibitor.	  
Nature	  387,	  924-­‐929,	  doi:10.1038/43219	  (1997).	  132	   Hilton,	   D.	   J.	   et	   al.	   Twenty	   proteins	   containing	   a	   C-­‐terminal	   SOCS	   box	   form	   five	  structural	  classes.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  95,	  114-­‐119	  (1998).	  133	   Sasaki,	   A.	   et	   al.	   Cytokine-­‐inducible	   SH2	   protein-­‐3	   (CIS3/SOCS3)	   inhibits	   Janus	  tyrosine	   kinase	   by	   binding	   through	   the	   N-­‐terminal	   kinase	   inhibitory	   region	   as	  well	  as	  SH2	  domain.	  Genes	  Cells	  4,	  339-­‐351	  (1999).	  134	   Yasukawa,	   H.	   et	   al.	   The	   JAK-­‐binding	   protein	   JAB	   inhibits	   Janus	   tyrosine	   kinase	  activity	   through	   binding	   in	   the	   activation	   loop.	   EMBO	   J	   18,	   1309-­‐1320,	  doi:10.1093/emboj/18.5.1309	  (1999).	  135	   Piessevaux,	  J.,	  Lavens,	  D.,	  Peelman,	  F.	  &	  Tavernier,	  J.	  The	  many	  faces	  of	  the	  SOCS	  box.	  Cytokine	  Growth	  Factor	  Rev	  19,	  371-­‐381,	  doi:10.1016/j.cytogfr.2008.08.006	  (2008).	  136	   Nicholson,	   S.	   E.	  et	  al.	   Suppressor	   of	   cytokine	   signaling-­‐3	  preferentially	   binds	   to	  the	  SHP-­‐2-­‐binding	  site	  on	  the	  shared	  cytokine	  receptor	  subunit	  gp130.	  Proc	  Natl	  
Acad	  Sci	  U	  S	  A	  97,	  6493-­‐6498,	  doi:10.1073/pnas.100135197	  (2000).	  137	   Giordanetto,	   F.	   &	   Kroemer,	   R.	   T.	   A	   three-­‐dimensional	   model	   of	   Suppressor	   Of	  Cytokine	  Signalling	  1	  (SOCS-­‐1).	  Protein	  Eng	  16,	  115-­‐124	  (2003).	  138	   Babon,	  J.	  J.	  et	  al.	  Suppression	  of	  cytokine	  signaling	  by	  SOCS3:	  characterization	  of	  the	   mode	   of	   inhibition	   and	   the	   basis	   of	   its	   specificity.	   Immunity	   36,	   239-­‐250,	  doi:10.1016/j.immuni.2011.12.015	  (2012).	  139	   Krebs,	   D.	   L.	   &	   Hilton,	   D.	   J.	   SOCS	   proteins:	   negative	   regulators	   of	   cytokine	  signaling.	  Stem	  Cells	  19,	  378-­‐387,	  doi:10.1634/stemcells.19-­‐5-­‐378	  (2001).	  140	   Yoshimura,	   A.,	   Suzuki,	   M.,	   Sakaguchi,	   R.,	   Hanada,	   T.	   &	   Yasukawa,	   H.	   SOCS,	  Inflammation,	   and	   Autoimmunity.	   Front	   Immunol	   3,	   20,	  doi:10.3389/fimmu.2012.00020	  (2012).	  141	   Matsumoto,	  A.	  et	  al.	   Suppression	  of	   STAT5	   functions	   in	   liver,	  mammary	  glands,	  and	  T	  cells	   in	  cytokine-­‐inducible	  SH2-­‐containing	  protein	  1	   transgenic	  mice.	  Mol	  
Cell	  Biol	  19,	  6396-­‐6407	  (1999).	  
V	  References	  
	  149	  
142	   Ram,	   P.	   A.	   &	   Waxman,	   D.	   J.	   Role	   of	   the	   cytokine-­‐inducible	   SH2	   protein	   CIS	   in	  desensitization	  of	  STAT5b	  signaling	  by	  continuous	  growth	  hormone.	  J	  Biol	  Chem	  
275,	  39487-­‐39496,	  doi:10.1074/jbc.M004755200	  (2000).	  143	   Kile,	   B.	   T.	   et	   al.	   The	   SOCS	   box:	   a	   tale	   of	   destruction	   and	   degradation.	   Trends	  
Biochem	  Sci	  27,	  235-­‐241	  (2002).	  144	   Babon,	   J.	   J.	  et	  al.	  The	  SOCS	  box	  domain	  of	  SOCS3:	  structure	  and	  interaction	  with	  the	   elonginBC-­‐cullin5	   ubiquitin	   ligase.	   J	   Mol	   Biol	   381,	   928-­‐940,	  doi:10.1016/j.jmb.2008.06.038	  (2008).	  145	   Fenner,	   J.	   E.	   et	   al.	   Suppressor	   of	   cytokine	   signaling	   1	   regulates	   the	   immune	  response	   to	   infection	   by	   a	   unique	   inhibition	   of	   type	   I	   interferon	   activity.	   Nat	  
Immunol	  7,	  33-­‐39,	  doi:10.1038/ni1287	  (2006).	  146	   Egli,	  A.,	  Santer,	  D.	  M.,	  O'Shea,	  D.,	  Tyrrell,	  D.	  L.	  &	  Houghton,	  M.	  The	  impact	  of	  the	  interferon-­‐lambda	   family	  on	   the	   innate	   and	  adaptive	   immune	   response	   to	   viral	  infections.	  Emerg	  Microbes	  Infect	  3,	  e51,	  doi:10.1038/emi.2014.51	  (2014).	  147	   Makowska,	  Z.,	  Duong,	  F.	  H.,	  Trincucci,	  G.,	  Tough,	  D.	  F.	  &	  Heim,	  M.	  H.	   Interferon-­‐beta	   and	   interferon-­‐lambda	   signaling	   is	   not	   affected	   by	   interferon-­‐induced	  refractoriness	   to	   interferon-­‐alpha	   in	   vivo.	   Hepatology	   53,	   1154-­‐1163,	  doi:10.1002/hep.24189	  (2011).	  148	   Sarasin-­‐Filipowicz,	  M.	  et	  al.	  Alpha	   interferon	   induces	   long-­‐lasting	   refractoriness	  of	  JAK-­‐STAT	  signaling	  in	  the	  mouse	  liver	  through	  induction	  of	  USP18/UBP43.	  Mol	  
Cell	  Biol	  29,	  4841-­‐4851,	  doi:10.1128/MCB.00224-­‐09	  (2009).	  149	   Wormald,	   S.	   et	   al.	   The	   comparative	   roles	   of	   suppressor	   of	   cytokine	   signaling-­‐1	  and	  -­‐3	  in	  the	  inhibition	  and	  desensitization	  of	  cytokine	  signaling.	  J	  Biol	  Chem	  281,	  11135-­‐11143,	  doi:10.1074/jbc.M509595200	  (2006).	  150	   Brand,	  S.	  et	  al.	  IL-­‐28A	  and	  IL-­‐29	  mediate	  antiproliferative	  and	  antiviral	  signals	  in	  intestinal	   epithelial	   cells	   and	   murine	   CMV	   infection	   increases	   colonic	   IL-­‐28A	  expression.	   Am	   J	   Physiol	   Gastrointest	   Liver	   Physiol	   289,	   G960-­‐968,	  doi:10.1152/ajpgi.00126.2005	  (2005).	  151	   Nicholson,	   S.	   E.	   &	   Hilton,	   D.	   J.	   The	   SOCS	   proteins:	   a	   new	   family	   of	   negative	  regulators	  of	  signal	  transduction.	  J	  Leukoc	  Biol	  63,	  665-­‐668	  (1998).	  152	   Babon,	   J.	   J.,	  Varghese,	  L.	  N.	  &	  Nicola,	  N.	  A.	   Inhibition	  of	   IL-­‐6	   family	  cytokines	  by	  SOCS3.	  Semin	  Immunol	  26,	  13-­‐19,	  doi:10.1016/j.smim.2013.12.004	  (2014).	  153	   Song,	  M.	  M.	  &	  Shuai,	  K.	  The	  suppressor	  of	  cytokine	  signaling	  (SOCS)	  1	  and	  SOCS3	  but	  not	  SOCS2	  proteins	  inhibit	  interferon-­‐mediated	  antiviral	  and	  antiproliferative	  activities.	  Journal	  of	  Biological	  Chemistry	  273,	  35056-­‐35062	  (1998).	  154	   Nicholson,	   S.	   E.	   et	   al.	   Mutational	   analyses	   of	   the	   SOCS	   proteins	   suggest	   a	   dual	  domain	  requirement	  but	  distinct	  mechanisms	  for	  inhibition	  of	  LIF	  and	  IL-­‐6	  signal	  transduction.	  EMBO	  J	  18,	  375-­‐385,	  doi:10.1093/emboj/18.2.375	  (1999).	  155	   Vlotides,	  G.	  et	  al.	  SOCS-­‐1	  and	  SOCS-­‐3	  inhibit	  IFN-­‐alpha-­‐induced	  expression	  of	  the	  antiviral	   proteins	   2,5-­‐OAS	   and	  MxA.	  Biochem	  Biophys	   Res	   Commun	  320,	   1007-­‐1014,	  doi:10.1016/j.bbrc.2004.06.051	  (2004).	  156	   Croker,	  B.	  A.	  et	  al.	  SOCS3	  negatively	  regulates	  IL-­‐6	  signaling	  in	  vivo.	  Nat	  Immunol	  
4,	  540-­‐545,	  doi:10.1038/ni931	  (2003).	  157	   Brand,	  S.	  et	  al.	  SOCS-­‐1	  inhibits	  expression	  of	  the	  antiviral	  proteins	  2',5'-­‐OAS	  and	  MxA	  induced	  by	  the	  novel	  interferon-­‐lambdas	  IL-­‐28A	  and	  IL-­‐29.	  Biochem	  Biophys	  
Res	  Commun	  331,	  543-­‐548,	  doi:10.1016/j.bbrc.2005.04.004	  (2005).	  158	   Zitzmann,	   K.	   et	   al.	   Novel	   interferon-­‐lambdas	   induce	   antiproliferative	   effects	   in	  neuroendocrine	   tumor	   cells.	   Biochem	   Biophys	   Res	   Commun	   344,	   1334-­‐1341,	  doi:10.1016/j.bbrc.2006.04.043	  (2006).	  
V	  References	  	  
	  150	  
159	   Liu,	   B.,	   Chen,	   S.,	   Guan,	   Y.	  &	  Chen,	   L.	   Type	   III	   Interferon	   Induces	  Distinct	   SOCS1	  Expression	   Pattern	   that	   Contributes	   to	   Delayed	   but	   Prolonged	   Activation	   of	  Jak/STAT	  Signaling	  Pathway:	   Implications	   for	  Treatment	  Non-­‐Response	   in	  HCV	  Patients.	  PLoS	  One	  10,	  e0133800,	  doi:10.1371/journal.pone.0133800	  (2015).	  160	   Brysha,	   M.	   et	   al.	   Suppressor	   of	   cytokine	   signaling-­‐1	   attenuates	   the	   duration	   of	  interferon	   gamma	   signal	   transduction	   in	   vitro	   and	   in	   vivo.	   J	   Biol	   Chem	   276,	  22086-­‐22089,	  doi:10.1074/jbc.M102737200	  (2001).	  161	   Marine,	   J.	   C.	   et	   al.	   SOCS1	   deficiency	   causes	   a	   lymphocyte-­‐dependent	   perinatal	  lethality.	  Cell	  98,	  609-­‐616	  (1999).	  162	   Starr,	   R.	   et	   al.	   Liver	   degeneration	   and	   lymphoid	   deficiencies	   in	   mice	   lacking	  suppressor	   of	   cytokine	   signaling-­‐1.	   Proc	  Natl	   Acad	   Sci	   U	   S	   A	   95,	   14395-­‐14399	  (1998).	  163	   Alexander,	  W.	  S.	  et	  al.	  SOCS1	  is	  a	  critical	  inhibitor	  of	  interferon	  gamma	  signaling	  and	  prevents	  the	  potentially	  fatal	  neonatal	  actions	  of	  this	  cytokine.	  Cell	  98,	  597-­‐608	  (1999).	  164	   Marine,	  J.	  C.	  et	  al.	  SOCS3	  is	  essential	  in	  the	  regulation	  of	  fetal	  liver	  erythropoiesis.	  
Cell	  98,	  617-­‐627	  (1999).	  165	   Roberts,	   A.	   W.	   et	   al.	   Placental	   defects	   and	   embryonic	   lethality	   in	   mice	   lacking	  suppressor	   of	   cytokine	   signaling	   3.	   Proc	   Natl	   Acad	   Sci	   U	   S	   A	   98,	   9324-­‐9329,	  doi:10.1073/pnas.161271798	  (2001).	  166	   Honke,	  N.,	  Shaabani,	  N.,	  Zhang,	  D.	  E.,	  Hardt,	  C.	  &	  Lang,	  K.	  S.	  Multiple	  functions	  of	  USP18.	  Cell	  Death	  Dis	  7,	  e2444,	  doi:10.1038/cddis.2016.326	  (2016).	  167	   Liu,	  L.	  Q.	  et	  al.	  A	  novel	  ubiquitin-­‐specific	  protease,	  UBP43,	  cloned	  from	  leukemia	  fusion	   protein	   AML1-­‐ETO-­‐expressing	   mice,	   functions	   in	   hematopoietic	   cell	  differentiation.	  Mol	  Cell	  Biol	  19,	  3029-­‐3038	  (1999).	  168	   Schwer,	  H.	  et	  al.	  Cloning	  and	  characterization	  of	  a	  novel	  human	  ubiquitin-­‐specific	  protease,	   a	   homologue	   of	   murine	   UBP43	   (Usp18).	   Genomics	   65,	   44-­‐52,	  doi:10.1006/geno.2000.6148	  (2000).	  169	   Burkart,	   C.,	   Fan,	   J.	   B.	   &	   Zhang,	   D.	   E.	   Two	   independent	   mechanisms	   promote	  expression	  of	  an	  N-­‐terminal	   truncated	  USP18	   isoform	  with	  higher	  DeISGylation	  activity	   in	   the	   nucleus.	   J	   Biol	   Chem	   287,	   4883-­‐4893,	  doi:10.1074/jbc.M111.255570	  (2012).	  170	   Malakhov,	  M.	  P.,	  Malakhova,	  O.	  A.,	  Kim,	  K.	   I.,	  Ritchie,	  K.	   J.	  &	  Zhang,	  D.	  E.	  UBP43	  (USP18)	   specifically	   removes	   ISG15	   from	  conjugated	  proteins.	   J	  Biol	  Chem	  277,	  9976-­‐9981,	  doi:10.1074/jbc.M109078200	  (2002).	  171	   Malakhova,	  O.,	  Malakhov,	  M.,	  Hetherington,	  C.	  &	  Zhang,	  D.	  E.	  Lipopolysaccharide	  activates	   the	   expression	   of	   ISG15-­‐specific	   protease	   UBP43	   via	   interferon	  regulatory	  factor	  3.	  J	  Biol	  Chem	  277,	  14703-­‐14711,	  doi:10.1074/jbc.M111527200	  (2002).	  172	   Malakhov,	   M.	   P.	   et	   al.	   High-­‐throughput	   immunoblotting.	   Ubiquitiin-­‐like	   protein	  ISG15	  modifies	   key	   regulators	   of	   signal	   transduction.	   J	   Biol	   Chem	  278,	   16608-­‐16613,	  doi:10.1074/jbc.M208435200	  (2003).	  173	   Francois-­‐Newton,	  V.	  et	  al.	  USP18-­‐based	  negative	   feedback	  control	   is	   induced	  by	  type	   I	   and	   type	   III	   interferons	   and	   specifically	   inactivates	   interferon	   alpha	  response.	  PLoS	  One	  6,	  e22200,	  doi:10.1371/journal.pone.0022200	  (2011).	  174	   Malakhova,	   O.	   A.	   et	   al.	   Protein	   ISGylation	   modulates	   the	   JAK-­‐STAT	   signaling	  pathway.	  Genes	  Dev	  17,	  455-­‐460,	  doi:10.1101/gad.1056303	  (2003).	  
V	  References	  
	  151	  
175	   Potu,	   H.,	   Sgorbissa,	   A.	   &	   Brancolini,	   C.	   Identification	   of	   USP18	   as	   an	   important	  regulator	  of	   the	   susceptibility	   to	   IFN-­‐alpha	   and	  drug-­‐induced	  apoptosis.	  Cancer	  
Res	  70,	  655-­‐665,	  doi:10.1158/0008-­‐5472.CAN-­‐09-­‐1942	  (2010).	  176	   Kim,	   K.	   I.	   et	   al.	   Ube1L	   and	   protein	   ISGylation	   are	   not	   essential	   for	   alpha/beta	  interferon	   signaling.	   Mol	   Cell	   Biol	   26,	   472-­‐479,	   doi:10.1128/MCB.26.2.472-­‐479.2006	  (2006).	  177	   Dill,	   M.	   T.	   et	   al.	   Interferon-­‐gamma-­‐stimulated	   genes,	   but	   not	   USP18,	   are	  expressed	  in	  livers	  of	  patients	  with	  acute	  hepatitis	  C.	  Gastroenterology	  143,	  777-­‐786	  e771-­‐776,	  doi:10.1053/j.gastro.2012.05.044	  (2012).	  178	   Burkart,	  C.	  et	  al.	  Usp18	  deficient	  mammary	  epithelial	  cells	  create	  an	  antitumour	  environment	  driven	  by	  hypersensitivity	  to	  IFN-­‐lambda	  and	  elevated	  secretion	  of	  Cxcl10.	  EMBO	  Mol	  Med	  5,	  967-­‐982,	  doi:10.1002/emmm.201201864	  (2013).	  179	   Meuwissen,	   M.	   E.	   et	   al.	   Human	   USP18	   deficiency	   underlies	   type	   1	  interferonopathy	   leading	   to	   severe	   pseudo-­‐TORCH	   syndrome.	   J	   Exp	   Med	   213,	  1163-­‐1174,	  doi:10.1084/jem.20151529	  (2016).	  180	   Torre,	   L.	   A.	   et	   al.	   Global	   cancer	   statistics,	   2012.	   CA	   Cancer	   J	   Clin	   65,	   87-­‐108,	  doi:10.3322/caac.21262	  (2015).	  181	   Ferlay,	  J.	  et	  al.	  Cancer	  incidence	  and	  mortality	  worldwide:	  sources,	  methods	  and	  major	   patterns	   in	   GLOBOCAN	   2012.	   Int	   J	   Cancer	   136,	   E359-­‐386,	  doi:10.1002/ijc.29210	  (2015).	  182	   Mortality,	   G.	   B.	   D.	   &	   Causes	   of	   Death,	   C.	   Global,	   regional,	   and	   national	   age-­‐sex	  specific	   all-­‐cause	   and	   cause-­‐specific	   mortality	   for	   240	   causes	   of	   death,	   1990-­‐2013:	  a	  systematic	  analysis	  for	  the	  Global	  Burden	  of	  Disease	  Study	  2013.	  Lancet	  
385,	  117-­‐171,	  doi:10.1016/S0140-­‐6736(14)61682-­‐2	  (2015).	  183	   Gelband,	   H.	   et	   al.	   in	   Cancer:	  Disease	   Control	   Priorities,	   Third	  Edition	   (Volume	  3)	  	  	  (eds	  H.	  Gelband,	  P.	  Jha,	  R.	  Sankaranarayanan,	  &	  S.	  Horton)	  	  (2015).	  184	   Llovet,	   J.	   M.	   et	   al.	   Hepatocellular	   carcinoma.	   Nat	   Rev	   Dis	   Primers	   2,	   16018,	  doi:10.1038/nrdp.2016.18	  (2016).	  185	   European	  Association	  For	  The	  Study	  Of	  The,	  L.,	  European	  Organisation	  For,	  R.	  &	  Treatment	   Of,	   C.	   EASL-­‐EORTC	   clinical	   practice	   guidelines:	   management	   of	  hepatocellular	  carcinoma.	  J	  Hepatol	  56,	  908-­‐943,	  doi:10.1016/j.jhep.2011.12.001	  (2012).	  186	   Rothweiler,	   S.	   et	  al.	   Generation	   of	   a	  murine	   hepatic	   angiosarcoma	   cell	   line	   and	  reproducible	   mouse	   tumor	   model.	   Lab	   Invest	   95,	   351-­‐362,	  doi:10.1038/labinvest.2014.141	  (2015).	  187	   Bissig-­‐Choisat,	  B.	  et	  al.	  Novel	  patient-­‐derived	  xenograft	   and	  cell	   line	  models	   for	  therapeutic	   testing	   of	   pediatric	   liver	   cancer.	   J	   Hepatol,	  doi:10.1016/j.jhep.2016.04.009	  (2016).	  188	   McGlynn,	   K.	   A.,	   Petrick,	   J.	   L.	   &	   London,	   W.	   T.	   Global	   epidemiology	   of	  hepatocellular	  carcinoma:	  an	  emphasis	  on	  demographic	  and	  regional	  variability.	  
Clin	  Liver	  Dis	  19,	  223-­‐238,	  doi:10.1016/j.cld.2015.01.001	  (2015).	  189	   Farazi,	  P.	  A.	  &	  DePinho,	  R.	  A.	  Hepatocellular	  carcinoma	  pathogenesis:	  from	  genes	  to	  environment.	  Nat	  Rev	  Cancer	  6,	  674-­‐687,	  doi:10.1038/nrc1934	  (2006).	  190	   de	  Martel,	  C.	  et	  al.	  Global	  burden	  of	  cancers	  attributable	  to	  infections	  in	  2008:	  a	  review	   and	   synthetic	   analysis.	   Lancet	   Oncol	   13,	   607-­‐615,	   doi:10.1016/S1470-­‐2045(12)70137-­‐7	  (2012).	  191	   El-­‐Serag,	   H.	   B.	   &	   Rudolph,	   K.	   L.	   Hepatocellular	   carcinoma:	   epidemiology	   and	  molecular	   carcinogenesis.	   Gastroenterology	   132,	   2557-­‐2576,	  doi:10.1053/j.gastro.2007.04.061	  (2007).	  
V	  References	  	  
	  152	  
192	   El-­‐Serag,	   H.	   B.	   Epidemiology	   of	   viral	   hepatitis	   and	   hepatocellular	   carcinoma.	  
Gastroenterology	   142,	   1264-­‐1273	   e1261,	   doi:10.1053/j.gastro.2011.12.061	  (2012).	  193	   El-­‐Serag,	   H.	   B.	   Hepatocellular	   carcinoma.	   N	   Engl	   J	   Med	   365,	   1118-­‐1127,	  doi:10.1056/NEJMra1001683	  (2011).	  194	   Sung,	   W.	   K.	   et	   al.	   Genome-­‐wide	   survey	   of	   recurrent	   HBV	   integration	   in	  hepatocellular	  carcinoma.	  Nat	  Genet	  44,	  765-­‐769,	  doi:10.1038/ng.2295	  (2012).	  195	   Koike,	   K.	   et	   al.	   High-­‐level	   expression	   of	   hepatitis	   B	   virus	   HBx	   gene	   and	  hepatocarcinogenesis	  in	  transgenic	  mice.	  Hepatology	  19,	  810-­‐819	  (1994).	  196	   Brechot,	   C.,	   Pourcel,	   C.,	   Louise,	   A.,	   Rain,	   B.	   &	   Tiollais,	   P.	   Presence	   of	   integrated	  hepatitis	   B	   virus	   DNA	   sequences	   in	   cellular	   DNA	   of	   human	   hepatocellular	  carcinoma.	  Nature	  286,	  533-­‐535	  (1980).	  197	   Chakraborty,	   P.	  R.,	   Ruiz-­‐Opazo,	  N.,	   Shouval,	  D.	  &	   Shafritz,	  D.	  A.	   Identification	  of	  integrated	   hepatitis	   B	   virus	   DNA	   and	   expression	   of	   viral	   RNA	   in	   an	   HBsAg-­‐producing	   human	   hepatocellular	   carcinoma	   cell	   line.	   Nature	   286,	   531-­‐533	  (1980).	  198	   Shafritz,	   D.	   A.,	   Shouval,	   D.,	   Sherman,	   H.	   I.,	   Hadziyannis,	   S.	   J.	   &	   Kew,	   M.	   C.	  Integration	  of	  hepatitis	  B	  virus	  DNA	  into	  the	  genome	  of	  liver	  cells	  in	  chronic	  liver	  disease	  and	  hepatocellular	  carcinoma.	  Studies	  in	  percutaneous	  liver	  biopsies	  and	  post-­‐mortem	   tissue	   specimens.	   N	   Engl	   J	   Med	   305,	   1067-­‐1073,	  doi:10.1056/NEJM198110293051807	  (1981).	  199	   Wang,	  J.,	  Chenivesse,	  X.,	  Henglein,	  B.	  &	  Brechot,	  C.	  Hepatitis	  B	  virus	  integration	  in	  a	   cyclin	   A	   gene	   in	   a	   hepatocellular	   carcinoma.	   Nature	   343,	   555-­‐557,	  doi:10.1038/343555a0	  (1990).	  200	   Lok,	   A.	   S.	   Prevention	   of	   hepatitis	   B	   virus-­‐related	   hepatocellular	   carcinoma.	  
Gastroenterology	  127,	  S303-­‐309	  (2004).	  201	   Nault,	   J.	   C.	   et	   al.	   High	   frequency	   of	   telomerase	   reverse-­‐transcriptase	   promoter	  somatic	   mutations	   in	   hepatocellular	   carcinoma	   and	   preneoplastic	   lesions.	   Nat	  
Commun	  4,	  2218,	  doi:10.1038/ncomms3218	  (2013).	  202	   Levrero,	   M.	   &	   Zucman-­‐Rossi,	   J.	   Mechanisms	   of	   HBV-­‐induced	   hepatocellular	  carcinoma.	  J	  Hepatol	  64,	  S84-­‐101,	  doi:10.1016/j.jhep.2016.02.021	  (2016).	  203	   Zhang,	   W.	   et	   al.	   Genetic	   Features	   of	   Aflatoxin-­‐Associated	   Hepatocellular	  Carcinoma.	   Gastroenterology	   153,	   249-­‐262	   e242,	  doi:10.1053/j.gastro.2017.03.024	  (2017).	  204	   Hsu,	   I.	   C.	   et	   al.	   Mutational	   hotspot	   in	   the	   p53	   gene	   in	   human	   hepatocellular	  carcinomas.	  Nature	  350,	  427-­‐428,	  doi:10.1038/350427a0	  (1991).	  205	   Wild,	  C.	  P.	  &	  Gong,	  Y.	  Y.	  Mycotoxins	  and	  human	  disease:	  a	  largely	  ignored	  global	  health	  issue.	  Carcinogenesis	  31,	  71-­‐82,	  doi:10.1093/carcin/bgp264	  (2010).	  206	   Omer,	  R.	  E.	  et	  al.	  Population-­‐attributable	  risk	  of	  dietary	  aflatoxins	  and	  hepatitis	  B	  virus	  infection	  with	  respect	  to	  hepatocellular	  carcinoma.	  Nutr	  Cancer	  48,	  15-­‐21,	  doi:10.1207/s15327914nc4801_3	  (2004).	  207	   Wu,	   H.	   C.	   et	   al.	   Aflatoxin	   B1	   exposure,	   hepatitis	   B	   virus	   infection,	   and	  hepatocellular	  carcinoma	  in	  Taiwan.	  Cancer	  Epidemiol	  Biomarkers	  Prev	  18,	  846-­‐853,	  doi:10.1158/1055-­‐9965.EPI-­‐08-­‐0697	  (2009).	  208	   Mittal,	  S.	  &	  El-­‐Serag,	  H.	  B.	  Epidemiology	  of	  hepatocellular	  carcinoma:	  consider	  the	  population.	   J	   Clin	   Gastroenterol	   47	   Suppl,	   S2-­‐6,	  doi:10.1097/MCG.0b013e3182872f29	  (2013).	  
V	  References	  
	  153	  
209	   Albeldawi,	   M.,	   Soliman,	  M.,	   Lopez,	   R.	   &	   Zein,	   N.	   N.	   Hepatitis	   C	   virus-­‐associated	  primary	  hepatocellular	  carcinoma	  in	  non-­‐cirrhotic	  patients.	  Dig	  Dis	  Sci	  57,	  3265-­‐3270,	  doi:10.1007/s10620-­‐012-­‐2260-­‐y	  (2012).	  210	   Lemon,	  S.	  M.	  &	  McGivern,	  D.	  R.	  Is	  hepatitis	  C	  virus	  carcinogenic?	  Gastroenterology	  
142,	  1274-­‐1278,	  doi:10.1053/j.gastro.2012.01.045	  (2012).	  211	   Hernandez-­‐Gea,	   V.,	   Toffanin,	   S.,	   Friedman,	   S.	   L.	   &	   Llovet,	   J.	   M.	   Role	   of	   the	  microenvironment	   in	   the	   pathogenesis	   and	   treatment	   of	   hepatocellular	  carcinoma.	   Gastroenterology	   144,	   512-­‐527,	   doi:10.1053/j.gastro.2013.01.002	  (2013).	  212	   Raimondi,	   S.,	   Bruno,	   S.,	   Mondelli,	   M.	   U.	   &	   Maisonneuve,	   P.	   Hepatitis	   C	   virus	  genotype	  1b	  as	  a	  risk	  factor	  for	  hepatocellular	  carcinoma	  development:	  a	  meta-­‐analysis.	  J	  Hepatol	  50,	  1142-­‐1154,	  doi:10.1016/j.jhep.2009.01.019	  (2009).	  213	   Rusyn,	   I.	  &	  Lemon,	  S.	  M.	  Mechanisms	  of	  HCV-­‐induced	   liver	  cancer:	  what	  did	  we	  learn	   from	   in	   vitro	   and	   animal	   studies?	   Cancer	   Lett	   345,	   210-­‐215,	  doi:10.1016/j.canlet.2013.06.028	  (2014).	  214	   Yoon,	  E.	  J.	  &	  Hu,	  K.	  Q.	  Hepatitis	  C	  virus	  (HCV)	  infection	  and	  hepatic	  steatosis.	  Int	  J	  
Med	  Sci	  3,	  53-­‐56	  (2006).	  215	   McClain,	   C.	   J.,	   Hill,	   D.	   B.,	   Song,	   Z.,	   Deaciuc,	   I.	  &	  Barve,	   S.	  Monocyte	   activation	   in	  alcoholic	  liver	  disease.	  Alcohol	  27,	  53-­‐61	  (2002).	  216	   Mittal,	   S.	   et	   al.	   Temporal	   trends	   of	   nonalcoholic	   fatty	   liver	   disease-­‐related	  hepatocellular	   carcinoma	   in	   the	   veteran	   affairs	   population.	   Clin	   Gastroenterol	  
Hepatol	  13,	  594-­‐601	  e591,	  doi:10.1016/j.cgh.2014.08.013	  (2015).	  217	   Karagozian,	   R.,	   Derdak,	   Z.	   &	   Baffy,	   G.	   Obesity-­‐associated	   mechanisms	   of	  hepatocarcinogenesis.	   Metabolism	   63,	   607-­‐617,	  doi:10.1016/j.metabol.2014.01.011	  (2014).	  218	   Deugnier,	  Y.	  M.	  et	  al.	  Primary	  liver	  cancer	  in	  genetic	  hemochromatosis:	  a	  clinical,	  pathological,	  and	  pathogenetic	  study	  of	  54	  cases.	  Gastroenterology	  104,	  228-­‐234	  (1993).	  219	   Perlmutter,	   D.	   H.	   Pathogenesis	   of	   chronic	   liver	   injury	   and	   hepatocellular	  carcinoma	   in	   alpha-­‐1-­‐antitrypsin	   deficiency.	   Pediatr	   Res	   60,	   233-­‐238,	  doi:10.1203/01.pdr.0000228350.61496.90	  (2006).	  220	   Yu,	   M.	   W.	   &	   Chen,	   C.	   J.	   Elevated	   serum	   testosterone	   levels	   and	   risk	   of	  hepatocellular	  carcinoma.	  Cancer	  Res	  53,	  790-­‐794	  (1993).	  221	   Schulze,	  K.	  et	  al.	  Exome	  sequencing	  of	  hepatocellular	  carcinomas	   identifies	  new	  mutational	  signatures	  and	  potential	   therapeutic	   targets.	  Nat	  Genet	  47,	  505-­‐511,	  doi:10.1038/ng.3252	  (2015).	  222	   Chang,	  M.	  H.	  et	  al.	  Decreased	  incidence	  of	  hepatocellular	  carcinoma	  in	  hepatitis	  B	  vaccinees:	   a	   20-­‐year	   follow-­‐up	   study.	   J	   Natl	   Cancer	   Inst	   101,	   1348-­‐1355,	  doi:10.1093/jnci/djp288	  (2009).	  223	   Romano,	  L.,	  Paladini,	  S.,	  Van	  Damme,	  P.	  &	  Zanetti,	  A.	  R.	  The	  worldwide	  impact	  of	  vaccination	   on	   the	   control	   and	   protection	   of	   viral	   hepatitis	   B.	  Dig	  Liver	  Dis	  43	  
Suppl	  1,	  S2-­‐7,	  doi:10.1016/S1590-­‐8658(10)60685-­‐8	  (2011).	  224	   Singal,	  A.	  K.	  et	  al.	   Antiviral	   therapy	   reduces	   risk	  of	   hepatocellular	   carcinoma	   in	  patients	   with	   hepatitis	   C	   virus-­‐related	   cirrhosis.	   Clin	   Gastroenterol	   Hepatol	   8,	  192-­‐199,	  doi:10.1016/j.cgh.2009.10.026	  (2010).	  225	   Lok,	  A.	  S.	  et	  al.	  Incidence	  of	  hepatocellular	  carcinoma	  and	  associated	  risk	  factors	  in	   hepatitis	   C-­‐related	   advanced	   liver	   disease.	   Gastroenterology	   136,	   138-­‐148,	  doi:10.1053/j.gastro.2008.09.014	  (2009).	  
V	  References	  	  
	  154	  
226	   Baumert,	  T.	  F.,	  Juhling,	  F.,	  Ono,	  A.	  &	  Hoshida,	  Y.	  Hepatitis	  C-­‐related	  hepatocellular	  carcinoma	   in	   the	   era	   of	   new	   generation	   antivirals.	   BMC	   Med	   15,	   52,	  doi:10.1186/s12916-­‐017-­‐0815-­‐7	  (2017).	  227	   Llovet,	   J.	  M.,	  Bru,	  C.	  &	  Bruix,	   J.	  Prognosis	  of	  hepatocellular	  carcinoma:	   the	  BCLC	  staging	  classification.	  Semin	  Liver	  Dis	  19,	  329-­‐338,	  doi:10.1055/s-­‐2007-­‐1007122	  (1999).	  228	   Bruix,	   J.,	   Sherman,	   M.	   &	   American	   Association	   for	   the	   Study	   of	   Liver,	   D.	  Management	  of	  hepatocellular	  carcinoma:	  an	  update.	  Hepatology	  53,	  1020-­‐1022,	  doi:10.1002/hep.24199	  (2011).	  229	   Yau,	   T.	   et	   al.	   Development	   of	   Hong	   Kong	   Liver	   Cancer	   staging	   system	   with	  treatment	   stratification	   for	   patients	   with	   hepatocellular	   carcinoma.	  
Gastroenterology	   146,	   1691-­‐1700	   e1693,	   doi:10.1053/j.gastro.2014.02.032	  (2014).	  230	   A	  new	  prognostic	  system	  for	  hepatocellular	  carcinoma:	  a	  retrospective	  study	  of	  435	   patients:	   the	   Cancer	   of	   the	   Liver	   Italian	   Program	   (CLIP)	   investigators.	  
Hepatology	  28,	  751-­‐755,	  doi:10.1002/hep.510280322	  (1998).	  231	   Kudo,	   M.,	   Chung,	   H.	   &	   Osaki,	   Y.	   Prognostic	   staging	   system	   for	   hepatocellular	  carcinoma	   (CLIP	   score):	   its	   value	   and	   limitations,	   and	   a	   proposal	   for	   a	   new	  staging	  system,	  the	  Japan	  Integrated	  Staging	  Score	  (JIS	  score).	  J	  Gastroenterol	  38,	  207-­‐215,	  doi:10.1007/s005350300038	  (2003).	  232	   Llovet,	   J.	  M.	  et	  al.	   Sorafenib	   in	  advanced	  hepatocellular	  carcinoma.	  N	  Engl	  J	  Med	  
359,	  378-­‐390,	  doi:10.1056/NEJMoa0708857	  (2008).	  233	   Livraghi,	   T.	   et	   al.	   Sustained	   complete	   response	   and	   complications	   rates	   after	  radiofrequency	   ablation	   of	   very	   early	   hepatocellular	   carcinoma	   in	   cirrhosis:	   Is	  resection	   still	   the	   treatment	   of	   choice?	   Hepatology	   47,	   82-­‐89,	  doi:10.1002/hep.21933	  (2008).	  234	   Llovet,	   J.	   M.	   et	   al.	   Arterial	   embolisation	   or	   chemoembolisation	   versus	  symptomatic	  treatment	  in	  patients	  with	  unresectable	  hepatocellular	  carcinoma:	  a	  randomised	   controlled	   trial.	   Lancet	   359,	   1734-­‐1739,	   doi:10.1016/S0140-­‐6736(02)08649-­‐X	  (2002).	  235	   Cheng,	  A.	   L.	  et	  al.	   Efficacy	  and	   safety	  of	   sorafenib	   in	  patients	   in	   the	  Asia-­‐Pacific	  region	  with	  advanced	  hepatocellular	  carcinoma:	  a	  phase	  III	  randomised,	  double-­‐blind,	   placebo-­‐controlled	   trial.	   Lancet	   Oncol	   10,	   25-­‐34,	   doi:10.1016/S1470-­‐2045(08)70285-­‐7	  (2009).	  236	   Wilhelm,	  S.	  M.	  et	  al.	  BAY	  43-­‐9006	  exhibits	  broad	  spectrum	  oral	  antitumor	  activity	  and	  targets	  the	  RAF/MEK/ERK	  pathway	  and	  receptor	  tyrosine	  kinases	  involved	  in	   tumor	   progression	   and	   angiogenesis.	   Cancer	   Res	   64,	   7099-­‐7109,	  doi:10.1158/0008-­‐5472.CAN-­‐04-­‐1443	  (2004).	  237	   Wilhelm,	  S.	  M.	  et	  al.	  Preclinical	  overview	  of	  sorafenib,	  a	  multikinase	  inhibitor	  that	  targets	   both	   Raf	   and	   VEGF	   and	   PDGF	   receptor	   tyrosine	   kinase	   signaling.	  Mol	  
Cancer	  Ther	  7,	  3129-­‐3140,	  doi:10.1158/1535-­‐7163.MCT-­‐08-­‐0013	  (2008).	  238	   Cheng,	  A.	  L.	  et	  al.	   Sunitinib	  versus	   sorafenib	   in	  advanced	  hepatocellular	   cancer:	  results	   of	   a	   randomized	   phase	   III	   trial.	   J	   Clin	   Oncol	   31,	   4067-­‐4075,	  doi:10.1200/JCO.2012.45.8372	  (2013).	  239	   Johnson,	  P.	  J.	  et	  al.	  Brivanib	  versus	  sorafenib	  as	  first-­‐line	  therapy	  in	  patients	  with	  unresectable,	   advanced	   hepatocellular	   carcinoma:	   results	   from	   the	   randomized	  phase	   III	   BRISK-­‐FL	   study.	   J	   Clin	   Oncol	   31,	   3517-­‐3524,	  doi:10.1200/JCO.2012.48.4410	  (2013).	  
V	  References	  
	  155	  
240	   Cainap,	   C.	   et	   al.	   Linifanib	   versus	   Sorafenib	   in	   patients	   with	   advanced	  hepatocellular	  carcinoma:	  results	  of	  a	  randomized	  phase	  III	  trial.	  J	  Clin	  Oncol	  33,	  172-­‐179,	  doi:10.1200/JCO.2013.54.3298	  (2015).	  241	   Zhu,	   A.	   X.	   et	   al.	   SEARCH:	   a	   phase	   III,	   randomized,	   double-­‐blind,	   placebo-­‐controlled	   trial	   of	   sorafenib	   plus	   erlotinib	   in	   patients	   with	   advanced	  hepatocellular	   carcinoma.	   J	   Clin	   Oncol	   33,	   559-­‐566,	  doi:10.1200/JCO.2013.53.7746	  (2015).	  242	   Worns,	  M.	  A.	  &	  Galle,	  P.	  R.	  HCC	  therapies-­‐-­‐lessons	  learned.	  Nat	  Rev	  Gastroenterol	  
Hepatol	  11,	  447-­‐452,	  doi:10.1038/nrgastro.2014.10	  (2014).	  243	   Bruix,	   J.	   et	   al.	   Regorafenib	   for	   patients	   with	   hepatocellular	   carcinoma	   who	  progressed	   on	   sorafenib	   treatment	   (RESORCE):	   a	   randomised,	   double-­‐blind,	  placebo-­‐controlled,	   phase	   3	   trial.	   Lancet	   389,	   56-­‐66,	   doi:10.1016/S0140-­‐6736(16)32453-­‐9	  (2017).	  244	   Feun,	  L.	  G.,	  Li,	  Y.-­‐Y.,	  Wangpaichitr,	  M.,	  Wu,	  C.-­‐J.	  &	  Savaraj,	  N.	  Immunotherapy	  for	  hepatocellular	  carcinoma:	   the	   force	  awakens	   in	  HCC?	  Hepatoma	  Research	  3,	  43,	  doi:10.20517/2394-­‐5079.2016.45	  (2017).	  245	   Greten,	  T.	  F.	  &	  Sangro,	  B.	  Targets	   for	   immunotherapy	  of	   liver	   cancer.	   J	  Hepatol,	  doi:10.1016/j.jhep.2017.09.007	  (2017).	  246	   Buttner,	   N.,	   Schmidt,	   N.	   &	   Thimme,	   R.	   Perspectives	   of	   immunotherapy	   in	  hepatocellular	   carcinoma	   (HCC).	  Z	  Gastroenterol	  54,	   1334-­‐1342,	  doi:10.1055/s-­‐0042-­‐120417	  (2016).	  247	   Zucman-­‐Rossi,	  J.,	  Villanueva,	  A.,	  Nault,	  J.	  C.	  &	  Llovet,	  J.	  M.	  Genetic	  Landscape	  and	  Biomarkers	   of	   Hepatocellular	   Carcinoma.	   Gastroenterology	   149,	   1226-­‐1239	  e1224,	  doi:10.1053/j.gastro.2015.05.061	  (2015).	  248	   Cancer	   Genome	   Atlas	   Research	   Network.	   Electronic	   address,	   w.	   b.	   e.	   &	   Cancer	  Genome	   Atlas	   Research,	   N.	   Comprehensive	   and	   Integrative	   Genomic	  Characterization	   of	   Hepatocellular	   Carcinoma.	   Cell	   169,	   1327-­‐1341	   e1323,	  doi:10.1016/j.cell.2017.05.046	  (2017).	  249	   Wiemann,	  S.	  U.	  et	  al.	  Hepatocyte	  telomere	  shortening	  and	  senescence	  are	  general	  markers	   of	   human	   liver	   cirrhosis.	   FASEB	   J	   16,	   935-­‐942,	   doi:10.1096/fj.01-­‐0977com	  (2002).	  250	   Plentz,	   R.	   R.	   et	   al.	   Hepatocellular	   telomere	   shortening	   correlates	   with	  chromosomal	   instability	   and	   the	   development	   of	   human	   hepatoma.	  Hepatology	  
40,	  80-­‐86,	  doi:10.1002/hep.20271	  (2004).	  251	   Farazi,	   P.	   A.	   et	  al.	   Differential	   impact	   of	   telomere	   dysfunction	   on	   initiation	   and	  progression	  of	  hepatocellular	  carcinoma.	  Cancer	  Res	  63,	  5021-­‐5027	  (2003).	  252	   Nault,	   J.	   C.,	   Bioulac-­‐Sage,	   P.	   &	   Zucman-­‐Rossi,	   J.	   Hepatocellular	   benign	   tumors-­‐from	  molecular	  classification	  to	  personalized	  clinical	  care.	  Gastroenterology	  144,	  888-­‐902,	  doi:10.1053/j.gastro.2013.02.032	  (2013).	  253	   Zucman-­‐Rossi,	   J.	   et	   al.	   Genotype-­‐phenotype	   correlation	   in	   hepatocellular	  adenoma:	  new	  classification	  and	  relationship	  with	  HCC.	  Hepatology	  43,	  515-­‐524,	  doi:10.1002/hep.21068	  (2006).	  254	   Alizadeh,	  A.	  A.	  et	  al.	  Toward	  understanding	  and	  exploiting	  tumor	  heterogeneity.	  
Nat	  Med	  21,	  846-­‐853,	  doi:10.1038/nm.3915	  (2015).	  255	   Totoki,	  Y.	  et	  al.	  Trans-­‐ancestry	  mutational	  landscape	  of	  hepatocellular	  carcinoma	  genomes.	  Nat	  Genet	  46,	  1267-­‐1273,	  doi:10.1038/ng.3126	  (2014).	  256	   Calderaro,	   J.	  et	  al.	  Histological	   subtypes	  of	  hepatocellular	   carcinoma	  are	   related	  to	   gene	  mutations	   and	  molecular	   tumour	   classification.	   J	  Hepatol	  67,	   727-­‐738,	  doi:10.1016/j.jhep.2017.05.014	  (2017).	  
V	  References	  	  
	  156	  
257	   de	  La	  Coste,	  A.	  et	  al.	  Somatic	  mutations	  of	  the	  beta-­‐catenin	  gene	  are	  frequent	   in	  mouse	  and	  human	  hepatocellular	  carcinomas.	  Proc	  Natl	  Acad	  Sci	  U	  S	  A	  95,	  8847-­‐8851	  (1998).	  258	   Audard,	  V.	  et	  al.	  Cholestasis	  is	  a	  marker	  for	  hepatocellular	  carcinomas	  displaying	  beta-­‐catenin	  mutations.	  J	  Pathol	  212,	  345-­‐352,	  doi:10.1002/path.2169	  (2007).	  259	   Minouchi,	   K.,	   Kaneko,	   S.	   &	   Kobayashi,	   K.	  Mutation	   of	   p53	   gene	   in	   regenerative	  nodules	  in	  cirrhotic	  liver.	  J	  Hepatol	  37,	  231-­‐239	  (2002).	  260	   Schlageter,	  M.,	  Terracciano,	  L.	  M.,	  D'Angelo,	  S.	  &	  Sorrentino,	  P.	  Histopathology	  of	  hepatocellular	   carcinoma.	   World	   J	   Gastroenterol	   20,	   15955-­‐15964,	  doi:10.3748/wjg.v20.i43.15955	  (2014).	  261	   Schlageter,	   M.	   et	   al.	   Clinicopathological	   Features	   and	   Metastatic	   Pattern	   of	  Hepatocellular	   Carcinoma:	   An	   Autopsy	   Study	   of	   398	   Patients.	  Pathobiology	  83,	  301-­‐307,	  doi:10.1159/000446245	  (2016).	  262	   Edmondson,	  H.	  A.	  &	  Steiner,	  P.	  E.	  Primary	  carcinoma	  of	  the	  liver:	  a	  study	  of	  100	  cases	  among	  48,900	  necropsies.	  Cancer	  7,	  462-­‐503	  (1954).	  263	   Bruix,	   J.,	   Sherman,	   M.	   &	   Practice	   Guidelines	   Committee,	   A.	   A.	   f.	   t.	   S.	   o.	   L.	   D.	  Management	   of	   hepatocellular	   carcinoma.	   Hepatology	   42,	   1208-­‐1236,	  doi:10.1002/hep.20933	  (2005).	  264	   Di	   Tommaso,	   L.	   et	   al.	   Diagnostic	   value	   of	   HSP70,	   glypican	   3,	   and	   glutamine	  synthetase	   in	   hepatocellular	   nodules	   in	   cirrhosis.	   Hepatology	   45,	   725-­‐734,	  doi:10.1002/hep.21531	  (2007).	  265	   Di	  Tommaso,	  L.	  et	  al.	  The	  application	  of	  markers	   (HSP70	  GPC3	  and	  GS)	   in	   liver	  biopsies	   is	   useful	   for	   detection	   of	   hepatocellular	   carcinoma.	   J	  Hepatol	  50,	   746-­‐754,	  doi:10.1016/j.jhep.2008.11.014	  (2009).	  266	   Tremosini,	   S.	   et	   al.	   Prospective	   validation	   of	   an	   immunohistochemical	   panel	  (glypican	  3,	  heat	  shock	  protein	  70	  and	  glutamine	  synthetase)	  in	  liver	  biopsies	  for	  diagnosis	   of	   very	   early	   hepatocellular	   carcinoma.	   Gut	   61,	   1481-­‐1487,	  doi:10.1136/gutjnl-­‐2011-­‐301862	  (2012).	  267	   International	   Consensus	   Group	   for	   Hepatocellular	   NeoplasiaThe	   International	  Consensus	   Group	   for	   Hepatocellular,	   N.	   Pathologic	   diagnosis	   of	   early	  hepatocellular	   carcinoma:	   a	   report	   of	   the	   international	   consensus	   group	   for	  hepatocellular	   neoplasia.	   Hepatology	   49,	   658-­‐664,	   doi:10.1002/hep.22709	  (2009).	  268	   Christa,	  L.	  et	  al.	  Overexpression	  of	  glutamine	  synthetase	  in	  human	  primary	  liver	  cancer.	  Gastroenterology	  106,	  1312-­‐1320	  (1994).	  269	   Osada,	   T.	   et	   al.	   Acquisition	   of	   glutamine	   synthetase	   expression	   in	   human	  hepatocarcinogenesis:	  relation	  to	  disease	  recurrence	  and	  possible	  regulation	  by	  ubiquitin-­‐dependent	  proteolysis.	  Cancer	  85,	  819-­‐831	  (1999).	  270	   Capurro,	   M.	   et	   al.	   Glypican-­‐3:	   a	   novel	   serum	   and	   histochemical	   marker	   for	  hepatocellular	  carcinoma.	  Gastroenterology	  125,	  89-­‐97	  (2003).	  271	   Zhu,	   Z.	  W.	   et	   al.	   Enhanced	   glypican-­‐3	   expression	   differentiates	   the	   majority	   of	  hepatocellular	   carcinomas	   from	   benign	   hepatic	   disorders.	   Gut	   48,	   558-­‐564	  (2001).	  272	   Sung,	  Y.	  K.	  et	  al.	  Glypican-­‐3	  is	  overexpressed	  in	  human	  hepatocellular	  carcinoma.	  
Cancer	  Sci	  94,	  259-­‐262	  (2003).	  273	   Baumhoer,	  D.	  et	  al.	  Glypican	  3	  expression	  in	  human	  nonneoplastic,	  preneoplastic,	  and	  neoplastic	  tissues:	  a	  tissue	  microarray	  analysis	  of	  4,387	  tissue	  samples.	  Am	  J	  
Clin	  Pathol	  129,	  899-­‐906,	  doi:10.1309/HCQWPWD50XHD2DW6	  (2008).	  
V	  References	  
	  157	  
274	   Gao,	   W.	   &	   Ho,	   M.	   The	   role	   of	   glypican-­‐3	   in	   regulating	   Wnt	   in	   hepatocellular	  carcinomas.	  Cancer	  Rep	  1,	  14-­‐19	  (2011).	  275	   Chuma,	   M.	   et	   al.	   Expression	   profiling	   in	   multistage	   hepatocarcinogenesis:	  identification	  of	  HSP70	  as	  a	  molecular	  marker	  of	  early	  hepatocellular	  carcinoma.	  
Hepatology	  37,	  198-­‐207,	  doi:10.1053/jhep.2003.50022	  (2003).	  276	   Makowska,	   Z.	   et	  al.	   Gene	   expression	   analysis	   of	   biopsy	   samples	   reveals	   critical	  limitations	   of	   transcriptome-­‐based	   molecular	   classifications	   of	   hepatocellular	  carcinoma.	  J	  Pathol	  Clin	  Res	  2,	  80-­‐92,	  doi:10.1002/cjp2.37	  (2016).	  277	   Boyault,	  S.	  et	  al.	  Transcriptome	  classification	  of	  HCC	  is	  related	  to	  gene	  alterations	  and	   to	   new	   therapeutic	   targets.	  Hepatology	   45,	   42-­‐52,	   doi:10.1002/hep.21467	  (2007).	  278	   Chiang,	   D.	   Y.	   et	   al.	   Focal	   gains	   of	   VEGFA	   and	   molecular	   classification	   of	  hepatocellular	   carcinoma.	   Cancer	   Res	   68,	   6779-­‐6788,	   doi:10.1158/0008-­‐5472.CAN-­‐08-­‐0742	  (2008).	  279	   Hoshida,	   Y.	  et	  al.	   Integrative	   transcriptome	   analysis	   reveals	   common	  molecular	  subclasses	   of	   human	   hepatocellular	   carcinoma.	   Cancer	   Res	   69,	   7385-­‐7392,	  doi:10.1158/0008-­‐5472.CAN-­‐09-­‐1089	  (2009).	  280	   Lee,	   J.	   S.	   et	   al.	   Classification	   and	   prediction	   of	   survival	   in	   hepatocellular	  carcinoma	   by	   gene	   expression	   profiling.	   Hepatology	   40,	   667-­‐676,	  doi:10.1002/hep.20375	  (2004).	  281	   Ng,	   C.	   K.	   Y.,	   Piscuoglio,	   S.	   &	   Terracciano,	   L.	   M.	   Molecular	   classification	   of	  hepatocellular	   carcinoma:	   The	   view	   from	   metabolic	   zonation.	   Hepatology	   66,	  1377-­‐1380,	  doi:10.1002/hep.29311	  (2017).	  282	   Lok,	   A.	   S.	   et	   al.	   Des-­‐gamma-­‐carboxy	   prothrombin	   and	   alpha-­‐fetoprotein	   as	  biomarkers	  for	  the	  early	  detection	  of	  hepatocellular	  carcinoma.	  Gastroenterology	  
138,	  493-­‐502,	  doi:10.1053/j.gastro.2009.10.031	  (2010).	  283	   Marrero,	   J.	   A.	   et	   al.	   Alpha-­‐fetoprotein,	   des-­‐gamma	   carboxyprothrombin,	   and	  lectin-­‐bound	   alpha-­‐fetoprotein	   in	   early	   hepatocellular	   carcinoma.	  
Gastroenterology	  137,	  110-­‐118,	  doi:10.1053/j.gastro.2009.04.005	  (2009).	  284	   Nakazawa,	  T.	  et	  al.	  Early	  increase	  in	  alpha-­‐fetoprotein	  for	  predicting	  unfavorable	  clinical	   outcomes	   in	   patients	   with	   advanced	   hepatocellular	   carcinoma	   treated	  with	   sorafenib.	   Eur	   J	   Gastroenterol	   Hepatol	   25,	   683-­‐689,	  doi:10.1097/MEG.0b013e32835d913b	  (2013).	  285	   Llovet,	   J.	  M.	  et	  al.	   Plasma	  biomarkers	  as	  predictors	  of	  outcome	   in	  patients	  with	  advanced	   hepatocellular	   carcinoma.	   Clin	   Cancer	   Res	   18,	   2290-­‐2300,	  doi:10.1158/1078-­‐0432.CCR-­‐11-­‐2175	  (2012).	  286	   Llovet,	  J.	  M.	  &	  Hernandez-­‐Gea,	  V.	  Hepatocellular	  carcinoma:	  reasons	  for	  phase	  III	  failure	   and	   novel	   perspectives	   on	   trial	   design.	   Clin	   Cancer	   Res	   20,	   2072-­‐2079,	  doi:10.1158/1078-­‐0432.CCR-­‐13-­‐0547	  (2014).	  287	   Munshi,	   N.	   et	   al.	   ARQ	   197,	   a	   novel	   and	   selective	   inhibitor	   of	   the	   human	   c-­‐Met	  receptor	  tyrosine	  kinase	  with	  antitumor	  activity.	  Mol	  Cancer	  Ther	  9,	  1544-­‐1553,	  doi:10.1158/1535-­‐7163.MCT-­‐09-­‐1173	  (2010).	  288	   Santoro,	  A.	  et	  al.	  Tivantinib	  for	  second-­‐line	  treatment	  of	  advanced	  hepatocellular	  carcinoma:	  a	  randomised,	  placebo-­‐controlled	  phase	  2	  study.	  Lancet	  Oncol	  14,	  55-­‐63,	  doi:10.1016/S1470-­‐2045(12)70490-­‐4	  (2013).	  289	   Aravalli,	   R.	   N.,	   Steer,	   C.	   J.,	   Sahin,	  M.	   B.	   &	   Cressman,	   E.	   N.	   Stem	   cell	   origins	   and	  animal	   models	   of	   hepatocellular	   carcinoma.	   Dig	   Dis	   Sci	   55,	   1241-­‐1250,	  doi:10.1007/s10620-­‐009-­‐0861-­‐x	  (2010).	  
V	  References	  	  
	  158	  
290	   Arellanes-­‐Robledo,	   J.,	   Hernández,	   C.,	   Camacho,	   J.	   &	   Pérez-­‐Carreón,	   J.	   I.	   In	  Vitro	  Models	  of	  HCC.	  563-­‐579,	  doi:10.1016/b978-­‐0-­‐12-­‐804274-­‐8.00042-­‐4	  (2017).	  291	   Bagi,	  C.	  M.	  &	  Andresen,	  C.	   J.	  Models	  of	  hepatocellular	  carcinoma	  and	  biomarker	  strategy.	  Cancers	  (Basel)	  2,	  1441-­‐1452,	  doi:10.3390/cancers2031441	  (2010).	  292	   Frese,	  K.	  K.	  &	  Tuveson,	  D.	  A.	  Maximizing	  mouse	  cancer	  models.	  Nat	  Rev	  Cancer	  7,	  645-­‐658,	  doi:10.1038/nrc2192	  (2007).	  293	   Clevers,	  H.	  Modeling	  Development	  and	  Disease	  with	  Organoids.	  Cell	  165,	  1586-­‐1597,	  doi:10.1016/j.cell.2016.05.082	  (2016).	  294	   Huch,	  M.	  et	  al.	  Long-­‐term	  culture	  of	  genome-­‐stable	  bipotent	  stem	  cells	  from	  adult	  human	  liver.	  Cell	  160,	  299-­‐312,	  doi:10.1016/j.cell.2014.11.050	  (2015).	  295	   Huch,	  M.,	  Knoblich,	  J.	  A.,	  Lutolf,	  M.	  P.	  &	  Martinez-­‐Arias,	  A.	  The	  hope	  and	  the	  hype	  of	   organoid	   research.	   Development	   144,	   938-­‐941,	   doi:10.1242/dev.150201	  (2017).	  296	   Broutier,	   L.	   et	   al.	   Human	   primary	   liver	   cancer-­‐derived	   organoid	   cultures	   for	  disease	  modeling	  and	  drug	  screening.	  Nat	  Med,	  doi:10.1038/nm.4438	  (2017).	  297	   Fatehullah,	  A.,	  Tan,	   S.	  H.	  &	  Barker,	  N.	  Organoids	  as	  an	   in	  vitro	  model	  of	  human	  development	   and	   disease.	   Nat	   Cell	   Biol	   18,	   246-­‐254,	   doi:10.1038/ncb3312	  (2016).	  298	   Gross,	   C.	   et	   al.	   Model	   Matters:	   Differences	   in	   Orthotopic	   Rat	   Hepatocellular	  Carcinoma	  Physiology	  Determine	  Therapy	  Response	  to	  Sorafenib.	  Clin	  Cancer	  Res	  
21,	  4440-­‐4450,	  doi:10.1158/1078-­‐0432.CCR-­‐14-­‐2018	  (2015).	  299	   Alshareeda,	  A.	  T.,	  Sakaguchi,	  K.,	  Abumaree,	  M.,	  Mohd	  Zin,	  N.	  K.	  &	  Shimizu,	  T.	  The	  potential	  of	  cell	  sheet	  technique	  on	  the	  development	  of	  hepatocellular	  carcinoma	  in	   rat	   models.	   PLoS	   One	   12,	   e0184004,	   doi:10.1371/journal.pone.0184004	  (2017).	  300	   Mulrooney-­‐Cousins,	  P.	  M.,	  Chauhan,	  R.,	  Churchill,	  N.	  D.	  &	  Michalak,	  T.	   I.	  Primary	  seronegative	   but	   molecularly	   evident	   hepadnaviral	   infection	   engages	   liver	   and	  induces	   hepatocarcinoma	   in	   the	  woodchuck	  model	   of	   hepatitis	   B.	  PLoS	  Pathog	  
10,	  e1004332,	  doi:10.1371/journal.ppat.1004332	  (2014).	  301	   Mitchell,	   J.	  et	  al.	  Validation	  of	  a	  Preclinical	  Model	  of	  Diethylnitrosamine-­‐Induced	  Hepatic	   Neoplasia	   in	   Yucatan	   Miniature	   Pigs.	   Oncology	   91,	   90-­‐100,	  doi:10.1159/000446074	  (2016).	  302	   Heindryckx,	   F.,	   Colle,	   I.	   &	   Van	   Vlierberghe,	   H.	   Experimental	   mouse	   models	   for	  hepatocellular	   carcinoma	   research.	   Int	   J	   Exp	   Pathol	   90,	   367-­‐386,	  doi:10.1111/j.1365-­‐2613.2009.00656.x	  (2009).	  303	   Caviglia,	   J.	  M.	  &	   Schwabe,	   R.	   F.	  Mouse	  models	   of	   liver	   cancer.	  Methods	  Mol	  Biol	  
1267,	  165-­‐183,	  doi:10.1007/978-­‐1-­‐4939-­‐2297-­‐0_8	  (2015).	  304	   Santos,	   N.	   P.,	   Colaco,	   A.	   A.	   &	   Oliveira,	   P.	   A.	   Animal	   models	   as	   a	   tool	   in	  hepatocellular	   carcinoma	   research:	   A	   Review.	   Tumour	   Biol	   39,	  1010428317695923,	  doi:10.1177/1010428317695923	  (2017).	  305	   Dragani,	  T.	  A.,	  Manenti,	  G.,	  Gariboldi,	  M.,	  De	  Gregorio,	  L.	  &	  Pierotti,	  M.	  A.	  Genetics	  of	  liver	  tumor	  susceptibility	  in	  mice.	  Toxicol	  Lett	  82-­‐83,	  613-­‐619	  (1995).	  306	   Wu,	   L.,	   Tang,	   Z.	   Y.	   &	   Li,	   Y.	   Experimental	   models	   of	   hepatocellular	   carcinoma:	  developments	   and	   evolution.	   J	   Cancer	   Res	   Clin	   Oncol	   135,	   969-­‐981,	  doi:10.1007/s00432-­‐009-­‐0591-­‐7	  (2009).	  307	   Fausto,	   N.	   &	   Campbell,	   J.	   S.	   Mouse	   models	   of	   hepatocellular	   carcinoma.	   Semin	  
Liver	  Dis	  30,	  87-­‐98,	  doi:10.1055/s-­‐0030-­‐1247135	  (2010).	  
V	  References	  
	  159	  
308	   Horie,	  Y.	  et	  al.	  Hepatocyte-­‐specific	  Pten	  deficiency	  results	   in	  steatohepatitis	  and	  hepatocellular	   carcinomas.	   J	  Clin	   Invest	  113,	   1774-­‐1783,	   doi:10.1172/JCI20513	  (2004).	  309	   Mauad,	  T.	  H.	  et	  al.	  Mice	  with	  homozygous	  disruption	  of	  the	  mdr2	  P-­‐glycoprotein	  gene.	   A	   novel	   animal	   model	   for	   studies	   of	   nonsuppurative	   inflammatory	  cholangitis	  and	  hepatocarcinogenesis.	  Am	  J	  Pathol	  145,	  1237-­‐1245	  (1994).	  310	   Bettermann,	   K.	   et	   al.	   TAK1	   suppresses	   a	   NEMO-­‐dependent	   but	   NF-­‐kappaB-­‐independent	   pathway	   to	   liver	   cancer.	   Cancer	   Cell	   17,	   481-­‐496,	  doi:10.1016/j.ccr.2010.03.021	  (2010).	  311	   Calvisi,	  D.	  F.,	  Factor,	  V.	  M.,	  Ladu,	  S.,	  Conner,	  E.	  A.	  &	  Thorgeirsson,	  S.	  S.	  Disruption	  of	  beta-­‐catenin	  pathway	  or	  genomic	   instability	  define	   two	  distinct	  categories	  of	  liver	  cancer	  in	  transgenic	  mice.	  Gastroenterology	  126,	  1374-­‐1386	  (2004).	  312	   Lee,	  J.	  S.	  et	  al.	  Application	  of	  comparative	  functional	  genomics	  to	  identify	  best-­‐fit	  mouse	   models	   to	   study	   human	   cancer.	   Nat	   Genet	   36,	   1306-­‐1311,	  doi:10.1038/ng1481	  (2004).	  313	   Dandri,	   M.	   &	   Petersen,	   J.	   Animal	   models	   of	   HBV	   infection.	   Best	   Pract	   Res	   Clin	  
Gastroenterol	  31,	  273-­‐279,	  doi:10.1016/j.bpg.2017.04.014	  (2017).	  314	   Dorner,	  M.	  et	  al.	  Completion	  of	  the	  entire	  hepatitis	  C	  virus	  life	  cycle	  in	  genetically	  humanized	  mice.	  Nature	  501,	  237-­‐241,	  doi:10.1038/nature12427	  (2013).	  315	   Dandri,	  M.	  et	  al.	  Repopulation	  of	  mouse	  liver	  with	  human	  hepatocytes	  and	  in	  vivo	  infection	   with	   hepatitis	   B	   virus.	   Hepatology	   33,	   981-­‐988,	  doi:10.1053/jhep.2001.23314	  (2001).	  316	   Billerbeck,	   E.	   et	   al.	   Mouse	   models	   of	   acute	   and	   chronic	   hepacivirus	   infection.	  
Science	  357,	  204-­‐208,	  doi:10.1126/science.aal1962	  (2017).	  317	   Li,	   Y.,	   Tang,	   Z.	   Y.	   &	   Hou,	   J.	   X.	   Hepatocellular	   carcinoma:	   insight	   from	   animal	  models.	  Nat	  Rev	  Gastroenterol	  Hepatol	  9,	  32-­‐43,	  doi:10.1038/nrgastro.2011.196	  (2011).	  318	   Kim,	  C.	  M.,	  Koike,	  K.,	  Saito,	  I.,	  Miyamura,	  T.	  &	  Jay,	  G.	  HBx	  gene	  of	  hepatitis	  B	  virus	  induces	   liver	   cancer	   in	   transgenic	   mice.	   Nature	   351,	   317-­‐320,	  doi:10.1038/351317a0	  (1991).	  319	   Dunsford,	  H.	  A.,	  Sell,	  S.	  &	  Chisari,	  F.	  V.	  Hepatocarcinogenesis	  due	  to	  chronic	  liver	  cell	  injury	  in	  hepatitis	  B	  virus	  transgenic	  mice.	  Cancer	  Res	  50,	  3400-­‐3407	  (1990).	  320	   Chisari,	   F.	  V.	  et	  al.	  A	   transgenic	  mouse	  model	  of	   the	   chronic	  hepatitis	  B	   surface	  antigen	  carrier	  state.	  Science	  230,	  1157-­‐1160	  (1985).	  321	   Lakhtakia,	  R.	  et	  al.	  Hepatocellular	  carcinoma	  in	  a	  hepatitis	  B	  'x'	  transgenic	  mouse	  model:	   A	   sequential	   pathological	   evaluation.	   J	   Gastroenterol	   Hepatol	   18,	   80-­‐91	  (2003).	  322	   Sell,	   S.,	  Hunt,	   J.	  M.,	  Dunsford,	  H.	  A.	  &	  Chisari,	   F.	  V.	   Synergy	  between	  hepatitis	  B	  virus	  expression	  and	  chemical	  hepatocarcinogens	  in	  transgenic	  mice.	  Cancer	  Res	  
51,	  1278-­‐1285	  (1991).	  323	   Koike,	   K.,	  Moriya,	   K.	   &	  Matsuura,	   Y.	   Animal	  models	   for	   hepatitis	   C	   and	   related	  liver	   disease.	   Hepatol	   Res	   40,	   69-­‐82,	   doi:10.1111/j.1872-­‐034X.2009.00593.x	  (2010).	  324	   Moriya,	   K.	   et	   al.	   The	   core	   protein	   of	   hepatitis	   C	   virus	   induces	   hepatocellular	  carcinoma	  in	  transgenic	  mice.	  Nat	  Med	  4,	  1065-­‐1067,	  doi:10.1038/2053	  (1998).	  325	   Koike,	  K.,	  Moriya,	  K.	  &	  Kimura,	  S.	  Role	  of	  hepatitis	  C	  virus	  in	  the	  development	  of	  hepatocellular	   carcinoma:	   transgenic	   approach	   to	   viral	   hepatocarcinogenesis.	   J	  
Gastroenterol	  Hepatol	  17,	  394-­‐400	  (2002).	  
V	  References	  	  
	  160	  
326	   Rao,	   K.	   V.	   &	   Vesselinovitch,	   S.	   D.	   Age-­‐	   and	   sex-­‐associated	   diethylnitrosamine	  dealkylation	  activity	  of	  the	  mouse	  liver	  and	  hepatocarcinogenesis.	  Cancer	  Res	  33,	  1625-­‐1627	  (1973).	  327	   Bakiri,	   L.	  &	  Wagner,	  E.	  F.	  Mouse	  models	   for	   liver	   cancer.	  Mol	  Oncol	  7,	   206-­‐223,	  doi:10.1016/j.molonc.2013.01.005	  (2013).	  328	   Hacker,	  H.	  J.,	  Mtiro,	  H.,	  Bannasch,	  P.	  &	  Vesselinovitch,	  S.	  D.	  Histochemical	  profile	  of	  mouse	  hepatocellular	   adenomas	  and	  carcinomas	   induced	  by	  a	   single	  dose	  of	  diethylnitrosamine.	  Cancer	  Res	  51,	  1952-­‐1958	  (1991).	  329	   Binato,	  M.	  et	  al.	  Mouse	  model	  of	  diethylnitrosamine-­‐induced	  gastric	  cancer.	  J	  Surg	  
Res	  148,	  152-­‐157,	  doi:10.1016/j.jss.2007.12.748	  (2008).	  330	   McGlynn,	  K.	  A.	  et	  al.	  Susceptibility	  to	  aflatoxin	  B1-­‐related	  primary	  hepatocellular	  carcinoma	  in	  mice	  and	  humans.	  Cancer	  Res	  63,	  4594-­‐4601	  (2003).	  331	   Weber,	  A.,	  O'Connor,	  T.	  &	  Heikenwalder,	  M.	  Next	  Generation	  of	  Preclinical	  Liver	  Cancer	  Models.	  Clin	  Cancer	  Res	  21,	  4254-­‐4256,	  doi:10.1158/1078-­‐0432.CCR-­‐15-­‐1152	  (2015).	  332	   Tentler,	  J.	  J.	  et	  al.	  Patient-­‐derived	  tumour	  xenografts	  as	  models	  for	  oncology	  drug	  development.	   Nat	   Rev	   Clin	   Oncol	   9,	   338-­‐350,	   doi:10.1038/nrclinonc.2012.61	  (2012).	  333	   Siolas,	  D.	  &	  Hannon,	  G.	  J.	  Patient-­‐derived	  tumor	  xenografts:	  transforming	  clinical	  samples	   into	   mouse	   models.	   Cancer	   Res	   73,	   5315-­‐5319,	   doi:10.1158/0008-­‐5472.CAN-­‐13-­‐1069	  (2013).	  334	   Yan,	  M.	  et	  al.	  Establishment	  of	  NOD/SCID	  mouse	  models	  of	  human	  hepatocellular	  carcinoma	  via	  subcutaneous	  transplantation	  of	  histologically	  intact	  tumor	  tissue.	  
Chin	  J	  Cancer	  Res	  25,	  289-­‐298,	  doi:10.3978/j.issn.1000-­‐9604.2013.05.02	  (2013).	  335	   Huynh,	   H.,	   Soo,	   K.	   C.,	   Chow,	   P.	   K.,	   Panasci,	   L.	   &	   Tran,	   E.	   Xenografts	   of	   human	  hepatocellular	   carcinoma:	   a	   useful	  model	   for	   testing	   drugs.	  Clin	  Cancer	  Res	  12,	  4306-­‐4314,	  doi:10.1158/1078-­‐0432.CCR-­‐05-­‐2568	  (2006).	  336	   Xin,	   H.	   et	   al.	   Establishment	   and	   characterization	   of	   7	   novel	   hepatocellular	  carcinoma	  cell	  lines	  from	  patient-­‐derived	  tumor	  xenografts.	  PLoS	  One	  9,	  e85308,	  doi:10.1371/journal.pone.0085308	  (2014).	  337	   Gu,	   Q.	   et	   al.	   Genomic	   characterization	   of	   a	   large	   panel	   of	   patient-­‐derived	  hepatocellular	   carcinoma	   xenograft	   tumor	  models	   for	   preclinical	   development.	  
Oncotarget	  6,	  20160-­‐20176,	  doi:10.18632/oncotarget.3969	  (2015).	  338	   Jiang,	   Z.	   et	   al.	   Anti-­‐GPC3-­‐CAR	   T	   Cells	   Suppress	   the	   Growth	   of	   Tumor	   Cells	   in	  Patient-­‐Derived	  Xenografts	  of	  Hepatocellular	  Carcinoma.	  Front	  Immunol	  7,	   690,	  doi:10.3389/fimmu.2016.00690	  (2016).	  339	   Sun,	   F.	   X.	   et	   al.	   Establishment	   of	   a	   metastatic	   model	   of	   human	   hepatocellular	  carcinoma	   in	   nude	   mice	   via	   orthotopic	   implantation	   of	   histologically	   intact	  tissues.	   Int	   J	   Cancer	   66,	   239-­‐243,	   doi:10.1002/(SICI)1097-­‐0215(19960410)66:2<239::AID-­‐IJC17>3.0.CO;2-­‐7	  (1996).	  340	   Armengol,	  C.	  et	  al.	  Orthotopic	  implantation	  of	  human	  hepatocellular	  carcinoma	  in	  mice:	   analysis	   of	   tumor	   progression	   and	   establishment	   of	   the	   BCLC-­‐9	   cell	   line.	  
Clin	  Cancer	  Res	  10,	  2150-­‐2157	  (2004).	  341	   Kotenko,	   S.	   V.	   IFN-­‐lambdas.	   Curr	   Opin	   Immunol	   23,	   583-­‐590,	  doi:10.1016/j.coi.2011.07.007	  (2011).	  342	   Bolen,	  C.	  R.,	  Ding,	  S.,	  Robek,	  M.	  D.	  &	  Kleinstein,	  S.	  H.	  Dynamic	  expression	  profiling	  of	  type	  I	  and	  type	  III	  interferon-­‐stimulated	  hepatocytes	  reveals	  a	  stable	  hierarchy	  of	  gene	  expression.	  Hepatology	  59,	  1262-­‐1272,	  doi:10.1002/hep.26657	  (2014).	  
V	  References	  
	  161	  





V	  References	  	  
	  162	  
	  
VI	  Curriculum	  Vitae	  
	  163	  
VI	  Curriculum	  Vitae	  
	  Name:	  Tanja	  Blumer	  Nationality:	  Swiss	  Date	  of	  Birth:	  13.09.1988	  Phone:	  +41	  79	  853	  52	  25	  e-­‐mail:	  t.blumer@unibas.ch	  	  	  
	  
EDUCATION	  AND	  EXPERIENCE	  
09/2012	  -­‐	  02/2018	   PhD;	  Cell	  Biology	  -­‐	  Liver	  cancer	  and	  interferon	  signaling	  Hepatology	   group,	   Department	   Biomedicine,	   University	   Hospital	  Basel	  	  
02/2012	  –	  06/2012	   Research	  Associate	  	   	   	   Bernhard-­‐Nocht	  Institute	  for	  Tropical	  Medicine	  Hamburg,	  Germany	  	  	  
09/2010	  –	  01/2012	   MSc;	  Infection	  Biology	  and	  Epidemiology	  Joint	   program	   of	   the	   Bernhard-­‐Nocht	   Institute	   for	   Tropical	  Medicine	  of	  Hamburg,	  Germany	  and	  the	  Swiss	  Tropical	  and	  Public	  Health	  Institute	  of	  Basel	  	  
09/2007	  –	  08/2010	   BSc;	  Biology	  
	   	   	   University	  of	  Basel	  	  
	  
LANGUAGES	  (Swiss-­‐)	  German	  	   native	  English	  	   	   fluent	  French	  	   	   basic	  
	  	  
VI	  Curriculum	  Vitae	  	  	  
	  164	  
COMPUTATIONAL	  SKILLS	  
MS	  Office,	  Prism,	  Illustrator,	  Photoshop	  and	  Endnote	  
	  
COURSES	  LTK	  Module	   1:	   Introductory	   Course	   in	   Laboratory	   Animal	   Science;	   Basel,	   Switzerland	  PyRAT	  –	  Animal	  Management	  System	  GCP-­‐Basiskurs;	  Clinical	  Trial	  Unit,	  University	  Hospital	  Basel	  GCP-­‐Aufbaukurs:	  Clinical	  Trial	  Unit,	  University	  Hospital	  Basel	  
	  	  
PUBLICATIONS	  
2017	   SOCS1	   is	   an	   inducible	   negative	   regulator	   of	   interferon	   λ	   (IFN-­‐	   λ)-­‐induced	  
gene	  expression	  in	  vivo.	  	  Blumer	  T,	  Coto-­‐Llerena	  M,	  Duong	  FHT,	  Heim	  MH.	  J	  Biol	  Chem	  	  	  
2015	   YAP	  promotes	  proliferation,	   chemoresistance,	  and	  angiogenesis	   in	  human	  
cholangiocarcinoma	  through	  TEAD	  transcription	  factors.	  	  Marti	   P,	   Stein	   C,	   Blumer	   T,	   Abraham	  Y,	   Dill	  MT,	   Pikiolek	  M,	   Orsini	   V,	   Jurisic	   G,	  Megel	  P,	  Makowska	  Z,	  Agarinis	  C,	  Tornillo	  L,	  Bouwmeester	  T,	  Ruffner	  H,	  Bauer	  A,	  Parker	  CN,	  Schmelzle	  T,	  Terracciano	  LM,	  Heim	  MH,	  Tchorz	  JS.	  Hepatology	  	  
2014	   WASH-­‐driven	   actin	   polmerization	   is	   required	   for	   efficient	  mycrobacterial	  
phagosome	  maturation	  arrest.	  	  Kolonko	   M,	   Geffken	   AC,	   Blumer	   T,	   Hagens	   K,	   Schaible	   UE,	   Hagedorn	   M.	   Cell	  
Microbiol	  	  
2013	   Sequential	   induction	   of	   type	   I	   and	   II	   interferons	   mediates	   a	   long-­‐lasting	  
gene	   induction	   in	   the	   liver	   in	   response	   to	   a	   novel	   toll-­‐like	   receptor	   9	  
agonist.	  Makowska	   Z,	   Blumer	   T,	   Duong	   FH,	   La	   Monica	   N,	   Kandimalla	   ER,	   Heim	   MH.	   J	  
Hepatol
VI	  Curriculum	  Vitae	  
	  165	  
	  
